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Abstract 
MicroRNAs are evolutionary conserved non-coding RNAs that control more than 60% of 
human protein-coding genes at the posttranscriptional level. MicroRNAs can either mediate 
translational repression or mRNA degradation by complementary base-pairing to the 3’-
UTR of mRNA. MicroRNAs have critical roles in the regulation of immune responses and 
inflammation. The expression of PD-L1 protein is found on some normal and cancer cells 
and contributes to suppression of T cell activity by acting as a brake on the immune response. 
Previously, it has been shown that posttranscriptional mechanisms regulate PD-L1 levels in 
cancer, it remains unknown whether such regulatory networks operate also in non-
transformed cells.  
Here, I tested the hypothesis that expression and function of PD-L1 in stromal, vascular and 
cancer cells is posttranscriptionally regulated by inflammatory-driven microRNAs. I 
demonstrate that PD-L1 expression in human dermal lymphatic endothelial cells (HDLECs) 
can be induced with the treatment of pro-inflammatory cytokines IFN- and TNF-. The 
microRNA landscape in HDLECs was activated by IFN- and TNF- treatment including 
some microRNAs that have predicted binding sites on PD-L1. A highly upregulated 
microRNA was microRNA-155 (miR-155), a multifunctional microRNA that regulates 
haematopoiesis, normal immune function and mediates the inflammatory response. I 
determined that miR-155 can bind to the 3’-UTR of PD-L1 on two functional binding sites, 
and that the kinetics of PD-L1 induction is fine-tuned by inflammation-induced miR-155 in 
HDLECs and dermal fibroblasts. Interestingly, I found that miR-155 can also silence PD-L1 
expression in renal, breast but only in a subset of lung cancer cell lines. These findings 
reveal that inflammatory activation induce PD-L1 expression on several different cell types 
presumably to avoid prolonged immune-mediated tissue damage. However, miR-155 can act 
in a cell type-specific manner to temporally release PD-L1 immunosuppression to regulate 
the balance between immune tolerance and autoimmunity. 
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1. Introduction 
1.1 Immune checkpoints 
1.1.1 Overview on T cells 
T cells regulate the initialisation and maintenance of immune responses, homeostasis and 
immunological memory in response to pathogens, tumours and allergens (Kumar et al. 2018). 
T cells are found in almost every organ and tissue, originating from bone marrow 
progenitors which are matured and selected in the thymus to maintain self-tolerance. The 
ability of the immune system to recognise self-antigen as a non-threat is defined as self-
tolerance. In a pathological context, T cells can also contribute towards inflammatory and 
autoimmune diseases when self-tolerance breaks down. On the other hand, cancer cells 
manipulate self-tolerance to evade the immune system. Naïve T cells in the periphery 
interact with antigen-presenting cells (APCs) and become activated upon recognition of 
antigen and co-stimulatory ligands (Kumar et al. 2018; van den Broek et al. 2018). Different 
subsets of T cells have been characterised due to the surface expression of either CD4+ or 
CD8+ glycoproteins, which assist in the recognition of antigen (Golubovskaya & Wu 2016). 
CD4+ T cells have a number of essential roles in the immune system: to facilitate B cells 
through the production of antibodies, support the functional responses of CD8+ T cells, 
regulate the strength of immune responses and help generate immunological memory (Zhu 
et al. 2010). Differentiation of naïve CD4+ T cells into T helper (Th) cells determines the 
effector function of CD4+ T cells, which is regulated by a network of transcription factors 
such as signal transducer and activator of transcription (STAT) proteins. There are a diverse 
number of Th lineages: Th1, Th2, Th9, Th17, Th22, regulatory T cells (T reg) and T 
follicular helper cells, and differentiation of T cells can be determined by the surrounding 
cytokine environment (Golubovskaya & Wu 2016). For example, Th1 cell differentiation 
requires interleukin-12 (IL-12) and interferon-gamma (IFN-), whereas Th2 cells require IL-
4 and IL-2 (Zhu et al. 2010). Each lineage can differ by factors including the pattern of 
cytokine production and antigen specificity but remain highly heterogeneous, plastic and can 
be reprogrammed to a different lineage (Zhu et al. 2010). On the other hand, CD8+ T cells 
(also called cytotoxic T lymphocytes or CTLs) become primed by APCs into cytotoxic 
effector cells that eliminate intracellular pathogens, infected cells and cancer cells (Zhang & 
Bevan 2011). CD8+ T cells release the cytokines IFN- and tumour necrosis factor-alpha 
(TNF-) and cytotoxic granules that enable the CD8+ to kill target cells. In addition, 
activation of CD8+ T cells induces the formation of memory cells that protect against further 
pathogenic infections.  
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1.1.2 T cell activation 
The T cell receptor (TCR) on T cells initiates detection of antigen that is presented by 
damaged or infected cells. The amplitude and quality of response by T cells is tightly 
regulated by a series of immune checkpoints that consist of co-stimulatory and co-inhibitory 
ligand-receptor interactions (Pardoll 2012). Immune regulation is required to limit damage 
to healthy tissues (Sun et al. 2018). Failure to maintain self-tolerance can lead to chronic 
inflammation and autoimmunity. T cell activation stems from the concept that two or three 
signals must be delivered to determine whether a T cell proliferates, differentiates and 
produces cytokines. In the absence of these specific signals, T cells fail to develop the 
necessary effector functions (anergy) or become deleted. The first required signal is 
mediated by the TCR upon recognition of antigen on the surface of APCs. The second signal 
is in the form of co-stimulatory signals that enhance TCR signalling and a third signal is 
delivered by inflammatory cytokines. The increasing number of factors reported to fine-tune 
T cell responses have evolved the original concept greatly. 
Peptide antigens are presented through major histocompatibility complex (MHC) molecules 
that consist of three -chains and a beta-2 microglobulin. CD4 and CD8 co-receptors 
facilitate the discrimination of antigen peptides that are bound to MHC class II molecules or 
MHC class I molecules, respectively. 
CD8+ T cells recognise peptides presented by MHC class I molecules, which are expressed 
on the surface of all nucleated cells and present endogenously synthesised peptides (Rock et 
al. 2016). Typically, normal and abnormal proteins are degraded by the proteasome into 
peptide fragments. To a large extent, the majority of fragments are destroyed by cytosolic 
peptidases. The few that survive are delivered to the endoplasmic reticulum (ER) through 
transporter associated with antigen processing (TAP) molecules. A peptide-loading complex 
is formed by TAP and includes chaperones TAP-associated glycoprotein (tapasin), 
calreticulin and ERp57 that mediate the binding between peptides and MHC class I 
molecules (Rock et al. 2016). Tapasin holds empty MHC class I molecules to promote 
binding. The repertoire of peptides undergoes further shaping and maturation to facilitate 
stability and specificity before surface presentation. Peptides can be trimmed by ER 
aminopeptidases (ERAP1 and ERAP2) or remodelled by a tapasin homology TAP-binding 
protein-related (TAPBPR) (Rock et al. 2016). A different type of MHC class I presentation 
is through cross-presentation of antigen. APCs such as dendritic cells (DCs) and phagocytes 
are important for immune surveillance and can acquire exogenous peptide-MHC class I 
antigens from infected or tumour cells and present these antigens to CD8+ T cells in 
lymphoid organs.  
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CD4+ T cells recognise peptides expressed by MHC class II molecules, which are generally 
restricted to antigen-presenting cells such as DCs, B cells, monocytes, macrophages but can 
be expressed on other cells following inflammatory signals (Rock et al. 2016). Peptide 
fragments tend to be larger and can extend out from the peptide-binding groove of MHC 
class II. Peptides are derived from extracellular proteins such as those from pathogens and 
from self-proteins that are degraded in the endosomal pathway. MHC class II molecules 
assemble in the ER with the invariant chain polypeptide, which designates these molecules 
to a specific endosomal MHC class II-containing compartment (MIIC). The invariant chain 
blocks the groove of MHC class II to prevent binding of peptides suitable for MHC class I 
presentation. Endosomal proteases cathepsin S and L degrade the invariant chain to a 
fragment known as class II-associated invariant chain peptide (CLIP), a prerequisite for 
loading of peptides (Rock et al. 2016). The high affinity human leukocyte antigen DM 
(HLA-DM) binds to the MHC class II molecules, releasing the low-affinity CLIP and allows 
peptides to bind to the groove of MHC class II. Peptide-MHC class II is then transported to 
the plasma membrane for presentation. 
The - and -chain of the TCR directly recognise the antigen and associate with CD3 co-
receptors that contain immunoreceptor tyrosine-based activation motifs (ITAMs), which are 
important for TCR signal transduction (Malissen et al. 2014). The close proximity of CD4 or 
CD8 to the TCR enables lymphocyte-specific protein tyrosine kinase (Lck) to phosphorylate 
the ITAMs on the cytoplasmic tail of CD3 (Smith-Garvin et al. 2009). This leads to the 
recruitment and activation of zeta-chain-associated protein kinase 70 (ZAP70), which binds 
to the ζ-chains and phosphorylates the transmembrane protein linker of activated T cells 
(LAT). The LAT signalosome constitutes a multi-protein complex that is responsible for 
most of the responses that result from TCR engagement (Malissen et al. 2014). The complex 
includes LAT, the cytosolic adaptor Src homology 2 domain-containing leukocyte 
phosphoprotein of 76 kDa (SLP-76), Vav1, IL-2-inducible T cell kinase (ITK) and 
phospholipase C (PLC1) that contribute to downstream signalling leading to T cell 
proliferation and differentiation.   
Co-stimulatory signals enhance T cell activation and one of the most important receptors is 
CD28. B7 family members CD80 (B7.1) and CD86 (B7.2) on APCs bind to CD28 and 
initiate downstream signalling through phosphoinositide 3-kinase (PI3K) to Akt (Smith-
Garvin et al. 2009). Activation of Akt leads to the phosphorylation of several proteins 
associated with cell survival, cellular metabolism, proliferation and cytokine production 
including nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B), nuclear 
factor of activated T cells (NFAT) and IL-2. CD28 promotes the expression of other key co-
stimulatory molecules in the CD28 and tumour necrosis factor receptor (TNFR) families 
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such as inducible T cell co-stimulator (ICOS; CD278), OX40 (CD134) and 4-1BB (CD137) 
that aid in sustaining the immune response (Smith-Garvin et al. 2009). Furthermore, 
cytokines can strengthen the activation of CD8+ T cells especially pro-inflammatory 
cytokines IL-12 and IFN-, which facilitate the increase in a larger CD8+ T cell population.  
Activation of T cells drives the expression of co-inhibitory receptors that negatively regulate 
TCR signalling. The receptor-ligand immune checkpoints of inhibitory pathways are most 
druggable using antagonist antibodies (Pardoll 2012). The first few immune checkpoint 
inhibitory receptors to be targeted for immunotherapy were cytotoxic T lymphocyte antigen-
4 (CTLA-4), and programmed cell death protein 1 (PDCD1, human chromosome 2; PD-1; 
CD279) of which the focus of this thesis is based on. Other co-inhibitory targets from the 
immunoglobulin superfamily now being investigated are B7-H3, LAG-3, TIGIT, TIM3 and 
VISTA of which our understanding is relatively premature in the identities of associated 
ligands or receptors (Wei et al. 2018). Some of these molecules are restricted to expression 
on Th1 T cells and NK cells that regulate T cell activity through non-redundant inhibitory 
mechanisms. In addition, there is a similar number of known co-stimulatory molecules 
(ICOS, OX40, GITR, 4-1BB, CD40, CD27), many of which are from the TNFR superfamily 
(Wei et al. 2018). Together, this shows the complexity of the regulatory mechanisms located 
at the immune checkpoint that maintain immune responses and protect the host from 
autoimmunity.             
1.1.3 The PD-1/PD-L1 immune checkpoint 
PD-1 was discovered in a murine T cell hybridoma where activation of PD-1 correlated with 
cell death (Ishida et al. 1992). The Pdcd1 locus located on chromosome 2 encodes PD-1, a 
288 amino acid type I transmembrane glycoprotein which is part of the immunoglobulin 
gene superfamily (Agata et al. 1996). Furthermore, PD-1 is heavily glycosylated with a 
molecular weight of 50-55 kDa. PD-1-/- deficient mice develop arthritis and lupus-like 
glomerulonephritis between 6 to 14 months of age (Nishimura et al. 1999) and fatal 
autoimmune cardiomyopathy (Nishimura et al. 2001). PD-1 expression is best characterised 
in T cells, with expression also observed on B cells, monocytes, DCs and natural killer (NK) 
cells (Keir et al. 2008). PD-1 exists as a monomeric receptor as it lacks a membrane-
proximal cysteine residue necessary for homodimerisation (Zhang et al. 2004).  
PD-1 has two ligands, PD-L1 (CD274, human chromosome 9; B7-H1) and PD-L2 
(PDCD1LG2, human chromosome 9; CD273; B7-DC) (Freeman et al. 2000; Latchman et al. 
2001). The two PD-1 ligands differ in their expression and binding affinity. PD-L1 is 
expressed on T cells, B cells, DCs, macrophages and on various non-haematopoietic cell 
types including vascular endothelial cells and tumour cells (Sun et al. 2018). PD-L2 
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expression is restricted to DCs, macrophages and B cells (Sun et al. 2018). The binding 
affinity of PD-L2 to PD-1 is three- to four-fold stronger compared to PD-L1 due to a three-
fold smaller dissociation rate for PD-L2 binding (Butte et al. 2007; Cheng et al. 2013). 
However, there are 5-fold fewer PD-1/PD-L2 than PD-1/PD-L1 complexes due to lower 
expression of PD-L2 at steady state (Cheng et al. 2013). PD-L1 is a 290 amino acid type I 
transmembrane protein encoded by the CD274 gene (Keir et al. 2008) (Figure 1.1). CD274 
contains seven exons, the first is a non-coding 5’-UTR followed by three exons that contain 
the signal sequence (exon 2), extracellular domains IgV-like domain (exon 3) and IgC-like 
domain (exon 4). The next two exons contain the transmembrane domain (exon 5) and 
cytoplasmic domain (exon 6). The last exon contains the remaining part of the cytoplasmic 
domain and the 3’-UTR (Keir et al. 2008).  
 
Figure 1.1. Domain structure of CD274/PD-L1. Human CD274 gene (located on 
chromosome 9) contains seven exons flanked by a 5’-UTR and 3’-UTR that encode for PD-
L1, a 290 amino acid glycoprotein consisting of IgV-like (variable) and IgC-like (constant) 
domains in the extracellular domain and ending with a short intracellular domain (30 amino 
acids). 
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Figure 1.2. The PD-1/PD-L1 immune checkpoint pathway. The T cell receptor (TCR) 
recognises antigens that are presented through major histocompatibility (MHC) molecules 
on antigen presenting cells (APCs). This results in a signalling cascade initiated at the TCR 
that effectively activates the T cell, accompanied by a combination of co-stimulatory 
molecules and activating cytokines that determine the intensity of T cell activation. The 
inhibitory receptor PD-1 is induced upon T cell activation. Upon engagement of PD-1 by its 
ligand PD-L1 consequently leads to phosphorylation of tyrosine residues found on the 
immunoreceptor tyrosine-based switch motif (ITSM) on the tail of PD-1. This leads to the 
recruitment of Src homology phosphatase 2 (SHP2) to the ITSM which inhibits downstream 
TCR signalling and CD28-mediated PI3K activation, resulting in the downmodulation of T 
cell activation and function.     
Engagement of PD-1 by PD-L1 on the surface of T cells inhibits T cell activation and 
function by downregulation of TCR signalling and CD28-mediated activation of PI3K/Akt 
(Sun et al. 2018) (Figure 1.2). The cytoplasmic domain of PD-1 contains two tyrosine 
phosphorylation sites located in an immunoreceptor tyrosine-based inhibitory motif (ITIM) 
and an immunoreceptor tyrosine-based switch motif (ITSM) (Keir et al. 2008). PD-1 is 
phosphorylated on two tyrosine residues (Y224 and Y248) of the cytoplasmic domain by Src 
family tyrosine kinases Lck and to a lesser effect by Csk, and results in the recruitment of 
Src homology phosphatase 2 (SHP2) and SHP1 to the ITSM (Chemnitz et al. 2004; 
Sheppard et al. 2004; Hui et al. 2017). SHP2 directly binds phosphorylated PD-1 with a 29-
fold selectivity over SHP1 and may negatively regulate Lck tyrosine phosphorylation of PD-
1 in a slow dissociating manner (Hui et al. 2017). Recruitment of SHP2 to PD-1 was 
reported to dephosphorylate proximal signalling kinases of the TCR pathway including 
ZAP70, Vav1, PLC1, and CD3ζ, and protein kinase C (PKCθ) (Sheppard et al. 2004; 
Yokosuka et al. 2012). Another study found that CD28-mediated activation of PI3K/Akt was 
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affected by PD-1 signalling from the cytoplasmic tail (Parry et al. 2005). By comparing the 
effect of PD-1 on TCR and CD28 phosphorylation, Hui et al. demonstrated that CD28 was 
the most sensitive target of PD-1/SHP2 (Hui et al. 2017). PD-1 strongly co-localised with 
CD28 in plasma membrane micro-clusters in CD8+ T cells (Hui et al. 2017). 
Dephosphorylation did occur with TCR signalling components, CD3ζ, ZAP70, LAT and 
SLP-76 to a minor extent when there were high PD-L1 levels. Kamphorst et al. showed that 
CD28 signalling was necessary to restore PD-1+ CD8+ T cell responses during PD-1 
blockade in a mouse model of life-long chronic lymphocytic choriomeningitis virus (LCMV) 
infection (Kamphorst et al. 2017). A recent study has suggested that anti-PD-1 blockade in 
mice deficient of SHP-2 showed no significant improvement of anti-tumoural CD8+ T cell 
responses compared to control counterparts, suggesting alternative molecular factors 
involved in PD-1 signalling (Rota et al. 2018). 
CD80 was identified as an additional binding partner of PD-L1 by surface plasmon 
resonance in both mouse and human studies (Butte et al. 2007; Butte et al. 2008). CD80 is 
typically known as a ligand for CD28 and CTLA-4 on the T cell surface. Binding affinity 
between PD-L1 on T cells and CD80 on APCs in both murine and human models was 1.7 
µM and 1.4 µM, respectively, compared to the affinity of PD-L1 for PD-1, 0.5 µM and 0.77 
µM, respectively (Butte et al. 2007; Butte et al. 2008). The binding site of PD-L1 for PD-1 
partially overlaps with CD80. Typically, CD80 is expressed on B cells, DCs and 
macrophages. Potentially, PD-L1 could signal through CD80, which acts as the receptor. In 
vivo models of T-cell activation and tolerance showed that PD-L1 may transmit co-
inhibitory signals to CD80 on T cells and regulate T cell proliferation and apoptosis (Park et 
al. 2010; Deng et al. 2015).  
Some evidence has shown that the cytoplasmic tail of PD-L1 and not PD-L2 may play a role 
in signalling although there is a lack of canonical signalling motifs in the 30 amino acid 
sequence. Azuma et al. identified that PD-L1 on cancer cells can induce apoptotic resistance 
against T cell-mediated killing in in vivo but not in vitro, although the underlying 
mechanism remains to be defined (Azuma et al. 2008). Furthermore, PD-L1 has been 
implicated in angiogenesis, where deletion of PD-L1 in murine endothelial cells (MS1) 
resulted in increased vascular endothelial growth factor receptor 2 (VEGFR2) and 
proliferation suggesting PDL1 has negative regulatory effects on angiogenesis (Jin et al. 
2011). Moreover, deletion of CD80 also increased VEGFR2 expression and cell 
proliferation suggesting that the inhibitory effect was related to PD-L1 ligation with CD80 in 
either an autocrine or paracrine manner.   
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Regarding PD-1 intrinsic signalling, Kleffel et al. demonstrated in melanoma subpopulations 
that PD-1 promoted tumourigenesis independently of adaptive immunity (Kleffel et al. 
2015). PD-1 overexpression modulated downstream effectors of mammalian target of 
rapamycin (mTOR) signalling such as increased phosphorylation of S6. Inhibition of mTOR 
but not PI3K reversed PD-1-dependent S6 phosphorylation suggesting PD-1 signals through 
a PI3K/AKT-independent pathway. In addition, mutation of the ITSM or ITIM abrogated 
PD-1 mediated tumour growth.  
1.1.4 PD-1/PD-L1 in chronic infection and cancer 
The level of PD-1 expression and the extent of ligand engagement regulate the threshold for 
T cell activation and cytokine production (Sharpe et al. 2007). In a disease context, the PD-
1/PD-L1 immune checkpoint can often become manipulated or hijacked such that there is 
either too little or too much regulation of the immune response. During chronic infection or 
cancer, suppression of T cell activation can lead to T cell ‘exhaustion’ (or anergy) which is 
characterised by a loss of IL-2 production, reduced proliferative capacity, reduced cytotoxic 
capacity and impaired production of pro-inflammatory cytokines such as IFN- (Dyck & 
Mills 2017). Thus, the PD-1/PD-L1 pathway can contribute to a lack of viral control during 
chronic viral infection (Sharpe et al. 2007). 
In the presence of persisting infection using a LCMV mice model, virus-specific CD8+ T 
cells become exhausted and dysfunctional after more than 60 days of infection (Barber et al. 
2006). Exhausted CD8+ T cells displayed high expression of PD-1 and infected cells 
upregulated PD-L1. Blockade of the PD-L1 reinvigorated function of exhausted PD-1+ CD8+ 
T cells to produce IFN- and TNF- and enhanced the clearance of chronic viral infection 
(Barber et al. 2006). Moreover, LCMV infection affects the differentiation of CD8+ T cells 
through suppression of PI3K, Akt and mTOR signalling (Staron et al. 2014). Consequently, 
this led to elevated forkhead box protein O1 (FOXO1) activity which maintained PD-1 
expression in exhausted CD8+ T cells. Murine endothelial cells strongly upregulated PD-L1 
after LCMV infection which inhibited virus-specific CD8 T cell killing of infected 
endothelial cells (Mueller et al. 2010; Frebel et al. 2012). Absence of PD-L1 expression on 
endothelial cells and PD-1 expression on T cells can lead to systemic vascular leakage and 
fatality during early systemic LCMV infection. Deficiency of PD-1 in CD8+ T cells of PD-1 
knockout mice showed an increase in death of infected vascular endothelial cells via 
perforin-mediated cell lysis that led to the formation of pulmonary oedema (Frebel et al. 
2012).  
Anti-tumour immunity presents a significant barrier to tumour formation and progression in 
humans. Immune escape is a hallmark of cancer which enables cancer cells to limit the 
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extent of immunological killing (Hanahan & Weinberg 2011). Tumour cells of the lung, 
ovary, colon and skin can hijack the PD-1/PD-L1 pathway to promote tumour antigen-
specific T cell apoptosis (Dong et al. 2002). In a study of 150 melanocytic lesions from 
benign nevi to metastatic melanoma, 57 (38%) were PD-L1+ (Taube et al. 2012). Human 
PD-L1+ melanocytic lesions correlated with 98% presence of tumour-infiltrating 
lymphocytes (TILs) compared to 28% in PD-L1- melanocytic lesions (defined as <5% PD-
L1+) (Taube et al. 2012). This high correlation was observed with detection of IFN- at the 
boundary of TILs and PD-L1+ tumour cells (Taube et al. 2012). This suggests that TILs 
drive the expression of PD-L1 on tumour cells through production of IFN-, a mechanism 
referred to as adaptive immune resistance (Pardoll 2012).       
1.1.4.1 Immune checkpoint blockade in cancer 
Immune checkpoints have been much the focus of clinical developments due to the ability to 
reactivate anti-tumour immunity. The first development of an immune checkpoint inhibitor 
targeted the interaction of CTLA-4 binding to CD28, thereby preventing or sequestering the 
co-stimulation of T cells (Pardoll 2012). This is in contrast to PD-1 since CTLA-4 affects 
the early activation of T cell proliferation in lymph nodes (LNs) whereas PD-1 is induced 
upon activation of T cells and affects the long-term immune response in peripheral tissues. 
In addition, the expression of CTLA-4 is restricted to professional APCs or immune cells. 
The primary effect of CTLA-4 inhibition affected the Th and T reg subset of CD4+ T cells 
such that there was a downregulation of Th cell activity and enhancement of T reg 
immunosuppressive activity (Pardoll 2012). The first approved anti-CTLA-4 blockade was 
ipilimumab, which has been demonstrated to prolong survival in patients with advanced 
melanoma (Buchbinder & Desai 2016). This first development of an immune checkpoint 
blockade agent paved the way for future clinical developments such as targeting of PD-
1/PD-L1.   
The PD-1/PD-L1 immune checkpoint can be blocked by antibodies against PD-1 (anti-PD-1) 
or PD-L1 (anti-PD-L1) to remove the brakes on anti-tumour T cell responses. The first 
clinical trial showed that anti-PD-1 (nivolumab) blockade in patients with advanced 
melanoma had positive signs of anti-tumour activity and safety (Brahmer et al. 2010). Since 
then, the development of anti-PD-1 and anti-PD-L1 treatment has revolutionised cancer 
immunotherapy by improving the outcome of patient survival. Anti-PD-1/PD-L1 checkpoint 
inhibitors have expanded to treat cancers from melanoma to non-small cell lung cancer 
(NSCLC), renal clear carcinoma, head and neck squamous-cell carcinoma, urothelial 
carcinoma, Merkel cell carcinoma, Hodgkin lymphoma, microsatellite instability (MSI) 
colorectal cancer, hepatocellular carcinoma and gastric cancer (Sun et al. 2018). So far, five 
checkpoint inhibitors have been approved of which two are anti-PD-1 (nivolumab and 
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pembrolizumab) and three are anti-PD-L1 (atezolizumab, avelumab and durvalumab) (Sun 
et al. 2018).  
Observed toxicities from anti-PD-1 agents can include fatigue, low-grade pneumonitis (lung 
inflammation) and hyperthyroidism (Linardou & Gogas 2016). Anti-PD-L1 inhibitors are 
associated with few reports of severe toxicities (Linardou & Gogas 2016). A Phase 3 study 
using untreated patients with metastatic melanoma found that the number of adverse events 
were higher in patients with anti-CTLA-4 blockade (ipilimumab, 27.3%) than patients in the 
anti-PD-1 (nivolumab, 16.3%) (Larkin et al. 2015). The combination of PD-1 and CTLA-4 
blockade improved the length of progression-free survival but with increased number of 
adverse events (55.0%). 
1.1.4.2 Factors affecting the response to PD-1/PD-L1 checkpoint blockade 
Approved PD-1/PD-L1 blockade therapy appears to only benefit a fraction of patients and 
there is a large amount of heterogeneity in clinical responses (Sun et al. 2018). The overall 
response rate to anti-PD-1/PD-L1 immunotherapy ranges between 13.3% in hepatocellular 
carcinoma to 39.6% in microsatellite instability high (MSI-H) and mismatch repair deficient 
(dMMR) solid tumours (Sun et al. 2018). Blockade of anti-PD-1 can inhibit ligand 
engagement from PD-L1, PD-L2 and CD80. Tumour responses with anti-PD-1/PD-L1 are 
mediated by tumour antigen-specific T cells that have been previously blocked by PD-1/PD-
L1 interaction (Pardoll 2012). Responses to PD-1/PD-L1 therapy are mainly influenced by 
factors including: PD-L1 expression, presence of the T cell infiltrate within the tumour and 
the general immune status of patients (e.g. absolute lymphocyte count, T cell exhaustion) 
(Blank et al. 2016; Sun et al. 2018). Furthermore, lack of tumour cell recognition or 
immunogenicity from defects in antigen presentation machinery arising from tumour-
associated mutations or neoantigens, and defects in the IFN-γ receptor pathway on tumour 
cells can act as resistance to blockade therapy (Sun et al. 2018). A genetic screen in vivo 
identified that the loss of multiple genes can sensitise tumours to immunotherapy (Manguso 
et al. 2017). Loss of tyrosine-protein phosphatase non-receptor type 2 (PTPN2) sensitises 
tumour cells to IFN--mediated growth suppression in the presence of T cell-mediated 
immunity. Overall, analysis of clinical trial data has revealed three patient subpopulations: 
(1) responders to initial therapy which can be maintained, (2) failure to respond due to innate 
resistance, and (3) responders to initial therapy but later develop disease progression due to 
acquired resistance (Jenkins et al. 2018). The PD-1/PD-L1 pathway can affect the generation 
of T cell response, the effector function and the formation of effector memory T cells. 
Moreover, the effect of other additional immune checkpoints should not be ignored.  
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Tumours can be classed by PD-L1 expression and presence of TILs (mainly T cell infiltrate): 
(1) PD-L1+ TIL+, (2) PD-L1- TIL+, (3) PD-L1+ TIL-, (4) PD-L1- TIL- (Ribas & Hu-
Lieskovan 2016). Predictors of clinical response to PD-1 therapy have included CD8+, PD-
1+ and PD-L1+ cell density in the invasive tumour margin and inside tumours, rather than 
CD4+ density (Tumeh et al. 2014). PD-L1 expression in cancer histologies is more 
frequently observed as a result of IFN- induction rather than constitutive PD-L1 expression 
(Ribas & Hu-Lieskovan 2016). The induction of PD-L1 expression on the invasive tumour 
margin by IFN- producing T cells would be opportune for blockade therapy due to the 
presence of an ongoing immune response. Patients who do not respond to anti-PD-1/PD-L1 
are likely to be negative for PD-L1 and absent of an effector T cell infiltrate. In addition, 
blockade therapy in PD-L1+ tumours without T cell infiltrate may not induce a response, 
although, clinical responses were observed in patients with PD-L1-negative tumours (Robert 
et al. 2014; Shen & Zhao 2018). This may have been affected by the heterogeneous 
expression of PD-L1 in tumours and that the sampling location can affect the staining of PD-
L1 or perhaps due to molecular mechanisms that involve PD-L1 expression on non-
cancerous cells.  
PD-L1 expression can be a major factor in the response to anti-PD-1/PD-L1 agents, and the 
“inflamed” phenotype of the tumour (number of infiltrating CD8+ T cells, immune 
recognition of tumours and TCR clonality) can be predictive of immune checkpoint inhibitor 
response (Voong et al. 2017; Khunger et al. 2017). Patients who have at least 50% of 
tumours cells expressing PD-L1 had better outcome (29-30% overall response rate) from 
anti-PD-1 therapy (pembrolizumab) in previously-treated NSCLC, than the overall number 
of patients (>1% PD-L1 expression, 18% response rate) (Herbst et al. 2016) (overall 
response rate is defined as the number of patients with a tumour size reduction of a 
predefined amount for a minimum time period (Pazdur 2008)). Furthermore, anti-PD-L1 
(durvalumab) treatment in metastatic urothelial carcinoma had a higher overall response rate 
(27.6%) in patients with high PD-L1 ( 25% of tumour cells or immune cells staining for 
PD-L1) expression than PD-L1 negative ( 25%) patients (5.1%) (Powles et al. 2017). There 
are similar findings showing that there is an increased benefit associated with higher PD-L1 
expression has been observed with a second anti-PD-L1 agent (atezolizumab) (Rosenberg et 
al. 2016). Analysis of overall response rate found a PD-L1-associated response in patients 
with metastatic urothelial cancer: PD-L1  5% on infiltrating immune cells; 27% response, 
PD-L1  1%; 18% and PD-L1 1%; 8%. This also indicates that patients with low to none 
expression of PD-L1 on tumour-infiltrating immune cells or tumour cells can still respond to 
anti-PD-L1 therapy.  
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Conversely, clinical trials are affected by different parameters to classify PD-L1-negative 
tumours and the type of antibodies to detect expression of PD-L1 (cell surface or 
cytoplasmic). This can affect clinical data especially when expression of PD-L1 can be 
heterogeneous and not necessarily indicative of an ongoing immune response, such as in 
cases of IFN--independent induction (Sun et al. 2018; Blank et al. 2016). Expression of PD-
L1 alone is suggested to be insufficient as a prognostic biomarker since anti-PD-1/PD-L1 
blockade can benefit both PD-L1 positive and PD-L1 negative tumours (Carbognin et al. 
2015; Shen & Zhao 2018). Not all patients with PD-L1 positive tumours respond to therapy 
so the expression of PD-L1 should be thought more of a crude measure (Carbognin et al. 
2015; Blank et al. 2016). Furthermore, there may be a role of PD-L1 outside the tumour 
microenvironment; could targeting PD-L1-expressing stromal/vascular cells with PD-L1 
blockade improve the overall response rate?  
The combination of anti-PD-1 with anti-CTLA-4 agents can enhance sensitivity to 
immunotherapy compared to a single agent alone (Gong et al. 2018). Combining both 
nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) in the treatment of untreated 
melanoma has been shown to result in significantly longer progression-free survival and 
higher response rates than ipilimumab or nivolumab alone (Wolchok et al. 2013; Larkin et al. 
2015; Postow et al. 2015). In addition, patients with PD-L1 negative tumours had the most 
benefit from combination therapy (11.2 months median progression-free survival) than 
either agent alone (nivolumab – 5.3 months; ipilimumab – 2.8 months), suggesting PD-L1 
status could be a biomarker for choosing combination therapy over monotherapy (Larkin et 
al. 2015). In consideration, the number of treatment-related adverse events were higher in 
patients treated with nivolumab and ipilimumab (55.0%) than with nivolumab (16.3%) or 
ipilimumab (27.3%) (Larkin et al. 2015).    
1.1.4.3 PD-L1 expression on host cells – target for immune checkpoint blockade?  
There are implications that PD-L1 expression on host stromal cells can play an important 
role in the regulation of inflammatory responses since clinical responses can be observed in 
patients with PD-L1-negative tumours (Robert et al. 2014). The contribution of PD-L1 on 
tumour cell and host cells may determine the efficacy of anti-PD-1/PD-L1 blockade but the 
mechanistic target of these agents remains unclear (Sun et al. 2018; Tang & Zheng 2018).  
PD-L1 expression on host immune cells, as well as tumour cells, can contribute to 
immunosuppression and may be of importance as a predictive biomarker of response 
(Bellucci et al. 2015; Noguchi et al. 2017; Lau et al. 2017; Juneja et al. 2017). NK cells are 
an important source of IFN- and it was demonstrated that this release of IFN- can trigger 
tumour cell resistance to NK cell activity by upregulation of PD-L1 (Bellucci et al. 2015). In 
a mouse sarcoma model, tumour-associated macrophages (TAMs) were found to be a major 
13 
 
source of PD-L1 and retained the expression for a long period of time (Noguchi et al. 2017). 
The expression of PD-L1 on TAMs was IFN--dependent and -independent requiring CD4+ 
T cells. High PD-L1 expression on infiltrating myeloid DC and myeloid-derived suppressor 
cells in mice bearing PD-L1-deficient tumour cells, originating from murine colon 
carcinoma cell lines (MC38), can contribute to tumour escape by dampening cytotoxic 
activity of T cells (Lau et al. 2017). The relative contribution of tumour or host-derived PD-
L1 is context dependent, based on the type of tumour (Juneja et al. 2017). PD-L1-deficient 
tumour cells (MC38 and BRAF.PTEN) were injected into wild-type mice. PD-L1KO MC38 
tumours grew at a similar rate as control and some were eventually cleared. In contrast, the 
growth of PD-L1KO BRAF.PTEN tumours were slightly slowed and none of the tumours 
were cleared, suggesting a greater role of PD-L1 in non-tumour cells in this context (Juneja 
et al. 2017). In addition, MC38 tumours expressing PD-L1 were injected into mice lacking 
perforin, a cytolytic granule found in CD8+ T cells that is required for delivering granzymes 
and killing target cells. Blockade with anti-PD-1 resulted in slowed tumour growth but did 
not lead to clearance, PD-L1 was found to reduce CD8+ T cell cytotoxicity (Juneja et al. 
2017). 
Recent studies have provided further knowledge that the target of immune checkpoint 
blockade may be PD-L1 expressed by host cells, rather than tumour cells, in the tumour 
microenvironment (Tang et al. 2018; Lin et al. 2018). When PD-L1-deficient murine colon 
carcinoma cells (MC38) were transferred into PD-L1-knockout mice, anti-PD-L1 blockade 
did not induce an anti-tumour response (Lin et al. 2018). However, the transfer of PD-L1-
deficient MC38 into wild-type mice and subsequent treatment with anti-PD-L1 reduced 
tumour growth in mice and activated T cells in the tumour-draining LNs and tumour tissues. 
In addition, host PD-L1 expression in MC38 tumour tissues was found on macrophages, 
MDSCs and DCs (which expressed the highest levels of PD-L1) in the tumour and in 
tumour-draining LNs. Expression of PD-L1-positive APCs were demonstrated to correlated 
with clinical responses using PD-1/PD-L1 blockade in a small subset of patients with 
melanoma (Lin et al. 2018). A second study in MC38 tumour-bearing mice also found that 
myeloid cells (macrophages, MDSCs and DCs) in tumour-draining LNs expressed higher 
PD-L1 than the same cells in tumour tissues (Tang et al. 2018). Inoculation of wild-type 
MC38 or PD-L1-deficient MC38 into a wild-type host showed similar tumour growth. Upon 
anti-PD-L1 blockade, the response of the PD-L1-deficient MC38 tumour was similar to that 
of the wild-type tumour, suggesting PD-L1 on tumour cells is dispensable in the response to 
immune checkpoint therapy. Moreover, a bone marrow chimeric model showed that the 
expression of PD-L1 on myeloid cells was essential in response to PD-L1 blockade. 
Inhibition of lymphocyte trafficking using an analogue of sphingosine 1-phosphate (S1P) 
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reduced the effects of anti-tumour immunity in the presence of PD-L1 blockade, suggesting 
the migration of activated T cells from draining LNs was important in maintaining overall 
responses (Tang et al. 2018). This may also include therapeutic inhibition of PD-L1 
expression on LECs. Although, these studies suggest that tumour-derived PD-L1 is 
dispensable for the efficacy of PD-L1 blockade, this does not rule out that PD-L1 expression 
is important for cancer cell survival and tumour progression (Azuma et al. 2008; Gato-Cañas 
et al. 2017).  
A factor that could be explored further is the relative expression of PD-L1 on stromal and 
vascular cells and whether this may affect the immune response in the tumour 
microenvironment. Stromal cells such as endothelial cells and fibroblasts are able to actively 
interact with infiltrating leukocytes and modulate anti-tumour immunity (Turley et al. 2015) 
(see Chapter 1.3). The above studies lacked investigation into the effect of PD-L1 expression 
on fibroblasts or endothelial cells in the response to PD-L1 blockade. Overall, the findings 
from these studies imply that PD-L1 expression on host cells (i.e. APCs, stromal) could 
serve as a biomarker and mechanistic target for the response to anti-PD-1/PD-L1 therapy.     
1.1.5 Regulation of PD-L1 
The regulation of PD-L1 in immune, non-transformed and tumour cells is highly complex, 
which is reflected in the number of signalling networks and emerging mechanisms that 
affect the stability and expression of mRNA and protein (Sun et al. 2018). Moreover, PD-L1 
is regulated at the transcriptional, posttranscriptional and posttranslational levels.  
1.1.5.1 Inflammatory signalling 
The best characterised and most potent inflammatory signal for induction of PD-L1 on 
various cell types is IFN-γ, a type II interferon and pro-inflammatory cytokine 
predominantly produced by activated CD4+ and CD8+ T cells and NK cells (Freeman et al. 
2000; Dong et al. 2002; Mazanet & Hughes 2002; Brown et al. 2003; Rodig et al. 2003; 
Loke & Allison 2003; Lee et al. 2005; Lee et al. 2006; Pardoll 2012; Bellucci et al. 2015; 
Garcia-Diaz et al. 2017). Typically, IFN- binds to the IFN- receptor (IFNGR) that is 
composed of two ligand-binding IFNGR1 chains and two signal-transducing IFNGR2 chains 
(Schroder et al. 2004). IFN- induces rapid dimerization of IFNGR1 chains that is then 
recognised by IFNGR2 to form the complete receptor. This initiates downstream signalling 
via phosphorylation of the Janus kinase (JAK) family and to further recruit and 
phosphorylate STAT proteins. Following phosphorylation, STAT proteins homodimerise 
and translocate to the nucleus to bind to IFN--activated sequence (GAS) elements and 
promote expression of genes such as interferon regulatory factors (IRFs) (Schroder et al. 
2004). IRF1 was found responsible for constitutive expression and IFN--mediated PD-L1 
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upregulation in the A549 lung cancer cell line (Lee et al. 2006). Moreover, IFN- treatment 
resulted in a defined upregulation pattern of PD-L1 by the JAK2/STAT1/IRF1 axis in 
melanoma cells (Garcia-Diaz et al. 2017). There was also an increase in STAT2, STAT3 and 
IRF9 genes which could suggest an overlap between type II and type I interferon-signalling 
pathways. Two melanoma cell lines that have loss-of-function mutations for either JAK1 or 
JAK2 failed to respond to IFN- induction of PD-L1 (Garcia-Diaz et al. 2017). Mutations in 
JAK1/2 in melanoma may serve as a form of resistance since these particular tumours 
appeared to be unresponsive to PD-1/PD-L1 blockade therapy (Shin et al. 2017). A 
particular JAK2 mutation (JAK2V617F) is characteristic of myeloproliferative neoplasms 
(MPNs) mutations which spontaneously activates downstream STAT signalling (Prestipino 
et al. 2018). PD-L1 expression was revealed to be induced via STAT3 and STAT5 
phosphorylation in multiple cell types including megakaryocytes, which typically drive the 
disease in MPNs. Furthermore, MPNs were susceptible to anti-PD-1 (nivolumab) therapy 
with a higher ratio of effector to naïve CD8+ T cells and improved survival observed 
(Prestipino et al. 2018).  
IFN- upregulation of PD-L1 has been reported to be context dependent and that there are 
other signalling mechanisms involved as well as the JAK/STAT pathway. The promoter 
region of PD-L1 was found to contain a NF-B responsive element that can be induced by 
IFN- or TNF (Kondo et al. 2010). PD-L1+ myelodysplastic syndrome blasts were revealed 
to have greater intrinsic proliferative capacity and suppressed T cell proliferation and 
induced apoptosis (Kondo et al. 2010). PD-L1 was found to be induced by IFN- alone 
through NF-B in melanoma cell lines (Gowrishankar et al. 2015). Little effect was shown 
with inhibition of STAT3 on the expression of PD-L1 suggesting another pathway that IFN-
 can signal to NF-B. IFN- has been shown to induce NF-B via the mitogen-activated 
protein kinase (MAPK) and PI3K pathway in human dermal fibroblasts (Lee et al. 2005). 
Inhibition of PD-L1 by a MAPK and PI3K reduced promoter activity of PD-L1 by 39% and 
46%, respectively. The role of JAK/STAT signalling was not explored in this study.  
TNF- is a potent mediator of inflammation produced by macrophages, NK cells, T cells, 
endothelial cells and fibroblasts (Sedger & McDermott 2014). TNF- binds to TNFR1 or 
TNFR2 to form a trimer on the cell surface. A prominent downstream effector of TNF- is 
NF-B which typically involves the recruitment of TNF receptor-associated factor 2 
(TRAF2) that facilitates the signal transduction of TNF (Sedger & McDermott 2014). 
TRAF2 interacts with receptor interacting protein kinase (RIP) to activate the inhibitor of 
NF-B kinase (IKK), leading to ubiquitination and degradation of IKK. This allows NF-B 
to translocate into the nucleus and induce transcription by binding to DNA. Given that PD-
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L1 has been reported to be induced by NF-B through IFN- and TNF- stimulation in both 
cancer cells and human dermal fibroblasts (Lee et al. 2005). TNF- stimulation alone did 
not affect PD-L1 expression in human umbilical vein endothelial cells (HUVEC) but in 
combination with IFN- displayed a synergistic or add-on effect (Rodig et al. 2003; Mazanet 
& Hughes 2002). Furthermore, activation of NF-B by TNF- was shown to stabilise PD-
L1 expression at the posttranslational level in breast cancer cells (Lim et al. 2016). Induction 
of COP9 signalosome 5 (CSN5) by the p65 subunit of NF-B directly deubiquitinates and 
stabilises PD-L1 from degradation. The effect of TNF- on PD-L1 appears to revolve 
around the role of stability or localisation of PD-L1 to the cell surface and similarly to IFN- 
stimulation is also context dependent.    
PD-L1 is also induced by type I interferons IFN- and - (Eppihimer et al. 2002; Garcia-
Diaz et al. 2017), IL-6 and IL-10-induced STAT3 (Wölfle et al. 2011) and 
lipopolysaccharide (LPS) through toll-like receptor 4 (TLR4)/ NF-B signalling (Loke & 
Allison 2003). TLR4-mediated upregulation of PD-L1 was shown to be dependent on JAK2 
and myeloid differentiation primary response 88 (MyD88) in human stromal cells derived 
from normal mucosa (Beswick et al. 2014). MyD88 is an adaptor protein that is linked to 
NF-B, IRF and MAPK pathways and may play a critical role in PD-L1 expression 
(Kawasaki & Kawai 2014).  
1.1.5.2 Oncogenic signalling 
PD-L1 expression is often overexpressed in many cancers and has been implicated with 
several oncogenic signalling pathways that contribute to tumour growth, survival and 
proliferation. The majority of these mechanisms contribute to driving expression of PD-L1 
which facilitate the inhibition of T cell responses. PD-L1 has been linked to oncogenic 
signalling from anaplastic lymphoma kinase (ALK) which promotes the expression of PD-
L1 through induction of STAT3 in T cell lymphoma (Marzec et al. 2008).  
The MAPK/ extracellular signal-regulated kinase (ERK) pathway (also called MEK/ERK) is 
involved in PD-L1 regulation through crosstalk between IFN- and TLR inflammatory 
signalling (Liu et al. 2007). Blockade of MyD88 and TRAF6 adaptor proteins and 
MEK/ERK signalling inhibit IFN-/STAT1 induced transcription of PD-L1 in multiple 
myeloma plasma cells. In addition, induction of PD-L1 by phorbol 12-myristate 13-acetate 
(PMA), a known inducer of the MEK/ERK pathway was blocked with a MEK/ERK 
inhibitor (Liu et al. 2007). The MAPK/ERK pathway includes the RAS family of small 
GTPases and predominantly signalling initiates at the cell surface receptor, an example 
being epidermal growth factor receptor (EGFR). Oncogenic RAS signalling was 
demonstrated to drive PD-L1 expression by modulating a posttranscriptional control 
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mechanism affecting PD-L1 mRNA stability (Coelho et al. 2017). Adenylate-uridylate 
(AU)-rich element (ARE) binding protein tristetraprolin (TTP) negatively regulates PD-L1 
which could be inhibited by RAS/ERK activity. Epidermal growth factor receptor (EGFR) is 
a commonly mutated oncogene in patients with NSCLC and activation of the EGFR 
pathway induces an immunosuppressive environment, including PD-L1 expression (Akbay 
et al. 2013). In EGFR-driven murine lung cancer models, PD-1 blockade reduced tumour 
burden and improved the effector function of CD8+ T cells, such as production of IFN-. 
Rare mutations of EGFR that cause over-activation of EGFR signalling upregulate PD-L1 in 
head and neck cancers, which was found to be dependent on JAK2/STAT1 (Concha-
Benavente et al. 2016).          
The PI3K/Akt/mTOR pathway is an important pathway that regulates normal cellular 
processes and its dysregulation which contributes to cell survival and proliferation is 
frequently observed in many cancers. Phosphatase and tensin homolog (PTEN) is a tumour 
suppressor gene that inhibits Akt. PD-L1 is increased after loss of PTEN and activation of 
S6K1, a downstream effector of the Akt pathway in glioma, breast and prostate cancer cells 
(Parsa et al. 2007; Crane et al. 2009). Polysomal recruitment by S6K1 upregulates PD-L1, 
by facilitating the movement of mRNA to polysomes to increase translation of PD-L1. IFN- 
induction of PD-L1 has been demonstrated to be mediated by mTOR activation in NSCLC 
cell lines (Lastwika et al. 2015). In addition, it was suggested that regardless of the 
oncogenic or cytokine stimuli, Akt/mTOR signalling is necessary for driving PD-L1 protein 
expression.   
The MYC oncogene is a transcription factor that is involved in numerous growth signalling 
pathways that affect cell proliferation, differentiation and apoptosis (Dang 2012). MYC is 
estimated to be mutated in up to 70% of human cancers. MYC inactivation in both mice and 
human tumour cells induces tumour regression where PD-L1 mRNA and protein expression 
were also found to be suppressed  (Casey et al. 2016). MYC can regulate PD-L1 by binding 
to the promoter suggesting a transcriptional mechanism of control.      
Cyclin-dependent kinases (CDKs) regulate the stability cell cycle-related proteins during 
cell cycle progression. CDK5 is a serine-threonine kinase that facilitates the immune escape 
of medulloblastoma by maintaining expression of PD-L1 (Dorand et al. 2016). Disruption of 
CDK5 increases the abundance of IRF2, a competitive inhibitor of IRF-1-mediated 
activation and prevents further IFN--mediated production of PD-L1. In contrast, inhibition 
of CDK4 but not CDK6 elevates PD-L1 protein levels by regulating the phosphorylation of 
a cullin 3-based E3 ubiqutin ligase (Cullin 3SPOP), which mediates degradation of PD-L1 
(Zhang et al. 2018). Deletion of the last eight amino acids of PD-L1 (283-290) ablated the 
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binding of PD-L1 to SPOP. Treatment with different inhibitors of CDK4/6 and anti-PD-1 
immunotherapy increase the immunogenicity of cancer cells and enhance tumour regression 
(Zhang et al. 2018; Schaer et al. 2018).   
Hypoxia represents non-physiological levels of oxygen in the tumour and hypoxia-inducible 
factor 1-alpha (HIF-1) is typically induced in response to oxygen deficiency. HIF-1 was 
demonstrated by chromatin immunoprecipitation (ChIP) to directly interact with the hypoxia 
response element of the PD-L1 promoter in murine splenic myeloid-derived suppressor cells, 
human breast cancer and prostate cancer cells (Noman et al. 2014; Barsoum et al. 2014). In 
addition to HIF-1, HIF-2 was shown to target PD-L1 at both mRNA and protein levels in 
human renal carcinoma cells (Messai et al. 2016).  
Glycosylation of PD-L1 has been shown to affect the tumour-associated immune escape (Li 
et al. 2016). PD-L1 is extensively N-glycosylated at four glycan sites (N35, N192, N200 and 
N219), which mediate PD-L1 stability through protection against degradation. Glycogen 
synthase kinase 3 (GSK3) was demonstrated to facilitate the degradation of non-
glycosylated PD-L1 through formation of a complex with -transducin repeats-containing 
protein (-TrCP) (Li et al. 2016).     
Two papers identified CKLF-like MARVEL transmembrane domain containing protein 6 
(CMTM6) as a specific regulator of PD-L1 protein that maintains its cell surface expression 
in a broad range of cancer cells and primary DCs (Burr et al. 2017; Mezzadra et al. 2017). 
Mass spectrometry screening revealed PD-L1 as one of four interacting proteins of CMTM6 
from 4,935 quantified proteins that were decreased by more than two-fold at the cell surface 
after Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9-mediated 
disruption of CMTM6 (Burr et al. 2017). CMTM6 can bind directly to PD-L1 and facilitate 
protection against lysosome-mediated degradation (Burr et al. 2017; Mezzadra et al. 2017). 
Depletion of CMTM6 affects both constitutive and IFN- induced PD-L1 expression where 
the recycling of PD-L1 is markedly impaired. In addition, CMTM4 was identified as a 
second regulator of PD-L1 which shares the regulatory function with CMTM6 (Mezzadra et 
al. 2017).  
1.1.5.3 Genetic alteration 
PD-L1 is located on chromosome 9p24.1 and is 322 kb downstream of JAK2. Genetic 
amplification of the 9p24.1 chromosome and increased expression of PD-L1 was discovered 
in cases of Classical Hodgkin lymphoma (cHL) (6 of 16; 38%) and primary mediastinal 
large B cell lymphoma (PMBCL) (26 of 41; 63%) (Green et al. 2010). JAK2 amplification 
and increased expression was also detected and suggested to induce PD-L1 expression. A 
larger study of rearrangements in chromosome 9p of PMBCL showed an amplification 
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frequency of 29% and a break-point frequency of 20% in 125 cases (Twa et al. 2014). In 
addition, a large study in cHLs found that almost all cases had alterations in the 9p24.1 
chromosome. Copy gain and amplification accounted for 56% (61 f 108) and 36% (39 of 
108) of all analysed cases (Roemer et al. 2016). Moreover, a small number of patients with 
NSCLC were observed to have genetic amplification of the PD-L1 gene (5 of 89; 6%) which 
correlated with JAK2 gene amplification (Ikeda et al. 2016). Four of the five samples that 
showed PD-L1 gene amplification did not have PD-L1 protein overexpression. However, 
using the HCC4006 lung adenocarcinoma cell line which harbours PD-L1 and JAK2 gene 
amplification, the study showed that PD-L1 was significantly higher expressed after IFN- 
and TNF- treatment compared to other cell lines without this amplification (Ikeda et al. 
2016). In a small subset of SCLC patients (4 of 210; 2%), high-level and focal amplification 
of 9p24 was observed with high expression of PD-L1 (George et al. 2017). Whether patients 
with genetic alterations of the PD-L1 gene are sensitised to anti-PD-1/PD-L1 is less well-
studied.  
In addition, the 3’-untranslated region (UTR) is a crucial determinant of PD-L1 expression. 
Interestingly, an ovarian cancer patient harbouring a break-point in the 3’-UTR of PD-L1 
had strong expression of the extracellular domain of PD-L1 (Bellone et al. 2018). The 
structural variant involved a translocation/insertion of a 32 nt fragment from chromosome 9, 
exon 5 of the plasminogen receptor, C-terminal lysine (PLGRKT) gene into the 3’-UTR of 
PD-L1 (Bellone et al. 2018). The patient had a chemotherapy and radiation-resistance, high 
grade ovarian cancer and was given pembrolizumab treatment. High PD-L1-expressing 
tumour cells co-localised with a heavy infiltration of CD4+ and CD8+ TILs and it was 
reported that the patient experienced a complete and sustained response (Bellone et al. 2018). 
Adult patients with T cell leukaemia/lymphoma, diffuse large B cell lymphoma and stomach 
adenocarcinoma were revealed to harbour structural variations that truncated the 3’-UTR of 
the PD-L1 gene (Kataoka et al. 2016). Disruption of the 3’-UTR of PD-L1 led to increased 
stability of PD-L1 transcripts and expression. Furthermore, CRISPR-Cas9 deletion of the 
PD-L1 3’-UTR determined that truncation of the 3’-UTR induced a greater upregulation of 
PD-L1 expression than that of IFN-. Moreover, the loss of the 3’-UTR was shown to 
promote tumour growth and immune escape in in vitro and in vivo models. This suggests 
that the 3’-UTR of PD-L1 might serve as a genetic marker to determine cancers that may 
respond to anti-PD-1/PD-L1 therapy. Moreover, the 3’-UTR of PD-L1 is relatively long 
(2710 bp) and potentially contains several regulatory regions including microRNA response 
elements that function as mechanisms for posttranscriptional control.      
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1.2 MicroRNAs 
1.2.1 microRNA silencing 
microRNAs (miRNAs) are a class of highly conserved, small non-coding RNA (~22-24 nt) 
that regulate gene expression at the posttranscriptional level of all biological pathways 
including cell development, differentiation and function (O’Connell, Rao, et al. 2010). The 
function of miRNAs is to guide the RNA-induced silencing complex (RISC) to target 
mRNAs. miRNA binding sites are typically in the 3’-UTR of mRNAs (Bartel 2009). 
Nucleotide position 2 to 7 at the 5’-end of miRNAs serve as the seed sequence which 
determines target recognition. In addition, nucleotide(s) 8 and 13-16 may also contribute to 
target-base pairing (Ha & Kim 2014). The miRNA mechanism of action is to induce 
translation repression or mRNA degradation which acts to fine-tune gene expression. Due to 
their short seed sequence (6-8 nt), many miRNAs can be involved in regulating a single 
mRNA target or that a single miRNA can be involved in regulating many mRNA targets 
(Mehta & Baltimore 2016). Over 4,000 miRNAs in humans have been catalogued by the 
miRNA database (miRBase v22, March 2018 release) (Griffiths-Jones et al. 2006). It is 
predicted that more than 60% of human protein-coding genes are under the control of at least 
one conserved miRNA and thought to be exceeded because of the potential number of non-
conserved binding sites. Often in human diseases such as cancer, miRNAs can become 
dysregulated and function as potential oncogenes or oncosuppressor genes, and miRNA 
expression can be profiled to distinguish between normal and cancerous tissue (Iorio & 
Croce 2012). Now, although in its infancy, it has emerged that miRNAs can be used in the 
clinic as prognostic and predictive biomarkers through detection in biological fluids which 
provides an encouraging real-world use (Iorio & Croce 2012; Hayes et al. 2014).  
1.2.2 microRNA biogenesis 
In mammals, the canonical process of miRNA biogenesis encompasses the maturation of 
primary miRNA (pri-miRNA) transcripts (~1 kb) that are transcribed by RNA polymerase II 
in the nucleus (Figure 1.3). The majority of miRNAs undergoing the canonical process come 
from introns of non-coding or protein-coding genes that can share the promoter of the host 
gene, or from exonic regions (Ha & Kim 2014). Pri-miRNA transcripts consist of a stem-
loop structure (apical loop and stem) and single-stranded RNA tails at both 5’- and 3’- ends 
(the location where the stem extends to the tails is termed basal junction), which are 
processed by the RNase III endonuclease Drosha and the dsRNA-binding protein DiGeorge 
syndrome critical region 8 (DGCR8) (Lee et al. 2003; Ha & Kim 2014). Drosha and two 
DGCR8 molecules form a Microprocessor complex where the tandem RNase III domains of 
Drosha cut the 5’- and 3’- ends, one helical turn away from the basal junction (Kwon et al. 
2016). DGCR8 is recruited to facilitate RNA-binding activity for efficient pri-miRNA 
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processing. The C-terminus of DGCR8 can interact with Drosha through protein-protein 
interactions. Two dsRNA-binding domains (dsRBD) from DGCR8 can bind to haem of the 
pri-miRNA to provide a stable interface between Drosha and the pri-miRNA, leading to 
formation of a hairpin-shaped precursor miRNA (pre-miRNA, ~65 nt long) (Ha & Kim 
2014).  
As a side note, there have been reports of different non-canonical pathways, one of which 
involves the bypassing of the Drosha-mediated processing step through mRNA splicing such 
that a pre-miRNA is formed after a series of folds. These ‘mirtrons’ have extra sequences at 
the 5’- or 3’-end that requiring trimming by exonucleases (Ha and Kim, 2014). The vast 
majority of functional miRNAs follow the canonical pathway, where only 1% of conserved 
miRNAs are produced independently of Drosha or Dicer in vertebrates.   
 
Figure 1.3. The microRNA biogenesis canonical pathway. Initially, RNA polymerase II 
transcribes pri-miRNA from DNA. The single-stranded RNA tails at 5’- and 3-‘ends of the 
pri-miRNA are cleaved by the Microprocessor complex consisting of the RNase III 
endonuclease Drosha and its RNA-binding partner DGCR8, forming a pre-miRNA. 
Exportin-5 transports the pre-miRNA from the nucleus to the cytoplasm where a second 
cleavage takes place. The RNase III endonuclease Dicer assisted by its co factors TRBP and 
PACT cleaves the stem-loop giving arise to a mature miRNA. Next, the mature miRNA is 
unwound and a single ‘guide’ strand is loaded onto the RISC and directs the complex to a 
target mRNA to mediate mRNA degradation and/or translation repression. This figure is 
modified from previous publications (Ling et al. 2013; Ryan et al. 2015).       
Following this processing, pre-miRNA are exported into the cytoplasm through a transport 
complex consisting of the protein exportin-5 (XPO5) and a GTP-binding nuclear protein 
(RanGTP). RanGTP is hydrolysed in order for the pre-miRNA to be released into the 
cytoplasm where it is further processed (Ha & Kim 2014). The RNase III endonuclease 
Dicer consists of a catalytic centre at the C-terminal and an N-terminal helicase that allows 
Dicer to cleave off the stem-loop of the pre-miRNA. In addition to having a similar structure 
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to Drosha, Dicer also has cofactors that facilitate processing efficiency, transactivating 
response RNA-binding protein (TRBP) and protein activator of the interferon-induced 
protein kinase (PACT) assist in this cleavage, giving arise to a miRNA duplex (Ha & Kim 
2014). 
Multiple publications have reported the importance of core miRNA biogenesis components 
in animal development including cases of embryonic lethality from Drosha and Dicer 
deficiency by embryonic day 7.5 (E7.5) (Chong et al. 2010; Bernstein et al. 2003). 
Furthermore, binding partners are also key and DGCR8 deficiency has been shown to affect 
the maturation of miRNAs and downstream silencing function (Wang et al. 2007).  
1.2.3 microRNA function 
Prior to unwinding of the duplex, RISC assembles with a member of the Argonaute (AGO) 
family of RNA-binding proteins that act as downstream effectors. There are 4 types in 
humans (AGO1-4), all of which are capable of inducing translational repression, mRNA 
deadenylation and mRNA decay. Only AGO2 can slice perfectly matched mRNAs, however, 
all four types of AGO can associate with miRNAs (Ha and Kim, 2014). Most miRNA 
duplexes have central mismatches (that prevent slicing) such that unwinding is a general 
process. Mismatches in the guide strand at nucleotide positions 2-8 and 12-15 promote 
unwinding. Of the miRNA duplex (~20 nt), one miRNA represents the 5’-strand and the 
other the 3’-strand. When the duplex is unwound, the ‘guide’ strand is packaged onto RISC 
whereas the other miRNA strand (the ‘passenger’ strand, denoted by miRNA*) is normally 
degraded (Kim et al., 2009).  Determining which strand is degraded is related to the relative 
thermodynamic stability of the two ends of the duplex (Kim et al., 2009). The strand with 
relatively unstable base pairs, such as GU compared to GC, at the 5’-end typically becomes 
the guide strand (Kim et al., 2009). One other determinant, is the preference of AGO for 
guide strands with a U at nucleotide position 1 (Ha and Kim, 2014). Loading of the guide 
strand to the RISC is ATP-dependent with the aid of the heat shock cognate 70/heat shock 
protein 90 chaperone complex to facilitate binding of AGO to miRNA. In contrast, the 
release of the passenger strand is ATP-independent (Ha and Kim, 2014). The miRNA guides 
RISC to the 3’UTR region of target mRNAs leading to repression of protein-coding gene 
expression (Huntzinger and Izaurralde 2011). In mammals, the majority of miRNAs pair 
imperfectly with target mRNAs and direct translational repression, mRNA destabilisation or 
the combination of the two (Filipowicz et al. 2008; Bartel 2009).  
1.2.4 microRNAs in the inflammatory response 
miRNAs are a crucial regulatory body for development and normal function of the immune 
system (O’Connell et al. 2012). This section provides a brief overview about the importance 
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of miRNAs and miRNA biogenesis components for normal immune function. Deletion of 
Dicer during T cell development demonstrated the involvement of miRNAs in the 
maturation, proliferation and survival of T cells (Cobb et al. 2005; Muljo et al. 2005; Cobb 
et al. 2006). In addition, there is an overall reduction of CD4+ and CD8+ T cell numbers in 
the blood, LNs and spleen (Muljo et al. 2005). miRNAs are indispensable in inflammatory 
responses due to the regulation of T reg cells that repress spontaneous inflammation and 
autoimmunity (Chong et al. 2008; Liston et al. 2008; Zhou et al. 2008). Drosha and Dicer 
are required for the induction of forkhead box P3 (FOXP3), which regulates the 
development and function of T reg cells. Dicer is needed for the development of B cell 
lineage and antibody repertoire (Koralov et al. 2008). Gene-expression profiling identified a 
cluster of miRNAs, miR-17~92, which consists of six miRNAs (miR-17, -19a, -20a, -19b 
and -92) that share four distinct and conserved seed regions. High levels of the pro-apoptotic 
gene, Bim, and loss of miR-17~92 expression were found in Dicer knockout B cells.  Bim 
was shown as a target of miR-17~92, which contains nine potential binding sites for miR-
17~92 (Koralov et al. 2008).  
miRNAs are implicated in a number of inflammatory conditions such as multiple sclerosis, 
rheumatoid arthritis and systemic lupus erythematosus (O’Connell et al. 2012). The first 
miRNAs associated with the inflammatory response were miR-155, miR-146a and miR-132 
(O’Connell et al. 2007; O’Connell et al. 2009; Taganov et al. 2006; Tili et al. 2007; Shaked 
et al. 2009; Lagos et al. 2010). miR-155 and miR-146a are induced in monocytes, 
macrophages and DCs by NF-B and activator protein-1 (AP-1) in response to a broad range 
of TLRs and cytokine signals such as LPS. Expression of miR-155 tightly upregulates 
inflammatory signalling by suppressing negative regulators of Akt and IFN pathways, SH2 
domain-containing inositol 5’-phosphate 1 (SHIP1) and suppressor of cytokine signalling 1 
(SOCS1), respectfully (O’Connell et al. 2009; Androulidaki et al. 2009; Lu et al. 2009). In 
contrast to miR-155, miR-146a is a negative regulator of the immune response and regulates 
proteins involved in the NF-B pathway, IL-1 receptor-associated kinase 1 (IRAK1) and 
TRAF6 (Taganov et al. 2006; Boldin et al. 2011). Ablation of miR-146a expression in mice 
revealed the hyper-responsiveness of macrophages towards LPS and development of 
autoimmune disorder, characterised by multi-organ inflammation. This correlated with the 
activated phenotype of CD8+ and CD4+ T cells suggesting a loss of peripheral T cell 
tolerance (Boldin et al. 2011). Both miR-155 and miR-146a play opposing roles in the 
development of T follicular cells (Hu et al. 2014). Mice lacking miR-146a have elevated 
NF-B activation which increases miR-155 in activated T cells. In addition, miR-155 is 
required for development of CD4+ T follicular helper cells (Hu et al. 2014). Moreover in the 
context of anti-tumour immunity, miR-155 plays a protective role whereas miR-146a is 
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inhibitory and is demonstrated by their effects on the IFN- response of CD4+ and CD8+ T 
cells (Huffaker et al. 2012). Several other miRNAs have been implicated in regulation of the 
inflammatory response including miR-21 (Sheedy et al. 2010), let-7 (Iliopoulos et al. 2009) 
and miR-125b (Tili et al. 2007).  
1.2.5 Regulation of PD-L1 by microRNAs 
miRNAs have the potential to regulate the molecular pathways involved in the host immune 
response (Baltimore et al. 2008; O’Connell, Rao, et al. 2010; Mehta & Baltimore 2016). 
Recent evidence have placed miRNAs as one of the group of regulators of PD-L1 expression. 
The first miRNA implicated in regulation of PD-L1 is miR-513 (Gong et al. 2009). PD-L1 
mRNA but not protein is detectable, unless with IFN- stimulation, in normal human 
cholangiocytes. A significant decrease of miR-513 was detected in IFN-γ-exposed cells and 
overexpression of miR-513 was found to bind to the 3’-UTR of PD-L1 and repress 
translation of PD-L1 mRNA, suggesting miR-513 inhibits IFN--induced PD-L1 expression.  
The remaining studies have linked miRNAs to PD-L1 expression in a broad range of cancers. 
Several miRNAs including miR-200, miR-34a and miR-138, have been found to be 
downregulated in cancer cells to allow PD-L1 expression (Chen et al. 2014; Cortez et al. 
2016; Zhao et al. 2016). miR-200, a suppressor of metastasis by targeting zinc-finger E-box-
binding homeobox 1 (ZEB1) was found to target PD-L1 expression in NSCLC, revealing a 
possible link between epithelial-mesenchymal transition and T cell dysfunction (Chen et al. 
2014). miR-34 was shown to target PD-L1 in NSCLC via the tumour suppressor p53 that 
may facilitate tumour immune evasion because p53 is downregulated in most cancers (Wang 
et al. 2015; Cortez et al. 2016). Low miR-138-5p and high PD-L1 levels are correlated with 
tumour growth in colorectal cancer (Zhao et al. 2016). In pancreatic cancer, miR-142-5p 
expression was inversely correlated with PD-L1, and overexpression could block the PD-
1/PD-L1 pathway (Jia et al. 2017). PD-L1 is repressed by miR-106b-5p and miR-93-5p 
which are part of the miR-25-93-106b cluster, in pancreatic cancer cells, myeloid-derived 
suppressor cells and bone marrow stromal cells (Cioffi et al. 2017). In gastric 
adenocarcinoma, miR-570 regulates PD-L1 via the 3-UTR of PD-L1 mRNA, a G-to-C 
mutation in the 3-UTR caused reduced binding affinity of miR-570, resulting in elevated 
PD-L1 (Wang et al. 2012; Wang et al. 2013). Helicobacter pylori infection results in higher 
PD-L1 expression in gastric cancer cells and both miR-152 and miR-200b are suppressed 
(Xie et al. 2017). It was identified that miR-152 and miR-200b can suppress PD-L1 
expression by acting as tumour suppressors. In laryngeal cancer cells, miR-217 is found 
suppressed but overexpression of miR-217 was shown to target and repress PD-L1 protein 
levels (Miao et al. 2017). In melanoma, miR-17-5p is downregulated and shows an inverse 
correlation with PD-L1 (Audrito et al. 2017). In malignant pleural mesothelioma, miR-15a 
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and miR-16 were identified to target PD-L1 (Kao et al. 2017). Although, miR-193a is not 
predicted to have a target binding site on PD-L1, there was an alternative GU-containing 
target site that caused PD-L1 downregulation. Mutagenesis of miR-17-5p binding site in the 
3’-UTR of PD-L1 mRNA was used to confirm binding specificity between miR-17-5p and 
PD-L1. Indirect regulation of PD-L1 by miRNAs were observed when miR-20b, miR-21 
and miR-130b repress PTEN and resulted in PD-L1 overexpression in advanced colorectal 
cancer (Zhu et al. 2014). Furthermore, A miR-197/CKS1B/STAT3-mediated PD-L1 
network was found to promote lung cancer (Fujita et al. 2015). Downregulation of miR-197 
in lung cancer allows the cyclin-dependent CKS1B to promote PD-L1 expression via 
STAT3.  
Although, there has been a great deal of progress in the identification of dysregulated 
miRNAs that regulate PD-L1 expression in various cancer cell types. There is also a lack of 
studies in miRNAs of non-transformed cells, particularly of stromal cells which would help 
to understand their contribution in the context of normal physiology, disease or response to 
anti-PD-1/PD-L1 therapeutics. Another question is whether miRNA-mediated regulation of 
PD-L1 expression in macrophages, DCs, fibroblasts or endothelial cells affect or predict the 
response to PD-1/PD-L1 immunotherapy?   
1.3 Introduction to stromal/vascular cells 
There has been a great deal of studies into PD-1/PD-L1 pathway which have focused on the 
role of these molecules in immune cells, cancer cells or infected cells. These studies have 
broadened our knowledge of the PD-1/PD-L1 mechanism and also the regulation of the 
pathway. The response to PD-1/PD-L1 treatment occurs in a subset of patients suggesting 
there is a complexity in the number of intrinsic resistance mechanisms. The influence of the 
stromal landscape and the dynamic relationship of the environments that surround 
immunological target sites should be considered. Stromal and vascular cells have emerged as 
active regulators of immunity which can shape the responsiveness to immunotherapy 
(Turley et al. 2015). Stromal cells incorporate a number of different cell types including 
fibroblasts, macrophages and endothelial cells (Mao et al. 2013). 
Recent data has shown that transforming growth factor-β (TGF-) signalling from 
fibroblasts is attributed to the lack of response from treatment with anti-PD-L1 in patients 
with metastatic urothelial cancer (Mariathasan et al. 2018). In particular, there was an 
exclusion of CD8+ T cells from the tumour parenchyma, which were found sequestered in 
the peritumoural stroma. In addition, non-haematopoietic stromal cells contribute towards 
epithelial-mesenchymal transition (EMT)-related gene expression in urothelial cancer (Wang 
et al. 2018). Although there was a correlation between infiltrating numbers of T cells and 
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EMT-related gene expression, this was found to be associated with lower response rates to 
anti-PD-1 blockade, suggesting that stromal cells have a role in the resistance to anti-PD-1 
blockade.  
There is less known about the effect that PD-L1 expression on vascular/stromal cells has in 
the response to immune checkpoint blockade. In addition, the regulatory mechanisms behind 
PD-L1 expression and function in vascular/stromal cells, especially the role of miRNAs, 
under normal physiological responses need to be studied. This would help facilitate our 
understanding into the network of interactions between stromal or vascular cells and the 
immune response. The following subsections describe two different types of cells that 
interact with immune cells such as T cells to either activate or inhibit their function and 
response. These cell types are likely to play some role in the response to immune checkpoint 
blockade. Lymphatic endothelial cells (LEC) are reported to affect both T cell activity and 
lymphangiogenic pathways that can target the extravasation of T cells (Chapter 1.4) (Turley 
et al. 2015). Similarly, fibroblasts shape immune responses in local microenvironments 
through direct cell-cell contact or secreting chemokines and cytokines, affecting T cell 
responses (Turley et al. 2015) (Chapter 1.5). 
1.4 Lymphatic endothelial cells (LECs) 
The lymphatic system is a large transport network that is required for fluid clearance from 
tissues, including the trafficking of cytokines, immune cells and antigen to secondary 
lymphoid organs, such as LNs which orchestrate the adaptive immune response. The 
constant interaction between lymphatic vessels and the immune system enables the 
lymphatic system to serve as an important conduit in inflammation, infection, wound healing 
and cancer. The lymphatic system is also thought to link the brain and the immune system 
(Louveau et al. 2015). 
1.4.1 Development and maintenance of the lymphatic system 
Lymphatic vessels are made up of a single layer of partly overlapping LECs (Swartz 2001). 
The venous origin of the lymphatic system (Sabin 1902) has been supported by embryonic 
studies that have identified key transcription factors required for development and 
maintenance of the lymphatic system. Lymphatic differentiation and identity are 
characterised through expression of vascular endothelial growth factor receptor-3 (VEGFR3), 
lymphatic vessel hyaluronan receptor-1 (LYVE-1), podoplanin (Gp38) and prospero-related 
homeodomain protein 1 (PROX1) (Oliver 2004). VEGFR3 is a receptor tyrosine kinase for 
lymphatic-specific VEGF-C and VEGF-D (Tammela and Alitalo 2010). LYVE-1 is a 
widely-used lymphatic-specific marker, implicated in cellular trafficking and a homologue 
of the CD44 glycoprotein (Banerji et al. 1999; Jackson 2004). During early endothelial cell 
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development, both VEGFR3 and LYVE-1 are expressed and become restricted to LECs at 
later stages. VEGFR3 or VEGF-C knockout mice have defective lymphatic vascular 
development. In contrast, LYVE-1 knockout mice develop normal lymphatic vasculature 
(Gale et al. 2007).   
The murine lymphatic system begins to form in a subpopulation of venous endothelial cells, 
LEC precursors, at embryonic day (E) 8.5 that express PROX1, LYVE-1 and VEGFR3 
(Wigle & Oliver 1999). At E9.75, a lymphatic bias signal upregulates PROX1, LEC budding 
and formation of primary lymph sacs (Oliver 2004). PROX1-deficient embryos lack 
lymphatic vasculature, VEGFR3 or LYVE-1 expression, and are embryonic lethal at E14.5 
(Oliver 2004). Two upstream transcriptional regulators of PROX1, SOX18 (Francois et al. 
2008) and COUP-TFII promote the lymphatic bias signal until E13.5 (You et al. 2005; 
Srinivasan et al. 2010). Constant levels of PROX1 are required to maintain LEC lineage, 
which is supported by VEGF-C/VEGFR3 signalling (Srinivasan et al. 2014). Postnatal LECs 
have lower PROX1 expression compared with embryonic lymphatic endothelium suggesting 
low expression of PROX1 is sufficient to maintain LEC identity (Kazenwadel et al. 2010). 
Additional transcription factors and regulators of lymphatic development have been reported 
including neuropilin 2 (NRP2) (Yuan et al. 2002; Xu et al. 2010), NOTCH (Emuss et al. 
2009; Kang et al. 2010), integrin-9α (Bazigou et al. 2009; Mishima et al. 2007), GATA2 
(Kazenwadel et al. 2015), FOXC2 (Petrova et al. 2004; Norrmen et al. 2009) and c-MAF 
(Hansen et al. 2010).  
Studies have highlighted the plasticity of LECs and that endothelial cell differentiation is 
reversible. Altering the levels of PROX1 expression during embryonic, postnatal or adult 
stages can reprogram LEC phenotype into blood endothelial cells (BECs) (Johnson et al. 
2008; Petrova et al. 2002; Mishima et al. 2007). PROX1 deletion results in the upregulation 
of BEC-specific markers in human and murine LECs (Johnson et al. 2008). Conversely, 
BECs can be transcriptionally reprogrammed by overexpression of PROX1 in vitro, 
resulting in upregulation of VEGFR3 and podoplanin and suppression of BEC-specific 
transcripts such as the transcription factor STAT6 (Petrova et al. 2002; Hong et al. 2002). In 
adult vasculature, endothelial cells are quiescent but able to respond to angiogenic signals. 
Angiogenesis is the growth of new blood vessels from pre-existing vessels. Angiopoietin-1 
(ANG-1) and ANG-2 are ligands for the receptor tyrosine kinase TIE2 and promote 
lymphatic vessel formation and patterning by VEGFR3 expression (Gale et al. 2002; Baluk 
et al. 2005; Morisada et al. 2005). 
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1.4.2 LECs in the inflammatory response 
LECs are actively involved in immune regulation and inflammation. These interactions can 
occur within the lymphatic vessels as antigen and immune cells are transported from the 
periphery to nearby LNs where the dermal immune response is initiated, or when immune 
cells exit lymphatic sinuses in the LN. LECs are grouped in the category of lymph node 
stromal cells (LNSCs) which broadly are, non-haematopoietic cells that regulate immunity 
and self-tolerance (Malhotra et al. 2012), constituting ~1% of LN cellularity. These include: 
LECs (gp38+ CD31+), fibroblastic reticular cells (FRCs; gp38+ CD31-), BECs (gp38+ CD31+) 
and double-negative cells (DNCs; gp38- CD31-). Transcriptomic analyses of mouse LNSC 
subsets identified that DNCs closely resemble FRCs in terms of global gene expression and 
cytokine production. Whereas, LECs and BECs have a closer developmental relationship 
and differ slightly in terms of expression of transcripts. LECs produce IL-7 transcripts 
whereas BECs do not (Malhotra et al. 2012). In addition, IL-7 was shown to be required for 
remodelling and homeostasis of the LN microenvironment after viral infection and 
transplantation (Onder et al. 2012). FRCs, BECs and LECs express TLR-4 and actively 
respond to the onset of inflammation by upregulation of IFN- and/or TLR-4-inducble genes 
including chemokine (C-X-C motif) ligand 9 (CXCL9) (Malhotra et al. 2012).   
LECs express the chemokine (C-C motif) ligand (CCL21) that attracts and guides the 
interactions of CCR7-positive T, B and DCs to LNs via the afferent lymphatics (Förster et al. 
2008). LN-LECs express different levels of CCL21 forming chemokine gradients that 
facilitate directional migration into the LNs through an atypical chemokine receptor, CCRL1 
(Ulvmar et al. 2014). Pro-inflammatory cytokines such as TNF- activate human dermal 
LECs (HDLECs) and induce vascular cell adhesion molecule 1 (VCAM-1), intercellular 
adhesion molecule 1 (ICAM-1) and E-selectin, facilitating adherence and transmigration of 
DCs (Johnson et al. 2006). Furthermore, chemokines secreted by activated HDLECs are 
significantly increased, including monocyte chemoattractant protein 1 (MCP-1 or CCL2), 
regulated on activation, normal T cell expressed and secreted (RANTES or CCL5) and 
macrophage inflammatory protein-3 (MIP-3 or CCL20), compared to resting HDLECs. 
Furthermore, ICAM-1 expression on inflamed HDLECs can directly regulate DCs via 
CD11b to suppress the co-stimulatory marker CD86, preventing effective T cell activation 
(Podgrabinska et al. 2009). Nitric oxide synthase 2 (NOS2 or iNOS) is a short-lived 
metabolic product that was demonstrated to regulate CD4+ and CD8+ T cell proliferation 
(Lukacs-Kornek et al. 2011). The combination of IFN- and TNF- secreted by activated T 
cells elevated the levels of NOS2 and the immune checkpoint molecule indoleamine 2,3-
dioxygenase (IDO) in primary LECs. Co-culture of wild-type LECs and IFN--deficient 
splenocytes restored T cell proliferation suggesting IFN- is essential for NOS2 production. 
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In addition, co-culture of NOS2-deficient LECs with wild-type splenocytes ablated the 
immunosuppressive effect.  
LECs have been demonstrated to induce peripheral tolerance of CD8+ T cells along with 
other lymph node stromal cells (Nichols et al. 2007; Cohen et al. 2010; Lund et al. 2012; 
Tewalt et al. 2012; Hirosue et al. 2014). VEGF-C-activated LECs in B16 melanoma and 
LECs under steady-state conditions can scavenge and cross-present exogenous antigen 
through MHC class I, leading to dysfunctional activation of antigen-specific CD8+ T cells 
(Lund et al. 2012; Hirosue et al. 2014). LN-LECs express endogenous peripheral tissue 
antigens (PTAs) that are independent of autoimmune regulator (AIRE) including tyrosinase 
(Nichols et al. 2007; Cohen et al. 2010). Direct presentation to tyrosinase-specific CD8+ T 
cells led to their deletion (Nichols et al. 2007; Cohen et al. 2010). It is suggested that viral 
antigens are “archived” in LECs following viral infection for at least three weeks but are not 
presented by LECs (Tamburini et al. 2014). These antigens are transferred to DCs for cross-
presentation to T cells in order to maintain memory CD8+ T cell responses when the 
lymphatic endothelium contracts following lymphoangiogenesis.  
Notably, LEC express PD-L1 and induce peripheral deletion of CD8+ T cells mediated via 
PD-1/PD-L1 pathway (Fletcher et al. 2010; Cohen et al. 2014; Tewalt et al. 2012; Hirosue et 
al. 2014; Rouhani et al. 2015). Murine LECs from the LN can express PD-L1 after polyI:C 
stimulation (Fletcher et al. 2010). PD-L1 is expressed higher in LECs of the LN than 
peripheral tissues such as the diaphragm, colon or liver (Cohen et al. 2014; Michonneau et al. 
2016). Radioresistant LECs could induce deletional tolerance to tyrosinase-specific CD8+ T 
cells through a lack of 4-1BBL (CD137) co-stimulatory molecule expression, which resulted 
in the upregulation of PD-1 expression (Tewalt et al. 2012). As a consequence, PD-1/PD-L1 
engagement blocked upregulation of IL-2R on CD8 T cells, necessary for survival. Blockade 
of PD-1 rescued CD8+ T cells from deletion. Furthermore, LECs can present endogenous -
galactosidase (-gal) antigen via MHC class I to -gal-specific CD8+ T cells and induce 
deletion through the PD-1/PD-L1 pathway (Rouhani et al. 2015).  
LECs may act as non-professional antigen-presenting cells, LECs express MHC class II after 
activation and in some cases carry the capacity to acquire peptide-antigen for cross-
presentation (Malhotra et al. 2012; Nörder et al. 2012; Baptista et al. 2014; Dubrot et al. 
2014; Rouhani et al. 2015). LPS, ovalbumin and IFN- stimulation of human or murine 
LECs have been shown to induce MHC class II expression (Malhotra et al. 2012; Nörder et 
al. 2012). LECs were shown to present self-antigen to both OVA-specific CD8+ OT-I and 
CD4+ OT-II T cells in vitro which increased CD25 expression (Baptista et al. 2014). In 
contrast to the previous report, murine DCs can transfer functional peptide-loaded MHC 
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class II complexes to LECs under steady state conditions in vitro in mainly a cell-cell 
contact-dependent manner to promote CD4+ T cell apoptosis (Dubrot et al. 2014). Additional 
evidence have suggested that LEC indirectly induce CD4+ T cell anergy by transfer of PTAs 
to DCs (Rouhani et al. 2015). Moreover, LN-LECs were shown to express MHC class II 
molecules in vivo either through endogenous expression or from acquisition. LEC MHC 
class II was demonstrated to directly induce tolerance of -gal-specific CD8+ T cells via the 
lymphocyte activation gene 3 (LAG-3)/MHC class II immune checkpoint pathway. LECs 
were unable to directly present -gal to MHC class II because they lack HLA-DM, which is 
required for loading of peptide to MHC class II (Rouhani et al. 2015). The mechanism of 
antigen transfer from LEC to DCs requires further clarification. The transfer of antigens 
from LECs to DCs could potentially pass through exosomes, gap junctions or DC 
phagocytosis of excess LEC generated by lymphangiogenesis or undergoing apoptosis 
(Randolph et al. 2017). 
Inflammatory activation of the lymphatic system induces lymphatic remodelling in both 
peripheral tissues and in LNs (Kim et al. 2014). The main pathways that regulate 
inflammation-induced lymphangiogenesis include VEGF-C/VEGFR3 and VEGF-
A/VEGFR2 signalling (Tammela & Alitalo 2010). Lymphangiogenesis is induced by the 
upregulation of VEGF-A, -C and -D from macrophages during acute inflammation of the 
skin or chronic infection of the airway, to facilitate antigen clearance and prevention of 
lymphedema (Baluk et al. 2005; Kataru et al. 2009). Overexpression of VEGF-C was 
demonstrated to restore lymphatic vessels during chronic skin inflammation (Huggenberger 
et al. 2010). In addition, treatment of inflamed skin with VEGF-C initiated LECs to generate 
anti-inflammatory prostaglandin synthase, leading to increased IL-10 on DCs and 
suppression of DC maturation (Christiansen et al. 2016). Production of VEGF can be 
enhanced by B cells in order to facilitate the growth of LN lymphatic vasculature and 
upregulate the trafficking of DCs to the LN (Angeli et al. 2006). In contrast, T cell 
production of IFN- can suppress the sprouting of LN lymphatic vasculature in vivo and 
suppress the expression of key LEC lineage factors PROX1, LYVE-1 and podoplanin in 
vitro in a mechanism that is JAK/STAT-dependent (Kataru et al. 2011). IFN-γ knockout 
mice express a higher baseline of lymphatic vasculature in the LN. During acute skin 
inflammation, the levels of PROX1, VEGFR3 and LYVE-1 are suppressed (Vigl et al. 2011; 
Huggenberger et al. 2011). In human dermal LECs, TNF- stimulation or TGF-β can lead to 
reduced PROX1 and LYVE-1 expression (Johnson et al. 2007; Oka et al. 2008). In contrast, 
studies in a murine peritonitis model have indicated that NF-κB induction of PROX1 and 
VEGFR3, increased the sensitivity of pre-existing lymphatic vessels to leukocytes 
expressing VEGF-C and VEGF-D (Flister et al. 2010). Moreover, IL-3 can upregulate the 
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expression of PROX1 and podoplanin, which indicates that IL-3 is important for the 
maintenance of LEC phenotype in vitro (Gröger et al. 2004).  
1.4.3 microRNA regulation in LECs 
Several miRNAs have emerged as key determinants of LEC differentiation and 
inflammatory responses. miRNA biogenesis are crucial for vertebrate development and 
tissue-specificity of miRNAs has been found in angiogenesis in mice and human studies 
(Bernstein et al. 2003; Yang et al. 2005; Kuehbacher et al. 2007; Suárez et al. 2007). 
Deletion of Dicer in mice leads to improper vascular formation and maintenance, 
consequently results in embryonic lethality (Bernstein et al. 2003; Yang et al. 2005). Key 
vascular and growth factors such as TIE1, FLT1 (encoding for VEGFR1), KDR (encoding 
VEGFR2), ANG-1 and PTEN are significantly dysregulated in Dicer mutant embryos and 
HUVECs (Yang et al. 2005; Suárez et al. 2007). Of note, in human studies, knockdown of 
Dicer resulted in significant but not complete loss of mature miRNA expression suggesting 
the long half-life of endogenous miRNAs (Kuehbacher et al. 2008; Suárez et al. 2007).   
A key miRNA in the normal function of endothelial cells is miR-126, which mediates 
maintenance and angiogenesis of vascular integrity (Harris et al. 2008; Wang et al. 2008; 
Fish et al. 2008; Pedrioli et al. 2010). Loss of miR-126 results in leaky vessels and 
embryonic lethality in a subset of mutant mice (Wang et al. 2008). The remaining mice 
survived to adulthood but were prone to defective cardiac rupture. Possible targets of miR-
126 include sprout-related protein-1 (SPRED-1) and VCAM-1 in human and murine cells. 
VCAM regulates leukocyte adherence and contributes towards vascular inflammation 
(Harris et al. 2008). On the other hand, SPRED-1 is an inhibitor of angiogenic and MAP 
kinase signalling that regulates the expression of pro-angiogenic genes VEGF and fibroblast 
growth factor in mice (Wang et al. 2008). Moreover, VEGF induces miR-132 and promotes 
angiogenesis by suppressing p120RasGAP in human vascular endothelial cells (Anand et al. 
2010). Anti-miR-132 was shown to inhibit angiogenesis and decrease tumour burden in a 
mouse model of human breast carcinoma. Activated LECs can be regulated by the 
microRNA biogenesis machinery (Leonov et al. 2015). An auto-regulatory feedback 
mechanism links AGO2 suppression by miR-132 to the regulation of the miR-221 and miR-
146, which are involved in angiogenic and inflammatory responses, respectively.  
Studies have identified the role of miRNA regulation in LEC lineage commitment. PROX1 
has a long 3’-UTR (5.4kb) that is conserved among vertebrates (Yoo et al. 2010). The length 
of the 3’-UTR suggests that PROX1 expression may be posttranscriptionally regulated by 
miRNAs. Whereas, SOX18 has a short 3’-UTR (585bp) and less likely to have many 
miRNA binding sites. The characterisation of miRNAs in human LECs and BECs has led to 
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the finding that BEC miRNA signatures can regulate lymphatic development (Pedrioli et al. 
2010). Overexpression of miR-31 was demonstrated to repress LEC-signature genes 
including FOXC2. PROX1 is regulated by both miR-31 and miR-181a and consequently 
repress LEC-specific genes, including VEGFR3, and development of vasculature in 
embryonic LECs (Pedrioli et al. 2010; Kazenwadel et al. 2010). In addition, signalling from 
bone morphogenetic protein (BMP) 2, a member of the TGF-β family, can inhibit PROX1 
expression and lymphatic differentiation during development of zebrafish and mice 
(Dunworth et al. 2014). Moreover, signalling from BMP2 increased the expression of: miR-
92a, miR-99a, miR-186, miR-194, and also of miR-31 and miR-181a (Dunworth et al. 2014). 
SMAD4 deletion by siRNA reduced the expression of miR-31 and miR-181a, suggesting 
BMP2 signalling acts as a negative regulator of LEC identity (Dunworth et al. 2014). In 
addition, PROX1 expression can be suppressed by miR-466 in human dermal LECs and 
both miR-181a and miR-466 were shown to inhibit corneal lymphangiogenesis in rats (Seo 
et al. 2015).    
A substantial understanding of gene regulation in LECs comes from Kaposi’s sarcoma (KS), 
a tumour of LEC origin and is the most common cancer in untreated HIV-positive patients 
(Cancian et al. 2013). Both LECs and BECs can be infected by Kaposi’s sarcoma-associated 
herpesvirus (KSHV) and in doing so induces transcriptional reprogramming, giving rise to 
assorted phenotypes of LECs and BECs (Hong et al. 2004; Wang et al. 2004). KS resembles 
a LEC-like phenotype and occurs at sites rich in LECs such as LNs, skin and mucosa (Wang 
et al. 2004). Infection of human LECs by KSHV induces an initial anti-viral miRNA 
response from miR-132 and miR-146a and suppression of these miRNAs inhibits viral gene 
expression (Lagos et al. 2010). Overexpression of miR-132 negatively regulates 
inflammation by targeting the expression of IFN- and interferon-stimulated gene 15 
(ISG15). KSHV infection regulates the interferon response by interaction of miR-132 and 
the transcriptional co-activator p300. Moreover, KSHV can determine endothelial cell 
motility by downregulating the miR-221/miR-222 cluster and upregulating miR-31 (Wu et al. 
2011). It is possible that upregulation of miR-31 may regulate PROX1 during KSHV 
infection but this remains unknown. Kaposin B, a KSHV latent gene, was found to stabilize 
PROX1 mRNA and drive lymphatic reprogramming of BECs (Yoo et al. 2010). Other 
KSHV targets include c-MAF, which represses BEC-specific identity in human LECs, and is 
downregulated throughout viral infection (Hansen et al. 2010; Hong et al. 2004). The KSHV 
orthologue of miR-155 was identified to be miR-K12-11 (Gottwein et al. 2007), which was 
demonstrated to regulate MAF in human LECs (Hansen et al. 2010).  
In addition, rat mesenteric LECs have shown a distinct miRNA signature after TNF- 
stimulation (Chakraborty et al. 2015). Numerous miRNAs involved in angiogenesis, 
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endothelial cell growth and migration were induced while miRNAs connected with cell 
survival and proliferation were suppressed after 24 or 96 h stimulation. NF-κB is a 
downstream effector of TNF- signalling of which miR-9 was induced and also shown to 
directly target and regulate TNF--mediated inflammatory mechanisms. Furthermore, 
overexpression of miR-9 upregulates the expression of VEGFR3 and tube formation, 
suggesting a possible role in lymphangiogenesis. VEGFR3 was also demonstrated to be 
regulated by miR-1236, a mirtron generated from a spliced intron that is independent of 
Drosha processing in human LECs (Jones et al. 2012).    
LECs have much heterogeneity throughout the body, including organ-specific functions 
(Ulvmar & Mäkinen 2016). There is evidence that the plasticity of LECs is under miRNA 
regulation and facilitates the swift response of lymphatic endothelium to inflammatory and 
angiogenic stimuli. Studying miRNAs in different types of lymphatic vessels and niches, 
such as the skin or LN will facilitate our knowledge in their contribution towards 
inflammation and peripheral tolerance.  
1.5 Fibroblasts 
Fibroblasts are a class of stromal cells that consist of a heterogeneous and quiescent 
population (Van Linthout et al. 2014). Typically, fibroblasts maintain the structural 
framework and remodel the extracellular matrix (ECM) of local tissues in order to manage 
the mechanical stress (Turley et al. 2015). The ECM structures allow similar cells to connect 
and interact with each other with a common biological function (Kendall & Feghali-
Bostwick 2014). These structural scaffolds are important for tissue regeneration in wound 
healing, creating boundaries between epithelial and endothelial tissues as well as protecting 
against the migration and invasion of cancer cells. Fibrosis is a process where excess ECM 
proteins are deposited due to the activation and accumulation of fibroblasts, leading to 
scarring of tissue (Turley et al. 2015). Consequently, tissues or organs can become 
dysregulated in structure and function and in essence, fibrosis is an exaggeration of the 
wound healing response. Fibroblast characteristics can vary between tissues and from 
cellular origin, where cells can have a type of positional memory (Van Linthout et al. 2014).  
Primarily, fibroblasts are formed from primary mesenchymal cells but in some cases from 
transition of epithelial or endothelial to mesenchymal or from circulating mesenchymal 
stromal cells and fibrocytes (Van Linthout et al. 2014). These include tumour- or cancer-
associated fibroblasts (TAFs/CAFs, referred to as CAFs from hereby) that promote tumour 
growth and resistance to therapy as well as influencing the immune response within the 
tumour microenvironment (Bussard et al. 2016). Fibroblasts are not a cell type that is 
terminally differentiated and have the plasticity to be differentiated into subtypes of 
fibroblast-like cells (Kendall & Feghali-Bostwick 2014). Myofibroblasts which are essential 
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for the wound healing response can differentiate into various other cells such as epithelial 
cells, endothelial cells, pericytes or even monocytes.  
1.5.1. Fibroblasts in the inflammatory response 
Like LECs, fibroblasts are also an active player of the immune system in addition to its 
structural role. Fibroblasts are highly responsive to components of innate and adaptive 
immunity, including cytokines, chemokines and growth factors (Van Linthout et al. 2014). 
Activated macrophages produce TGF-, TNF- and IL-1 which have been demonstrated to 
stimulate fibroblast secretion of ECM products (Sica & Mantovani 2012; Sullivan et al. 
2009). TNF- and TGF- knockout mice fail to develop fibrosis in the lungs and it is 
thought that TNF- induction of TGF- via AP-1 is required for the appearance of 
pulmonary fibrosis (Sullivan et al. 2009). Moreover, fibroblasts are responsive to 
prostaglandins and leukotrienes that can enhance or inhibit the fibrotic response through 
modulation of fibroblast proliferation and collagen or matrix production (Kendall & Feghali-
Bostwick 2014).  
Fibroblasts modulate the behaviour of immune cells in the local environment by 
conditioning the cellular and cytokine microenvironment (Van Linthout et al. 2014; Turley 
et al. 2015). Similar to LECs, fibroblasts also express chemokines MCP-1, MIP-1, RANTES 
and IP-10 which can modulate the immune landscape of T cells, B cells and macrophages or 
have paracrine effects on other fibroblasts (Gharaee-Kermani et al. 1996; Turley et al. 2015). 
Activation of fibroblasts by MCP-1 was shown to lead to elevation of collagen expression 
and TGF- secretion (Gharaee-Kermani et al. 1996). TGF- has effects on the regulation of 
development and function of all immune cell types (Barnas et al. 2010). As well as the 
ability to induce oncogenic transformation of fibroblasts (Kendall & Feghali-Bostwick 
2014). Moreover, stromal fibroblasts can modulate endothelial cell recruitment of 
lymphocytes and response to cytokines (McGettrick et al. 2009). This depended on whether 
the fibroblast was activated or not. Dermal fibroblasts from non-inflamed tissue were able to 
modulate the capacity of IFN- and TNF--activated HUVECs to recruit circulating 
lymphocytes, whereas fibroblasts from chronic inflamed tissue induced lymphocyte 
adhesion. IL-6 was found to have opposing effects, in the presence of IFN- and TNF-, IL-
6 inhibited the effects of fibroblast and TGF-. Furthermore, fibroblasts can form physical 
interactions between leukocytes, with expression of CD40 on its cell surface (Yellin et al. 
1995). IFN- upregulates CD40 on fibroblasts, whereas TNF- has minimal effects. T cell 
and fibroblast CD40L-CD40 interactions induce VCAM-1 and ICAM-1 expression on 
fibroblasts as well as augmenting the production of IL-6 to enhance proliferation of 
fibroblasts.   
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Dermal fibroblasts were demonstrated to express PD-L1 upon IFN- activation, whereas IL-
1 and TNF- did not (Lee et al. 2005). Further investigation revealed that a putative NF-B 
binding site in the PD-L1 promoter of the 5’-UTR played a large role in IFN--mediated PD-
L1 induction. IFN- stimulation of the ERK and PI3K pathway were then shown to activate 
NF-B activity and inhibition of either pathway repressed some PD-L1 expression (Lee et al. 
2005). Gut stromal myofibroblasts and fibroblasts were revealed to express PD-L1 and PD-
L2 and contribute to regulation of CD4+ T helper cell proliferation (Pinchuk et al. 2008). In 
addition, simultaneous blockade of PD-L1/2 partially rescued T cell proliferation. 
Furthermore, dermal fibroblasts were able to mediate suppression of allogeneic T cell 
activation through IFN--mediated IDO secretion (Haniffa et al. 2007). IDO typically 
inhibits tryptophan accumulation and limits growth and survival of cells. Suppression of T 
cells was partly reversed by the addition of L-tryptophan. Murine mesenchymal stem cells 
(MSCs) which are fibroblast-like cells were shown to express PD-L1, IDO and 
prostaglandin E2 (PGE-2) after IFN- and TNF- activation (English et al. 2007). 
Furthermore, MSCs were demonstrated to modulate the pro-inflammatory environment of 
allogeneic immune responses which was widely dependent on IFN- signalling. 
CAFs are one of the most abundant stromal populations in the tumour microenvironment 
and can promote inflammation through the release of inflammatory cytokines (Bussard et al. 
2016). IL-6 is a key regulator for the transition from normal fibroblasts to CAFs in prostate 
cancer (Giannoni et al. 2010). In addition, IL-6 stimulates the secretion of matrix 
metalloproteinases (MMPs) from activated fibroblasts to influence EMT of prostate cancer 
cells. Co-cultures of CAFs and tumour-associated T cells were demonstrated to both 
enhance and suppress the function of T cells responding to stimulation (Nazareth et al. 2007). 
In addition, CAFs were shown to express PD-L1 and PD-L2 in NSCLC and demonstrated 
that some CAFs elicited a suppressive effect on tumour-associated T cells via the PD-1/PD-
L1 or PD-L2 pathway (Nazareth et al. 2007). CAFs from murine lung tumours can directly 
interact with CD8+ T cells in an antigen-dependent manner via PD-L2 and Fas ligand (FasL) 
and induce T cell suppression (Lakins et al. 2018). PD-L2 ligation to PD-1 and FasL to Fas 
drove the death and dysfunction of tumour specific T cells. No significant change was 
observed with PD-L1 due to the lack of expression on the CAFs that were tested. 
In rheumatoid arthritis (RA), where progressive joint damage is a result of aggressive 
proliferation of the synovial membrane (Miranda-Carus et al. 2004). Synovial and dermal 
fibroblasts express IL-15 on the cell surface which can enhance the secretion of cytokines, 
such as IFN- and TNF-, and proliferation of T cells through direct cell contact 
independent of antigen recognition (Miranda-Carus et al. 2004; Rappl et al. 2001).  
36 
 
Overall, these studies show that these heterogeneous fibroblasts express a diverse repertoire 
of receptors, ligands including PD-L1, and secrete cytokines and chemokines that allow 
them to modulate both activation and inhibition of the local immune environment.      
1.5.2. microRNA regulation in fibroblasts 
Cancer cells have been shown to influence the transition from normal fibroblasts to CAFs. 
Microvesicles containing miR-155 that are derived from murine pancreatic cancer cells have 
been shown to induce the conversion of fibroblasts into CAF-like cells in vitro (Pang et al. 
2015). Moreover, miR-31 and miR-214 were found downregulated while miR-155 was 
upregulated when comparing CAFs to normal fibroblasts in ovarian cancer patients (Mitra et 
al. 2012). Further investigation demonstrated that these miRNAs facilitate the conversion to 
CAFs through transfection of anti-miR-31, anti-miR-214 and pre-miR-155. This conversion 
could be reversed by performing the opposite experiment and led to reduced migration and 
invasion of co-cultured ovarian cancer cells (Mitra et al. 2012).  
1.6 Summary of introduction 
PD-1/PD-L1 immunotherapy has revolutionised current treatments for cancer and PD-L1 
expression may serve as a biomarker. However, the complex regulation of PD-L1 has 
introduced resistance mechanisms to therapy. Thus, an increase depth of knowledge in the 
basic biological roles of these immune checkpoints can provide rational for development of 
new immunotherapies and combinations (Wei et al. 2018). PD-L1-positive cancer patients 
respond better to PD-1/PD-L1 therapy but there are also a subset of tumour PD-L1-negative 
responders (Sunshine & Taube 2015). One possibility is the role of host PD-L1 expression 
on stromal/vascular cells that cannot be ignored. Further understanding is required to 
appreciate the contribution of these cells towards regulation of the local immune response in 
both physiological and pathological contexts. In addition, the difference in the amount of 
studies in PD-L1 between non-transformed cells and cancer cells suggests that there is still a 
large amount of knowledge to be covered within normal physiological environments. These 
studies can also facilitate our awareness in the minimisation of immune-related adverse 
effects especially in the context of combination therapies. Such immune-related adverse 
effects refers to events of autoimmune origin that can affect almost any organ system and are 
relatively common in patients treated with immune checkpoint inhibitors (estimated 30% 
with anti-PD-1/PD-L1 therapies) (Calabrese et al. 2018). Checkpoint therapy is connected 
with revitalising T cell phenotype to become more active which is shown by the increased 
production of inflammatory cytokines. Anti-PD-1 therapy is commonly associated with 
hypothyroidism which is rarely seen in patients given anti-CTLA-4 drugs, meaning that 
adverse events can be associated with the pathways targeted (June et al. 2017).      
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miRNAs have been demonstrated to regulate a variety of inflammatory responses in a broad 
range of cell types, and miRNA expression can be highly tissue-specific. Changes in levels 
of inflammatory-related miRNAs could facilitate our understanding in the modulation of 
immune pathways (Paladini et al. 2016). IFN- is a major inducer of PD-L1 expression and 
downstream signalling has been shown to affect miRNA-mediated suppression of PD-L1 
(Figure 1.4). In addition, miRNA-based signatures could serve as an approach to predict 
immune-related adverse events and as a biomarkers of therapeutic response. There is still a 
large gap for additional inflammatory miRNA networks that regulate PD-L1, particularly in 
non-transformed cells, awaiting to be revealed.  
 
Figure 1.4. IFN- signalling influences miRNA regulation of PD-L1. IFN- is a major 
inducer of PD-L1 expression. In cholangiocytes, miR-513 was shown to suppress PD-L1 
expression by directly binding to the 3’-UTR (Gong et al. 2009). IFN- was demonstrated to 
block the levels of miR-513, thereby enabling PD-L1 expression. Only one miRNA that 
interacts with PD-L1 has been shown to be regulated through IFN- signalling and it is 
likely that there are many more miRNAs to be identified due to the importance of the 
induction of PD-L1 by IFN-.   
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1.7 Thesis aims and hypotheses 
This thesis aims to determine posttranscriptional regulation of PD-L1 by miRNAs in 
primary HDLECs, fibroblasts and cancer cells, and to elucidate this mechanism. In addition, 
to determine whether this mechanism is differentially controlled under inflammatory 
conditions when PD-L1 is induced and to develop a functional assay to test these findings.  
Hypothesis: Expression and function of PD-L1 in stromal, vascular and cancer cells is 
posttranscriptionally regulated by inflammatory-driven microRNAs.  
Aims: 
 To characterise PD-L1 expression and under inflammatory conditions, using 
inflammatory mediators IFN- and TNF- (Chapter 3).  
 To determine the dynamics of the microRNA landscape in vascular and stromal cells 
exposed to inflammatory stimuli (Chapter 3). 
 To investigate the effect of inflammatory-altered microRNAs on regulation of PD-L1 
expression (Chapter 3). 
 To compare microRNA-mediated mechanisms of PD-L1 expression between primary 
stromal cells and human cancer cell lines (Chapter 4). 
 To develop a co-culture model that can be used to functionally test the relevance of the 
above findings, particularly the mechanism of a miRNA/PD-L1 regulatory loop 
(Chapter 5). 
 To determine whether PD-L1 expression or signalling affects miRNA regulatory loops 
(Chapter 6). 
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2. Materials and Methods 
2.1. Cell culture 
All cultured cells were incubated at 37°C in a humidified atmosphere of 5% CO2. Primary 
human dermal lymphatic endothelial cells (HDLECs) originating from an adult donor were 
purchased from Promocell (C-12219) and grown in endothelial cell growth media MV 
(Promocell, C-22020) supplemented with 10 ng/ml vascular endothelial growth factor C 
(VEGF-C) (R&D). Culture media was replaced every 48 h. HDLECs were cultured from 
passage 1 and split when 80-90% confluent using a 1:5 solution of trypsin-EDTA (Gibco) 
and PBS (Gibco). HDLECs were pelleted by centrifugation for 5 min at 259 x g. HDLECs 
were seeded at 500,000 cells per 100 mm (diameter) dish (Corning). At passage 4, HDLECs 
were cryopreserved in a 1 ml mixture of 10% dimethyl sulfoxide (DMSO) and fetal calf 
serum (FCS) (Hyclone). All experiments with HDLECs were performed at passage 5. 
Primary human foreskin fibroblasts (HFFs) of passages around 8-10 were obtained from 
frozen stocks in the Lagos lab. HFFs were grown in 100 mm dishes with Dulbecco’s 
Modified Eagle Medium (DMEM) (Gibco) supplemented with 10% FCS, 1% L-glutamine 
and 1% pen/strep. Adherent cancer lines were grown in either 100 mm dishes or T75 flasks, 
all with Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) supplemented with 10% 
FCS, 1% L-glutamine and 1% pen/strep. The cells include lung cancer lines: A549, H838, 
HCC193, H1299, H358M and Hop62; breast cancer line: MDA-MB-231 and renal clear cell 
carcinoma lines: RCC4, RCC4 transfected with vector alone (RCC4-EV) and RCC4 
transfected with VHL (RCC4 +VHL). All adherent cultured cells (exception being HDLECs) 
were split with trypsin-EDTA (0.25%) and pelleted by centrifugation for 5 min at 259 x g. 
Wild-type Jurkat T cells (E6-1) were a kind gift from Nathalie Signoret (University of York). 
Jurkat cells in suspension were grown in T75 flasks (Corning) containing Roswell Park 
Memorial Institute (RPMI) 1640 media (Gibco), supplemented with 10% FCS, 1% L-
glutamine and 1% pen/strep. A modified Jurkat T cell line overexpressing PD-1 and 
harbouring a luciferase reporter construct under the control of a NFAT promote was 
generously donated by Grzegorz Dubin (Jagiellonian University, Poland). PD-1 NFAT-Luc 
Jurkat cells were cultured in RPMI 1640 media, supplemented with 10% FCS, 1% L-
glutamine, 1% pen/strep and in constant presence of hygromycin B (50 μg/ml) and G418 
(250 μg/ml) to maintain stable expression of transduced constructs. Hygromycin B and 
G418 were omitted from experiments. All Jurkat cell types were pelleted by centrifugation 
for 5 min at 162 x g.      
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2.2. Reagents 
Human recombinant IFN- was obtained from Peprotech and used at 1000 U/ml. TNF- was 
purchased from R&D was used at 25 ng/ml. Recombinant human PD-L1 Fc was acquired 
from R&D. Nivolumab or anti-hPD1-Ni-hlgG4 (S228P) was purchased from InvivoGen. 
AlamarBlue reagent was obtained from ThermoFisher Scientific. 
2.3. RNA interference and miRNA inhibitors and mimics 
Cells were seeded one day before transfection. A transfection mixture was prepared using 
Opti-MEM reduced serum medium with the GlutaMAX supplement (Gibco) and TransIT-
siQUEST (Mirus Bio). The following nucleic acids (all from Dharmacon) were formulated 
with the transfection mixture: miRIDIAN hsa-miR-155-5p mimic (25-50 nM), hsa-miR-155-
5p hairpin inhibitor (50-100 nM) based on the mature hsa-miR-155-5p sequence (5’-
UUAAUGCUAAUCGUGAUAGGGGU-3’) or siRNAs targeting PD-L1 (50 nM, On-
TargetPlus Smartpool). All experiments utilized respective negative controls, for miRNAs 
this was based on mature sequences from c. elegans (i.e. cel-miR-67), or control siRNAs 
that have minimal targeting of human, mouse or rat genes, tested by the manufacturer 
(Dharmacon). 1 ml of media of which the cells are typically grown in was added 5 to 6 h 
posttransfection. The following day, cells were given fresh media and left to recover. 48 h 
posttransfection, cells were stimulated with IFN- and TNF- for 24 h and further 
experimental analysis. 
2.4. RNA isolation, cDNA synthesis and qRT-PCR 
Total RNA was isolated based on the manufacturer’s instructions for the miRNeasy Kit 
(Qiagen). In addition, extra RNA spin columns (NBS Biologicals, SD5008) and 1.5 ml 
RNase-free tubes (Appleton Woods) were purchased and used alongside pre-made 
concentrated buffers from the Qiagen kit. All samples for RNA isolation had 700 μl of 
QIAzol added to lyse the cells. Nucleic acids were separated from proteins and lipids by 
phenol-chloroform extraction. Subsequently, RNA was eluted in 30 μl RNase-free H2O and 
purity was analysed on the NanoDrop ND 2000 (ThermoFisher Scientific) according to the 
A260/A280 ratio. An absorbance measurement of >2.0 is generally accepted for ‘pure’ RNA. 
Quantitative RT-PCR (qRT-PCR) was performed in a two-step manner.  
Isolated RNA was first processed for either mRNA cDNA synthesis with either 
polyadenylated or random hexamer primers or microRNA (miRNA) cDNA synthesis using 
TaqMan primers. For mRNA cDNA synthesis with polyadenylated RNA of one sample, 1 μl 
of RNA (typically between 50-200 ng/μl) was combined with 0.75 μl anchored oligo(dT)23 
primers (5 μM) (Sigma), 1 μl of dNTP (10 mM) (ThermoFisher Scientific) and made up to 
12 μl with RNase-free H2O (Qiagen). The reaction mixture was incubated at 70°C for 6 min 
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on Thermal Cycler 7500 system (Bio-Rad). After, the reaction mixture was combined with 4 
μl 5x First-Strand buffer (Invitrogen), 2 μl DTT (0.1 M), 1 μl RNase OUT recombinant 
ribonuclease inhibitor (40 U, Invitrogen) and 1 μl SuperScript II Reverse Transcriptase (200 
U, Invitrogen). The sample mix was placed on a thermal cycler at 42°C for 1 h and 70°C for 
10 min (to inactivate reverse transcriptase) before being cooled on ice.  
For mRNA cDNA synthesis with random hexamers of one sample, 1 μl of RNA was added 
to 1 μl of random hexamer primer (50 ng/μl, ThermoFisher Scientific), 1 μl of dNTP (10 
mM) and made up to 12.5 μl with RNase-free H2O. The reaction mix was incubated at 70°C 
for 6 min on a thermal cycler. Subsequently, the reaction mixture was combined with 4 μl 5x 
First-Strand buffer, 2 μl DTT (0.1 M), 1 μl RNase OUT (40 U) and 1 μl SuperScript III 
Reverse Transcriptase (200 U, Invitrogen). Samples were incubated at 25°C for 10 min, 
50°C for 50 min and 85°C for 5 min (to inactivate the reverse transcriptase) before being 
cooled on ice.  
miRNA cDNA synthesis was made using the TaqMan miRNA Reverse Transcription Kit 
(Applied Biosystems). 5 μl RNA (typically between 1-5 ng/μl) was mixed with 0.15 μl 
dNTP, 1.5 μl buffer, 0.19 μl RNase inhibitor, 0.5 μl reverse transcriptase, 0.5 μl TaqMan 
primer for specific miRNA and made up to 15 μl with RNase-free H2O. The mixture was 
added to a thermal cycler and a program set for incubation at 16°C for 30 min, 42°C for 30 
min and 85°C for 5 min (to inactivate the reverse transcriptase). All cDNA products were 
stored at -20°C until further use.                              
qRT-PCR was performed to determine expression of levels of mRNA, using SYBR Green 
Master Mix (Applied Biosystems) and mature miRNA using commercially available primers 
(Applied Biosystems). Primers were used at a final concentration of 300 nM in a 20 μl 
reaction. qRT-PCR runs were done on a StepOnePlus Real-Time PCR system (Applied 
Biosystems) with a default program of 40 cycles of amplification. Relative gene expression 
was calculated by the comparative CT method. This involved using GAPDH or -actin as 
housekeeping genes for mRNA expression and U6 snRNA as a loading control for mature 
miRNAs.    
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Table 2.1. Primers for SYBR Green qRT-PCR 
Target mRNA (human) Forward primer (5’-3’) Reverse primer (5’-3’) 
CD274 (PD-L1) CATCTTATTATGCCTTGGT
GTAGCA 
GGATTACGTCTCCTCCAA
ATGTG 
PDCD1 (PD-1) TGCGGACTACAAGCGAAT
CA 
GATCCACGGAAATTCTCT
GGTT 
IL-1 AGGATGACTTGTTCTTTG
AAGCTGA 
TGCCTGAAGCCCTTGCTG 
IL-2 GAATCCCAAACTCACCAG
GATGCTC 
TAGCACTTCCTCCAGAGG
TTTGAGT 
ActB (-actin) CACCATTGGCAATGAGCG
GTTC 
AGGTCTTTGCGGATGTCC
ACGT 
CD47 GGCAATGACGAAGGAGG
TTA 
ATCCGGTGGTATGGATGA
GA 
Vegfr2 CAGAATCCCTGCGAAGTA
CCTT 
GTCAGTACATGCCCCGCT
TTAA 
Vegfr3 AGTACATCAAGGCACGCA
TCGA 
ACCAAGAGCGTGTCAGGC
TTGT 
Prox1 CCCAGGACAGTTTATTGA
CCGA 
GGTTGTAAGGAGTTTGGC
CCAT 
NR2F2 (COUP-TFII) CACCGTCTCCTCCTCAGT
CA 
CATATCCCGGATGAGGGT
TTC 
2.5. PCR and agarose gel electrophoresis 
A total of 300-500 ng/μl purified RNA was reverse transcribed to cDNA using random 
hexamer primers (described above). 1 μl cDNA (typically estimated to be 100 ng/μl) was 
combined with 10 μl 5X colourless GoTaq Flexi buffer (Promega), 2 μl MgCl2 (25 mM, 
Promega), 1 μl dNTP (10 mM), 2.5 μl upstream primer, 2.5 μl downstream primer, 0.25 μl 
GoTaq (5 U/μl) Promega) and made up to 50 μl with RNase-free H2O. The mixture was 
added to a thermal cycler which was programmed to run at 95°C for 2 min (initial 
denaturation), 95°C for a further 30 s (Step 2, denaturation), 57.5°C for 30 s (annealing, 
which was decreased by 1°C per every cycle, based on touchdown PCR (Korbie & Mattick 
2008)), 72°C for 3 min (extension) and repeated from Step 2 (inclusive) for a further 9 
cycles. Then samples were incubated at 95°C for 30 s (Step 5, denaturation), 47°C for 30 s 
(annealing), 72°C for 3 min (extension) and repeated from Step 5 (inclusive) for a further 24 
cycles. A final extension at 72°C for 5 min was added and PCR products were incubated at 
4°C prior to use. For agar gel electrophoresis, a 1% agar solution was made using Tris-
acetate-EDTA (TAE) buffer and ethidium bromide was added to a final concentration of 0.8 
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μg/ml. 6X purple loading dye, no SDS (New England Biolabs) was added to each PCR 
product and loaded on to the agar gel which was ran at 140V for 30-40 min. Subsequently, 
DNA was detected using ultraviolet light and the brightness/contrast ratio was processed 
through GeneSnap software (Syngene).  
Table 2.2. Primers for PCR of CD274 (PD-L1) 3’-UTR 
PD-L1 3’-UTR sites Forward primer (5’-3’) Reverse primer (5’-3’) 
Full length (2671 bp) GATACACATTTGGAGGAG
ACG 
AATGGACATGCTGGTGTA
CC 
miR-155 binding sites 
(2nd half, 1446 bp) 
GGAGGAAATAGGCCAAT
GTG 
AATGGACATGCTGGTGTA
CC 
2.6. Small RNA sequencing 
RNA were isolated and enriched for small RNA using the PureLink miRNA isolation kit 
(Ambion). RNA integrity was assessed using the Agilent 2100 Bioanalyzer (Agilent 
Technologies). Sequencing libraries were generated using NEBNext Multiplex Small RNA 
Library Prep Set for Illumina (Set 1) (New England Biolabs) according to the 
manufacturer’s instructions (performed by the Genomics lab at the Technology Facility, 
University of York). Samples were sequenced using Illumina MiSeq (pair ended, 75 bp, 
MiSeq v3). Sequencing reads were examined for quality and mapped against all annotated 
human mature and precursor miRNA sequences (miRBase version 21.0). Residual adapter 
sequences and indexes were removed with Cutadapt (version 1.8.3), in paired-end mode, 
first trimming any low-quality ends with a cutoff of Q10 (-q 10), then removing flanking Ns 
(--trim-n) and any reads with >20% Ns (--max-n 0.2). Reads were quality trimmed with 
Sickle (version 1.330), with a cutoff of >Q20 (-q 20), and truncating at the position of the 
first N (-n). Reads were mapped with Bowtie (version 1.0.1) with a seed length of 15 (-l 15), 
a maximum total quality score at mismatched positions of 99999 (-e 99999), reporting all 
valid alignments per read or read pair (-a) and the --best option to pick the best reported 
alignments. Reads were mapped separately for merged reads and a concatenated file of 
unmerged forward and reverse reads. Reads were counted using Subread featureCounts 
(version 1.5.0-p1), with a minimum fragment length of 5 (-d 5).  Reads were counted against 
all features in the HsGRCh38 GFF file as well as against features from mirBASE release 21. 
Counts for the mapped merged reads were doubled and then added to the counts for the 
mapped unmerged reads. Duplicate features, i.e. those with identical numbers of mapped 
reads across all samples and identical lengths, were removed. RPKM (reads per kilobase 
transcript per million mapped reads) were calculated and then log2-transformed and 75th 
percentile-shifted. Reads mapping to protein-coding or pseudogenes were presumed to 
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correspond to degraded RNA and were excluded, from descriptive analyses of data. For each 
feature across all of the samples the baseline was set to the median value (i.e. the median 
subtracted from all of the values for that feature). A two-tailed t test and FDR p-value 
correction were used to assess statistical significance (analysis performed by the Genomics 
lab at the Technology Facility, University of York).  
2.7. Western blot 
All samples were initially washed once with ice-cold PBS. Subsequently, cells were lysed 
with either 30 or 50 μl of ice-cold radioimmunoprecipitation assay (RIPA) buffer  (5 mM 
EDTA, 150 mM NaCl, 10 nM Tris HCl pH 7.2, 0.1% SDS, 0.1% Triton X-100 and 1% 
sodium deoxycholate) containing protease cocktail inhibitors P8340, P5726 and P0044 
(Sigma). The lysate was kept on ice for approximately 15 min and then centrifuged at 10,000 
x g for 15-20 min at 4°C to transfer the supernatant. Protein concentration was determined 
by the Pierce Bicinchoninic acid assay (BCA) protein assay kit (ThermoFisher Scientific) 
according to the manufacturer’s protocol, using bovine serum albumin (BSA) to generate the 
standard curve. Samples were incubated at 37°C for 30 min and the absorbance was read on 
a VersaMax Microplate Reader (Molecular Devices) at 562 nm. Protein samples were 
denatured at 95°C with the use of 4X sample loading buffer (250 mM Tris HCl pH 6.8, 8% 
(w/v) SDS, 40% (v/v) glycerol, 5% (v/v) -mecaptoethanol and 0.05% (w/v) bromophenol 
blue). Denatured proteins were resolved on 8, 10 or 12% SDS-PAGE gel containing 
acrylamide using a Bio-Rad PowerPac HC for 1.5 h at 120V and transferred onto PVDF 
membranes (Millipore) at 200 mA and voltage limited to under 25V for 1-1.5 h using a 
Trans-Blot SD semi-dry transfer cell (Bio-Rad). The PageRuler Plus Protein Ladder 
(ThermoFisher Scientific) was used to label size standards (10-250 kDa). Immediately after 
transfer, membranes were blocked with either 2% BSA (Fisher Scientific) or 5% non-fat dry 
milk (Sigma-Aldrich) in 0.1% (v/v) TBST for 1 h at room temperature. Membranes were 
probed overnight at 4°C or for 1 h at room temperature for GAPDH and β-actin (Table 2.3). 
Membranes were further incubated with horseradish peroxidase (HRP)-conjugated 
secondary antibodies (Dako, 1:5000). Membranes were washed with TBST, 3X for 5 min 
after each antibody incubation and finally visualized with ECL (GE Healthcare), according 
to the manufacturer’s protocol. Band intensity was quantified using ImageJ v1.50e (NIH, 
Bethesda, Maryland).  
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Table 2.3. Primary antibodies for western blot  
Supplier Target (human) Antibody (1:1000 unless stated) 
Cell Signalling 
PD-L1  E1L3N 
SOCS1 A156 
STAT1 9172 
P-STAT1 Tyr 701 D4A7 
STAT3 9132 
P-STAT3 Tyr 705 D3A7 
AKT C67E7 
P-AKT Ser 473 D9E (1:500) 
P-AKT Thr 308 C31E5E 
ERK1/2 137F5 
P-ERK1/2 Thr202/204 D13.14.4E 
mTOR 7C10 
P-mTOR Ser 2481 2974 
rpS6 5G10 
P-rpS6 Ser 235/236 D57.2.2E 
Dicer D38E7 
Drosha D28B1 
AGO1 9388 
AGO2 C34C6 
TIE2 AB33 
Abcam 
Actin AC-15 
GAPDH 6C5 
PACT Ab31967 
TRBP Ab42018 
Proteintech PROX1 11067-2-AP 
 
2.8. PNGase F treatment 
Peptide: N-glycosidase F (PNGase F) was acquired from New England Biolabs (P0704). 
PNGase F was added to denatured protein lysates according to the manufacturer’s protocol 
and subsequently analysed by western blot.  
2.9. PD-L1 3’-UTR luciferase assays 
PD-L1 3’-UTR were amplified from HeLa cells and subcloned into the psiCheck2 vector 
using Xhol and Pmel enzymes. Mutations were introduced at the PD-L1 3’-UTR at the miR-
155 binding site (Site1: 5’-AGCAUUA-3’ to 5’-UCUACAG-3’ and Site2: 5’-GCAUUAA-3’ 
to 5’-UCUACAG-3’) using Q5 site-directed mutagenesis kit (NEB) and confirmed by DNA 
sequencing. The PU.1 3’-UTR constructs were described previously (Vigorito et al. 2007). 
Luciferase assays were performed in HeLa cells transfected with hsa-miR-155-5p mimic (50 
46 
 
nM) and PD-L1 or PU.1 3’-UTR constructs for 48 h using JetPrime reagent. Samples were 
assayed with the Dual-Luciferase reporter assay system kit (Promega) for Firefly and Renilla 
luciferase activities and measured on a Perkin-Elmer Wallac Victor2 1420 multi-label 
counter (performed by Kunal Shah, Bart’s Cancer Institute).  
2.10. Flow cytometry / Fluorescence assisted cell sorting (FACS) 
Cells were washed with ice-cold PBS before staining for the live/dead marker, Zombie Aqua 
(Biolegend) for 5 min on ice. Samples were subsequently washed with FACS buffer (1X 
PBS / 0.5% BSA / 0.05% sodium azide) and Ig Fc receptor-blocked with Human TruStain 
FcX (Biolegend) for a further 5 min on ice. Sodium azide can prevent capping and shedding 
or internalisation of the antibody-antigen complex. Next, samples were incubated with 
antibodies for 20-30 min on ice and then washed with FACS buffer x3. After the final wash, 
samples were transferred to FACS tubes and analysed on a BD LSR Fortessa (BD 
Biosciences) using FACS DIVA software. Post-analysis was done using FlowJo V10 (Tree 
Star).  
For FACS, PD-1 NFAT-Luc Jurkat cells were prepared with no live/dead marker and 
antibody incubation was done in culture medium (described above). FACS analysis was 
performed on a MoFlo Astrios EQ Sorter (Beckman Coulter). Cells were sorted for purity (1 
drop) with 80% efficiency. Sorted cells were immediately washed with media x2 to dilute 
sheath fluid and subsequently cultured (described above).   
Table 2.4. Antibodies for flow cytometry 
Supplier Target (human) Antibody Isotype 
Biolegend 
 
PD-1  EH12.2H7 (APC) Mouse IgG1,  
CD69 FN50 (FITC) Mouse IgG1,  
PD-L1 29E.2A3 (PE) Mouse IgG2b,  
HLA-DR L243 (PE-Cy5) Mouse IgG2a,  
Lieping Chen lab PD-L1 5H1 (Biotin) Mouse IgG1,  
eBioscience 
 
CD80 2D10.4 (Biotin) Mouse IgG1,  
HLA-ABC W6/32 (PE-Cy5) Mouse IgG2a,  
 
2.11. Immunofluorescence confocal microscopy 
Cells were cultured in 35 mm glass-bottom dishes with a 14 mm microwell (MatTek). After 
48 h, cells were stimulated with IFN- or in combination with TNF- for 24 h. Cells were 
fixed in 4% paraformaldehyde and permeabilized with 0.5% Triton X-100, and then blocked 
with 5% goat serum for 1 h. Samples were incubated overnight at 4°C with anti-PD-L1 (5H1, 
1:50), washed with PBST x2, followed by goat anti-mouse secondary Alexa Fluor 488 
(Invitrogen, 1:200) for 1 h and washed again with PBST x2. ProLong Gold antifade 
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mountant with DAPI (Invitrogen) was used to mount the slide and stain the nucleus. Slides 
were analysed and images were acquired with a Zeiss LSM 880 on a 40X oil immersion 
objective lens using Zeiss Zen software. 
2.12. Enzyme-Linked Immunosorbent Assay (ELISA) 
The Human IL-2 ELISA MAX Standard kit (Biolegend) was used for all ELISA 
experiments, following the instructions provided by the manufacturer. Rat monoclonal anti-
human IL-2 (capture antibody) was coated overnight on Nunc MaxiSorp flat-bottom 96-well 
plates (ThermoFisher Scientific). The next day, wells were blocked with 5% FCS in 0.05% 
TBST and samples were added. A biotinylated goat polyclonal anti-human IL-2 (detection 
antibody) was incubated with supernatants and followed by avidin-HRP. Amount of IL-2 
was detected using 3,3’,5,5’-tetramethylbenzidine (TMB) substrate solution followed by a 
stop solution (2N H2SO4). Absorbance was read at 450 nm and 570 nm using the VersaMax 
Microplate Reader. An IL-2 standard curve (up to 500 pg/ml) was generated as shown: 
absorbance readings at 450 nm (TMB) – 570 nm (wavelength correction) – blank.          
2.13. Co-culture using wild-type Jurkat T cells / IL-2 ELISA 
For most of the experiments, adherent cells (e.g. HFFs) were plated in 24 well plates in 500 
l DMEM at 15,000 cells/well and left to attach for 16-20 h. Next, media was replaced with 
fresh media consisting of IFN- and TNF- for 24 h. If valid, transfection of cells with PD-
L1 siRNA or miR-155 mimics would occur prior to stimulation, followed by an extra day to 
recover the cells. During seeding of HFFs, a separate parallel 24 well plate was set up 
containing wild-type Jurkat T cells in 500 l RPMI. Subsequently, Jurkat cells were treated 
for 48 h with 1-5 μg/ml phytohaemagglutinin (PHA) and 50 ng/ml phorbol 12-myristate 13-
acetate (PMA), both reagents were obtained from Sigma-Aldrich. On day 3, pre-activated 
Jurkat T cells were co-culture with pre-stimulated HFFs for 24 h and supernatants were 
collected for IL-2 ELISA.  
2.14. Co-culture using PD-1 NFAT-Luc Jurkat T cells 
Primarily, adherent cells (e.g. HFFs) were plated in flat bottom 96 well plates in 100 l 
DMEM at 10,000 cells/well and left for 16-20 h.  The following day, media was removed 
and cells were stimulated with IFN- and TNF- in 100 l for 24 h. If applicable, 
transfection of cells would occur prior to stimulation, followed by an extra day to recover 
the cells. Post-stimulation, the media was replaced with 75 l RPMI 1% FCS containing PD-
1 NFAT-Luc Jurkat T cells at 20,000 cells/well. Cells were preliminary co-cultured for 3 h 
at 37°C and then given anti-human CD3 (OKT3, Biolegend) and anti-human CD28 (CD28.2, 
Biolegend) stimulation at 2 g/ml. CD3/CD28 antibodies were added in 25 l solutions on 
top of the 75 l present in the 96 well, and incubated for a further 3-4 h at 37°C. Following 
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this incubation, the 96 well plates were immediately analysed. First, the plates were 
equilibrated at room temperature for at least 10 min. The luciferase substrate Bio-Glo 
reagent (Promega) was brought to room temperature and 50 l was added to each well for 8 
min. Luminescence was measured by the CLARIOstar (BMG Labtech) plate reader, taking 
readings every 1 min for 5 cycles to determine stability of luciferase signal (equivalent to 8-
12 min incubation of Bio-Glo, where the 10 min reading was used). Plate background signal 
was subtracted using measurements from blank wells with Bio-Glo only. Co-culture 
luciferase quantifications were normalised using PD-1 NFAT-Luc Jurkat only activated 
controls (set to 100%). 
 
2.15. Statistical analysis 
Statistical analysis and graphs were made using GraphPad Prism 8 (GraphPad Software Inc.) 
or RStudio. Statistical significance was determined by comparing the means of at least three 
independent experiments (n  3), performed on different days, using two-sided unpaired 
Student’s t tests between two experimental groups or by one-way analysis of variance 
(ANOVA) with Tukey for more than two experimental groups. A p-value < 0.05 is generally 
considered to be statistically significant. Unspecified indicates no significance. An unpaired 
t-test was used because there are two different experimental conditions (e.g. NTC or miR-
155) that were tested such as in Chapter 3 (i.e. Figures 3.14, 3.15, 3.16, 3.18, 3.22 and 3.23). 
Experimental results are presented as mean ± standard deviation (S.D). 
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3. Posttranscriptional regulation of PD-L1 
3.1 Introduction 
Th1 CD4+ and CD8+ T cells commonly secrete pro-inflammatory cytokines IFN- and TNF-
 upon activation, which are required for their effector function (Zhu et al. 2010; Zhang & 
Bevan 2011). As described (Chapter 1), IFN- activation is a principal inducer of PD-L1 
expression. In addition, PD-L1 has been demonstrated to be induced in HUVECs by IFN- 
and TNF- between 24 and 48 h of activation using a concentration of 100-1000 U/ml IFN- 
and 10-25 ng/ml TNF- (Mazanet & Hughes 2002; Rodig et al. 2003). However, the 
expression of PD-L1 has not been studied in primary HDLECs that line the lymphatic 
system. Using this cellular model, I characterised HDLEC response to IFN- and TNF- 
treatment using similar concentrations to Mazanet, Rodig and colleagues. PD-L1 expression 
was analysed using various cellular biology techniques: western blot, qRT-PCR, flow 
cytometry and microscopy to determine levels of total protein, mRNA, surface expression 
and cellular localisation, respectfully. Furthermore, I determined the effects of IFN- and 
TNF- on the miRNA landscape in HDLECs using small RNA sequencing. In addition, I 
characterised the expression of PD-L1 in primary human foreskin fibroblasts (HFFs) to 
determine whether my findings were cell-type specific or not. This chapter highlights that 
primary stromal fibroblasts/vascular cells are strongly responsive to IFN- and TNF- 
inflammatory stimuli, which synergise to induce downstream genes such as PD-L1, and in 
parallel activate small RNA networks within miRNAs that act to fine-tune PD-L1. I propose 
that this is a response to inflammation during a physiological immune response to avoid 
prolonged immune suppression and provides new understanding into the regulation of 
immune checkpoints in human primary cells.       
3.2 HDLEC response to IFN- and TNF- activation 
The majority of nucleated cells express MHC class I and not MHC class II surface receptors, 
which are typically found on professional APCs. HDLECs display HLA-ABC molecules, 
which represent MHC class I cell surface receptors that can present peptides to CD8+ T cells 
(Figure 3.1). Treatment with IFN- and TNF- induced an increase in the surface expression 
of HLA-DR, suggesting HDLECs possess the expression of MHC class II receptors that 
present peptides to CD4+ T cells (Figure 3.1). Stimulation of HDLECs with TNF- alone did 
not change expression of HLA-DR compared to untreated cells. These data indicate similar 
findings to previous reports, suggesting HDLECs express MHC class II receptors when 
responding to IFN- activation. However, further evidence is required to understand whether 
HDLECs can present peptides through MHC class I or II molecules. 
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Figure 3.1. HDLECs express MHC class II molecules after IFN- stimulation. Pilot 
study to show the response of HDLECs to inflammatory activation. HDLECs were harvested 
after stimulation with IFN-, TNF- or both cytokines (24 h) for flow cytometry analysis 
and stained for HLA expression. Data showing HLA-ABC (MHC class I) or HLA-DR 
(MHC class II) surface expression,  measured by median fluorescence intensity, MFI, of 
cells gated on singlets. MFI of HLA-ABC staining: IFN- + TNF- = 12814, IFN- = 
12688, TNF- = 12226 UT = 8396. MFI of HLA-DR staining: IFN- + TNF- = 178, IFN- 
= 213, TNF- = 25.9 UT = 27.8, Black = unstained cells (MFI = 17.9 to 19.7). n = 1 
experiment. 
Furthermore, the effect of IFN- and TNF- was looked in various signalling pathways 
(Figure 3.2A). Phosphorylation of Akt at serine 473 is mediated by mTOR complex 2 
(mTORC2) and constitutes to activation of Akt. Phosphorylation of S473 was initially 
induced by IFN- and TNF- after 30 min but the effect was lost at 4 h compared to 
untreated cells. At 16 and 24 h, the cells had lower phosphorylation of Akt S473, suggesting 
IFN- and TNF- affected mTORC2-mediated effects. On further investigation, at lower 
concentrations of IFN- stimulation this appeared to drive downregulation of Akt S473 
which could be restored with addition of TNF- (Figure 3.2B). However, increasing the 
concentration of IFN- drove further downregulation which was then enhanced with the 
addition of TNF-. Stimulation with TNF- alone slightly decreased Akt S473 
phosphorylation. Downstream effector of the Akt pathway, ribosomal protein S6 
phosphorylation at S235/236 was increased upon IFN- and TNF- stimulation compared to 
untreated cells. Whereas, the phosphorylation of ERK at threonine 202/204 was transient but 
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noticeably increased at 16 and 24 h post-stimulation. These data indicate that IFN- and 
TNF- activation can modulate the transient expression of key signalling molecules in 
HDLECs.   
HDLEC lineage commitment markers were assessed after stimulation with IFN- and TNF-
. PROX1 protein expression was decreased by IFN- alone, TNF- alone and further 
downregulated in the combination of both cytokines (Figure 3.3A). This was further 
supported by an observe decrease at mRNA level in all tested lineage commitment markers 
of LECs (PROX1, VEGFR3, COUP-TFII and LYVE1) (Figure 3.3B). This highlights the 
lineage plasticity of HDLECs and suggests IFN- and TNF--activation causes the loss of 
HDLEC identity, which may lead to suppression of HDLEC growth in vitro. 
 
Figure 3.2. Effect of IFN- and TNF- on AKT or ERK pathways. Another preliminary 
study to show responsiveness of HDLECs to cytokine activation. HDLECs were treated with 
or without IFN-γ and TNF-α in 6-well plates for up to 24 h and lysed for western blot 
analysis at time-points indicated above. A) Protein expression following a time-course of 
IFN-γ and TNF-α stimulation in HDLECs showing various effects on the phosphorylation 
(P) of AKT, ERK and S6 proteins. B) Protein expression following a titration of IFN-γ with 
and without TNF-α stimulation (24 h). n = 2 independent experiments. 
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Figure 3.3. IFN- and TNF- activation of HDLECs results in loss of lineage 
commitment markers. Experiment to show the effects of inflammatory cytokines on 
lineage markers associated with LECs. A) Western blot analysis showing the PROX1 
expression in HDLECs after IFN- and TNF- stimulation (24 h). B) qRT-PCR showing 
mRNA expression of PROX1, VEGFR3, COUP-TFII and LYVE1 after IFN- and TNF- 
stimulation (24 h), gene expression is normalized to their respective untreated control, using 
-actin as a reference gene when calculating fold change expression. n = 2 independent 
experiments. 
3.3 HDLEC characterisation of PD-L1 expression and kinetics 
PD-L1 expression in HUVECs show a strong induction after IFN- and TNF- activation, 
where peak levels of mRNA transcripts were between 12 and 24 h (Mazanet & Hughes 
2002). In addition, surface expression of PD-L1 was highest around 24 h post-stimulation 
(Mazanet & Hughes 2002). In this study, PD-L1 expression was measured at basal levels 
and after IFN- and TNF- stimulation at time-points between 30 min and 24 h in HDLECs 
(Figure 3.4A and B). PD-L1 protein expression was notably induced after 4 h of stimulation 
and this upregulation was increased further by 24 h. Two distinct protein bands were 
observed for PD-L1 (around 40-50 kDa) in western blot analysis. IFN-γ signalling is capable 
of activating both STAT1/3. In HDLECs, phosphorylation of STAT1 at the activating 
tyrosine residue (P-STAT1 Y701) positively correlated with the increase of PD-L1 whereas 
the kinetics of STAT3 activation were transient but remained induced. Consistent with these 
results, PD-L1 mRNA levels were upregulated in activated HDLECs (Figure 3.5A). IFN- 
treatment resulted in a ten-fold induction of PD-L1 mRNA levels at 24 h post-treatment, 
compared to basal expression. The effect was significantly elevated by concurrent addition 
of TNF-, although addition of TNF- alone did not significantly affect PD-L1 mRNA 
53 
 
levels, demonstrating that the effect of stimulating with both cytokines was synergistic. 
Importantly, IFN- and TNF- enhanced surface PD-L1 expression (Figure 3.5B), where the 
functional relevance of PD-L1 has been described.  
 
Figure 3.4. PD-L1 is expressed in HDLECs and can be induced by IFN- and TNF-. A) 
Western blot analysis following a time-course of IFN- and TNF- stimulation in HDLECs, 
compared to untreated. The phosphorylation of STAT1/3 proteins shows that HDLECs 
respond to canonical IFN- and TNF- signalling. B) Western blot quantification from A 
(left) in untreated and IFN- and TNF--treated samples, relative to -actin, showing PD-L1 
protein expression. n = 2 independent experiments, showing one representative blot. 
Furthermore, titrating IFN- stimulation showed an upwards trend of PD-L1 mRNA 
expression, which was further augmented in combination with TNF- (Figure 3.6A). At the 
protein level, TNF- stimulation alone had no effect on PD-L1 or P-STAT1 (Figure 3.6B). 
TNF- in combination with IFN- induced further expression of P-STAT1 whilst having 
minimal effects on total PD-L1 protein levels in comparison to treatment with IFN- alone. 
Immunofluorescence determined the effect of IFN- and TNF- on PD-L1 expression in 
permeabilised cells (Figure 3.7). PD-L1 was localized at the cell membrane and throughout 
the cytoplasm following stimulation. There was increased perinuclear PD-L1 staining from 
the synergistic effect between IFN- and TNF-, which suggested that in IFN--treated 
HDLECs, TNF- can affect PD-L1 localization. Expression of IL-1β mRNA, a downstream 
target of NF-B pathway, was upregulated in a similar synergistic manner between IFN- 
and TNF- (Figure 3.8A). PD-L1 mRNA was measured at 8 h where it was strongly induced 
and remained at the same level at 24 h, consistent with the cumulative increase in PD-L1 
protein levels (Figure 3.8B). To confirm specificity of PD-L1 signal, transfection of small 
interfering RNA (siRNA) targeting PD-L1 abolished detection of both bands in western blot 
(Figure 3.9A). PNGase F is an enzyme which cleaves oligosaccharides from N-linked 
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glycoproteins. De-glycosylation treatment using PNGase F led to total disappearance of both 
PD-L1 bands and a new band appearing at 33 kDa, which is the expected molecular weight 
of unmodified PD-L1 (Figure 3.9B). Taken together, these data indicated that, as in the case 
of macrovascular endothelial cells, PD-L1 is inducible at the transcriptional level in 
HDLECs responding to inflammatory stimuli. 
 
Figure 3.5. PD-L1 transcription is induced by IFN- and TNF-. A) PD-L1 mRNA fold 
change measured by qRT-PCR after stimulation (as shown, 24 h), normalised to untreated 
(UT) HDLECs. B) Flow cytometric analysis showing PD-L1 surface expression (median 
fluorescence intensity, MFI) after stimulation (24 h) on live HDLECs. An isotype control 
(iso) was used as a negative control and lacks the specificity to bind PD-L1. MFI of PD-L1 
staining: IFN- + TNF- = 994, IFN- = 485, UT = 168, iso = 8.62. One-way analysis of 
variance (ANOVA) was calculated with Tukey's multiple comparisons test. **, p < 0.01 and 
****, p < 0.0001. n = at least 3 independent experiments. 
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Figure 3.6. The effect of titrating IFN- concentration with and without TNF- on PD-
L1 expression. HDLECs were treated (24 h) with increasing amounts of IFN- with or 
without TNF- to observe the effect on PD-L1 mRNA and protein expression. A) qRT-PCR 
showing PD-L1 mRNA expression in HDLECs, normalised to UT, in order of increasing 
IFN- concentration. n = 1 experiment. B) Expression of PD-L1 and STAT protein analysed 
from HDLEC lysates. n = 2 independent experiments, showing one representative 
experiment. 
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Figure 3.7. PD-L1 expression is increased by the combination of IFN- and TNF-. 
Immunofluorescence microscopy showing PD-L1 (Alexa Fluor 488) in HDLECs after 
stimulation (24 h) with IFN-γ, or in combination with TNF-α. Cells were fixed and 
permeabilized prior to staining to show total PD-L1 expression on the surface and in the 
cytoplasm. DAPI (blue) is shown to mark the nucleus. Scale bar = 50 μm. n = 1 experiment. 
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Figure 3.8. The expression of PD-L1 and IL-1 following IFN- and TNF- stimulation. 
A) IL-1 is a known downstream target of TNF- signalling. IL-1 levels were measured by 
qRT-PCR following 24 h stimulation in HDLECs. n = 1 experiment. B) qRT-PCR showing 
time-course of PD-L1 mRNA expression in cells treated with IFN- and TNF- for 8, 24 
and 48 h and normalized to untreated (24 h). n = average of 3 independent experiments.     
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Figure 3.9. Validation of antibody used to detect PD-L1 protein expression. These 
experiments show that the antibody (E1L3N) used to detect PD-L1 is specific from testing 
the knockdown of PD-L1 by siRNA and de-glycosylation of PD-L1. A) Western blot 
analysis following 48 h transfection of siRNA targeting PD-L1. HDLECs were stimulated 
with IFN- and TNF- for 4, 8 and 24 h after siRNA transfection and harvested for protein 
lysates. (B) IFN- and TNF- stimulated lysates were treated with PNGase F and the 
resultant protein was analyzed for de-glycosylation by western blot. 33 kDa marks the size 
of unmodified PD-L1 protein. n = 2 independent experiments, showing one representative 
experiment. 
3.4 Small RNA sequencing of IFN- and TNF--stimulated LECs reveal 
inflammation-responsive miRNAs 
In the previous section, I characterised PD-L1 expression in HDLECs and showed that IFN-
 and TNF- induce significant PD-L1 transcription and affect different pathways of 
characteristics of HDLECs. As described before (Chapter 1), IFN- and TNF- are known to 
regulate miRNA expression in a number of inflammatory conditions. From these results, I 
continued to investigate the effect of inflammatory stimuli on small RNAs using HDLECs, 
where the role of IFN- and TNF- on the small RNA transcriptome had not been 
determined at this point. This would lead to identification of possible candidates that were 
involved in posttranscriptional regulation of PD-L1 during inflammatory responses of 
primary human cells. To achieve this aim, small non-coding RNAs were analysed in 
HDLECs stimulated with or without IFN- and TNF- for 24 h. Harvested RNA were then 
enriched for small RNAs, and processed using next-generation sequencing via the Illumina 
MiSeq workflow (performed by Genomics Technology Facility, University of York). 
Sequencing analysis confirmed detection of small nuclear RNAs (snRNAs), small nucleolar 
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RNAs (snoRNAs) and miRNAs, which made up ~22% of the analysed sample size (Figure 
3.10A). As a result, 48 miRNAs were identified to be differentially regulated by IFN- and 
TNF- (adjusted p < 0.1) (Figure 3.10B). A small sample of 11 miRNAs that were 
upregulated or downregulated were selected for further assessment by qRT-PCR (Figure 
3.10C). We found that IFN- and TNF- resulted in significant upregulation of miR-155-5p, 
miR-4485-3p, miR-218-5p and miR-146a-5p and downregulation of miR-582-5p, miR-582-
3p, miR-93-5p, miR-217 and miR-125b-5p (Figure 3.10 and Tables 3.1A). Analysis of gene 
ontology utilising the miRNA enrichment analysis and annotation tool (Backes et al. 2016) 
indicated that predicted targets of these differentially regulated miRNAs were associated 
with cytokine-mediated signalling and regulation of inflammatory response (Figure 3.10D). 
These data suggest that the miRNA landscape in HDLECs is highly responsive to 
inflammatory stimuli and feedback into pathways associated with stress, proliferation and 
the inflammatory response.   
I tested the following miRNAs which are reported to regulate essential cellular responses 
from angiogenesis to immune responses, for their response to IFN- and TNF- stimulation 
after 24 h to understand the wide-spread effect of inflammatory activation in HDLECs 
(Figure 3.11A, Tables 3.1B). Both miR-126 and miR-221 have been reported to be involved 
in the regulation of angiogenesis (Wang et al. 2008; Fish et al. 2008; Nicoli et al. 2012); 
miR-16 is a regulator of apoptosis and the cell cycle (Cimmino et al. 2005; Linsley et al. 
2007); miR-29a, miR-132 and miR-21 have been demonstrated to regulate different arms of 
immunity (Park et al. 2009; Ma et al. 2011; Lagos et al. 2010; Kumarswamy et al. 2011). 
Expression of miRNA was measured using qRT-PCR, miR-221, miR-126 and miR-16 were 
downregulated after activation. Whereas, inflammatory-associated miR-29a and miR-21 
were upregulated by IFN- and TNF-. Time-course experiments showed that only after 8 h 
of stimulation, the expression of miR-146, miR-21, miR-126 and miR-221 were up- or 
downregulated compared to untreated cells (Figure 3.11B). In comparison to small RNA-seq 
data, there were some discrepancies between the two different forms of expression, 
particularly with miR-21, which is a highly expressed miRNA in HDLECs (Table 3.1B). In 
general, some of the selected miRNAs that are linked key cellular processes responded to 
IFN- and TNF- activation, indicating various cellular processes could be affected by 
changes to the miRNA landscape in HDLECs after inflammatory activation. However, the 
altered expression in most of these miRNAs were modest, compared to the significant 
upregulation of miR-155-5p.       
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3.5 miR-155 is synergistically induced by IFN- and TNF- in HDLECs. 
Having analysed differentially regulated miRNAs from small RNA sequencing, I cross-
compared these with 82 miRNAs predicted to target the 3’-UTR of PD-L1 using TargetScan 
software (Agarwal et al. 2015) Figure 3.12A). 49 detected miRNAs in basal or inflamed 
HDLECs also had predicted binding sites for PD-L1, this amounted to ~8% of total miRNAs 
detected in HDLECs and ~60% of total miRNAs predicted to target PD-L1. Amongst these 
candidate miRNAs was miR-155-5p (referred to as miR-155), which was abundant in 
normal expression and also significantly induced by IFN- and TNF- (Figure 3.12B). Other 
highly induced miRNAs were lowly expressed and can be subjected to high variance.  
I focused on miR-155 as a potential posttranscriptional regulator of PD-L1 expression in 
inflamed HDLECs. First, miR-155 response to IFN- and TNF- was profoundly due to 
TNF- as the primary inducer (Figure 3.12C). IFN- stimulation alone did not change miR-
155 levels but significantly elevated the effect of TNF- on miR-155 expression, suggesting 
a synergistic effect similar to activation of PD-L1. Upregulation of miR-155 by IFN- and 
TNF- was observed as early as 4 h and had a gradual rise, remaining at high levels after 48 
h (Figure 3.12D and E). Increasing the concentration of IFN- induced further miR-155 
expression (Figure 3.12F).    
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Figure 3.10. Identification of several inflammation-responsive miRNAs by small RNA 
sequencing of inflamed HDLECs. A) Percentage distribution of sequencing results from HDLECs, 
showing the total number of hits after a threshold to filter lowly expressed genes was applied (>50 
RPKM). B) Heat map showing fold-change in expression of 48 miRNAs after IFN-γ and TNF-α 
stimulation (24 h) in HDLECs (adjusted p < 0.1). Row Z-score represents mean ± S.D., n = 3 
independent samples performed in triplicate. C) Validation of selected IFN-γ- and TNF-α-regulated 
miRNAs targets by qRT-PCR. Unpaired Student's t test comparing IFN- and TNF- treated samples 
to UT per miRNA, *, p < 0.05, n = 3 independent samples. D) Gene ontology analysis of 48 IFN-γ 
and TNF-α-regulated miRNAs. 
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Figure 3.11. The effects of IFN- and TNF- on selected miRNAs. A) miRNA expression 
in HDLECs measured by qRT-PCR after IFN- and TNF- stimulation (24 h) normalized to 
untreated samples. n = average of 2 independent experiments. B) Time course showing 
kinetics of miRNA expression in HDLECs after 4, 8 or 24 h stimulation, normalised to 
untreated samples (24 h). n = average of 2 independent experiments.    
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Tables 3.1A and B. Validation of IFN- and TNF- regulated targets. A) Table showing 
data from small RNA sequencing and qRT-PCR (Figure 3.10). Values represent average 
fold change of miRNA expression following IFN- and TNF- stimulation (24 h) in 
HDLECs. B) Table showing the effect of IFN- and TNF- stimulation (24 h) on tested 
select miRNAs that have been reported in the literature to regulate angiogenesis, apoptosis 
or inflammation. Increase (red shading) or decrease (blue shading) in miRNA expression 
after IFN- and TNF- treatment (24 h) compared to untreated samples.  
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Figure 3.12. miR-155 is synergistically induced by IFN-γ and TNF-. A) Representing 
the overlap between the total number of detected miRNAs in HDLECs from small RNA 
sequencing and number of miRNAs predicted to target PD-L1 (TargetScan). B) Comparison 
of the 49 miRNAs detected in LECs and predicted to target PD-L1 between average 
expression (log10 RPKM) and change in fold-expression after 24 h IFN-γ and TNF-α 
stimulation (log2). C) Levels of miR-155 were measured by qRT-PCR after stimulation (24 
h) with IFN-γ, TNF-α, or both, normalized to untreated. Statistical test used was ANOVA 
using Tukey's multiple comparisons test, n = at least 3 independent samples. D) Time course 
of miR-155 expression following IFN-γ and TNF- stimulation (8, 24, and 48 h), 
normalized to untreated (24 h). E) Time course of miR-155 expression following IFN-γ and 
TNF-α stimulation (4, 8, and 24 h), normalized to untreated (24 h). F) Expression of miR-
155 were measured by qRT-PCR after stimulation (24 h) with TNF-, or in combination 
with increasing dosage of IFN-, normalized to untreated. *, p < 0.05 and ****, p < 0.0001. 
3.6 miR-155 directly binds to PD-L1 3’-UTR  
There are two potential binding sites for miR-155 on the 3’-UTR of PD-L1 (Figure 3.13A) 
that are conserved in human and mice. Site 1 is located at the far end of the 3’-UTR (2587-
2593) and Site 2 is situated in the middle of the 3’-UTR (1335-1341). Luciferase reporter 
assays were performed to determine direct regulation of PD-L1 by miR-155 (done by Kunal 
Shah, Barts Cancer Institute, UK) (Figure 3.13B). These are reporters that are transfected 
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into cells that can provide an indication of translation efficiency of the mRNA 3’-UTR. In 
addition, this provides an evaluation of the functional relevance of miRNAs on target 
mRNAs. A dual luciferase reporter system (Firefly/Renilla luciferase) is used to provide 
normalisation for the assay and to prevent off-target effects from transfection. The Renilla 
luciferase coding sequence is situated upstream of the 3’-UTR so that any regulation of the 
luciferase, or change in luminescence, is linked to the 3’-UTR itself. While a transfection 
control is provided by the Firefly luciferase. Furthermore, the assay required co-transfection 
of miR-155 mimic which are double-stranded RNA olignonucleotides that are designed to 
function as endogenous, mature miRNAs. A non-targeting mimic was used as a control for 
this particular transfection.  
To investigate whether miR-155 can directly bind to the 3’-UTR of PD-L1, mutagenesis of 
the miR-155 binding sites was performed to prevent binding. Wild-type, single or double 
mutated miR-155 binding sites were co-transfected with miR-155 mimics in HeLa cells 
(Figure 3.13C). Mutation of Site 1 in the PD-L1 3’-UTR led to a significant increase (~35%) 
in luciferase reporter activity compared to wild-type 3’-UTR. Whereas, mutation of Site 2 
had a lower effect (~22%). Mutation of both miR-155 binding sites further enhanced 
luciferase activity (~49%). Constructs containing the wild-type and mutated version of PU.1 
3’-UTR, a previously validated miR-155 target (Vigorito et al. 2007), were used as controls 
for these assays. Compared to wild-type, mutation of PU.1 increased luciferase activity by 
52%. These data suggest that the activity of miR-155 on the 3’-UTR of PD-L1 is relatively 
similar to a known target mRNA.   
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Figure 3.13. miR-155 directly binds to PD-L1 3’-UTR. A) Computer prediction software 
(Targetscan) identified two possible miR-155 binding sites on PD-L1 3’-UTR. B) The PD-
L1 3’-UTR from HeLa cells was subcloned either as wild-type or with mutations introduced 
at miR-155 binding sites (as described in Materials and Methods). A luciferase coding 
sequence is located upstream and linked to the 3’-UTR to measure translation efficiency. C) 
Relative Renilla luciferase (RLuc) to Firefly luciferase (FFLuc) activity for PD-L1 wild-type 
(WT) 3’-UTR, PD-L1 double mutant 3’-UTR, PD-L1 mutant 3’-UTR at 1335-1341 (Site 1) 
and 2587-2593 (Site 2), performed in HeLa cells transfected with miR-155 mimics (48 h). 
The WT and mutated 3’-UTR of PU.1, a known miR-155 target, was used as control. 
Statistical test used was one-way ANOVA using Tukey's multiple comparisons test, n = 3–4 
independent experiments, normalized to non-targeting control (NTC). **, p < 0.01; ***, p < 
0.001; ****, p < 0.0001. 
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3.7 miR-155 regulates PD-L1 expression in response to IFN- and TNF- 
To determine the effect of miR-155 expression on PD-L1, I transfected miR-155 mimics 
into HDLECs to overexpress miR-155 activity (Figure 3.14A and B). This introduced a 104-
fold increase in mature miR-155 expression compared to the NTC mimic. Overexpression of 
miR-155 increased the levels of PD-L1 mRNA in both untreated and IFN- and TNF--
activated HDLECs (Figure 3.14C and D). At protein level, miR-155 overexpression resulted 
in significant downregulation of induced PD-L1 expression after IFN- and TNF- 
stimulation (Figure 3.14E-G). No change in expression was observed in untreated cells. 
Moreover, the expression and phosphorylation of STAT1 were significantly increased in 
untreated and stimulated HDLECs (Figure 3.15A-C).   
Next, I established the function of endogenous miR-155 on PD-L1 expression using miRNA 
inhibitors. These are single-stranded, RNA oligonucleotides that can bind specifically to the 
target miRNA and sequester the function of the miRNA strand. Inhibition of miR-155 
resulted in significant upregulation of IFN- and TNF--induced PD-L1 expression (Figure 
3.16A-C). No significant change was observed in untreated cells or at the mRNA level in 
activated HDLECs. Suppressor of cytokine signalling 1 (SOCS1), a reported target of miR-
155 in macrophages and T reg cells (Androulidaki et al. 2009; Lu et al. 2009) was noticeably 
increased after inhibition of miR-155, although no change upon overexpression of miR-155 
was observed in HDLECs (Figure 3.14). No change in the fold induction of PD-L1 mRNA 
after IFN- and TNF- stimulation was observed, compared to NTC (Figure 3.16D). 
The kinetics of miR-155 activity on the induction of PD-L1 expression were assessed using 
an earlier (8 h) and later (48 h) time-point for IFN- and TNF- stimulation (Figure 3.17A 
and B). Inhibition of miR-155 showed an increase in PD-L1 protein expression at all time-
points compared to NTC. Where between 8-24 h the effect of miR-155 was most noticeable 
and is consistent with my findings on the kinetics of PD-L1 induction by IFN- and TNF- 
in HDLECs. The level of STAT1 was significantly increased in IFN- and TNF--
stimulated cells but resulted in no overall change in relative phosphorylation (Figure 3.18A-
E). Inhibition of miR-155 also increased expression of SOCS1 and STAT3. Taken together, 
these data demonstrate that miR-155 carries the functional capacity to affect the onset and 
maximal levels of PD-L1 expression following IFN- and TNF- activation. This may 
represent an incoherent feed-forward loop where activated HDLECs produce both PD-L1 
and miR-155, which in turn fine-tunes the induction of PD-L1 protein expression.   
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Figure 3.14. miR-155 regulates PD-L1 expression in response to IFN- and TNF-. 
HDLECs were transfected with miR-155 or NTC mimics (48 h) and treated with IFN- and 
TNF- (24 h). A and B) The expression of miR-155 in (A) untreated cells (no cytokine 
stimulation) and (B) IFN- and TNF- treated cells was measured by qRT-PCR and 
normalised to untreated NTC. C and D) PD-L1 mRNA expression was determined in (C) 
untreated cells and (D) treated cells after transfection of NTC / miR-155 mimic and with 
either nil or IFN- and TNF- stimulation by qRT-PCR and normalised to untreated NTC. 
E) Protein expression analysed by western blot following IFN-γ and TNF-α stimulation (24 
h) in HDLECs transfected with miR-155 mimics (48 h). F and G) Quantification of western 
blot analysis on PD-L1 expression in (F) untreated cells and (G) IFN-γ and TNF-α-treated 
cells following miR-155 mimic transfection, normalized to untreated (NTC) and GAPDH 
expression. Unpaired Student's t test was used to compare NTC/miR-155-transfected within 
untreated or IFN- and TNF--treated subgroups. Significance is marked with a p value. n = 
3 independent experiments.  
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Figure 3.15. miR-155 overexpression affects STAT1 protein expression. HDLECs were 
transfected with miR-155 mimics or NTC (48 h) and treated with IFN- and TNF- (24 h). 
Cells were subsequently harvested for protein lysates. A-C) Western blot quantification of 
STAT1 normalised to GAPDH expression in (A) untreated and (B) IFN- and TNF--
stimulated samples, (C) phosphorylated STAT1 expression normalised to total STAT1 levels 
in stimulated samples. Unpaired Student's t test was used to compare NTC/miR-155-treated 
samples within either untreated (no cytokine stimulation) or IFN- and TNF--treated 
subgroups. Significance is marked with a p value. n = 3 independent experiments. 
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Figure 3.16. Inhibition of miR-155 results in increased PD-L1 expression following IFN-
 and TNF- activation. HDLECs were transfected with miR-155 or NTC inhibitors (48 h) 
and treated with IFN- and TNF- (24 h). A) Cells were harvested and analysed for protein 
expression by western blot. B and C) Western blot quantification of PD-L1 expression in the 
presence of miR-155 inhibitors in (B) untreated and (C) IFN- and TNF- samples, 
normalized to untreated (NTC) and GAPDH expression. D) PD-L1 mRNA fold-induction 
following IFN-γ and TNF-α stimulation (24 h) in HDLECs transfected with miR-155 
inhibitors (48 h), measured by qRT-PCR and normalised to respective untreated samples. 
Unpaired Student's t test was used to compare miR-155-treated and NTC samples within 
either untreated (no cytokine stimulation) or IFN- and TNF--treated subgroups. 
Significance is marked with a p value. n = 3 independent experiments. 
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Figure 3.17. miR-155 regulates the kinetics of PD-L1 induction. HDLECs were 
transfected with miR-155 or NTC inhibitors (48 h) and treated with IFN- and TNF-. A) 
Lysates were analysed for protein expression by western blot. B) Western blot quantification 
of time course (A) showing expression of PD-L1 after transfection of miR-155 inhibitors, 
compared to NTC and relative to GAPDH expression. n = 1 experiment. 
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Figure 3.18. miR-155 inhibition affects induced STAT1 expression but not 
phosphorylation. HDLECs were transfected with miR-155 inhibitors (48 h), treated with 
IFN- and TNF- (8, 24 or 48 h) and analysed by western blot. A and B) Quantification of 
STAT1 protein expression after 24 h in (A) untreated and (B) IFN- and TNF--activated 
samples, normalised to GAPDH, as assessed by western blot. C) Quantification of 
phosphorylated STAT1 expression after 24 h, normalised to total STAT1 levels. D) Western 
blot quantification of STAT1 protein expression from time course (Figure 3.17), normalised 
to GAPDH. E) Quantification of phosphorylated STAT1 compared to total levels of STAT1 
from time course (Figure 3.17). Unpaired Student's t test was used to compare miR-155-
treated and NTC samples within either untreated (no cytokine stimulation) or IFN- and 
TNF--treated subgroups. Significance is marked with a p value. n = 3 independent 
experiments. 
3.8 HFF characterisation of PD-L1 expression and kinetics 
Next, I wanted to determine whether regulation of PD-L1 by miR-155 in vascular cells could 
occur in a stromal cell type. To this aim, primary human foreskin fibroblasts (HFFs) were 
characterised for PD-L1 and miR-155 expression. At basal levels, PD-L1 is lowly expressed 
but inducible by IFN- and TNF- in HFFs (Figure 3.19A). IFN- was the main inducer of 
PD-L1 and expression correlated with an increase in phosphorylation of STAT1. This was 
further amplified in combination with TNF-, which was translated to expression at the cell 
surface level (Figure 3.19B). PD-L1 is transcriptionally induced by IFN- and transcripts are 
clearly elevated in a synergistic pattern in combination with TNF- stimulation (Figure 
3.20A). Expression of IL-1β is also enhanced by TNF- and further increased with IFN- 
(Figure 3.20B). Although, IFN- stimulation alone does not affect IL-1β. I found that miR-
155 is similarly induced in response to inflammatory stimuli at a similar fold change to 
HDLECs (Figure 3.21A and B). In activated HFFs, miR-155 reached peak levels of 
expression at 24 h and stayed at high levels until 48 h. 
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Next, I overexpressed miR-155 expression using mimics in HFFs, which resulted in 
downregulation of induced PD-L1 protein expression (Figure 3.22A-C). An increase in 
phosphorylated STAT1 was observed as well as increased PD-L1 mRNA. Inhibition of miR-
155 in activated HFFs led to an increase in PD-L1 expression (Figure 3.23A-C). No 
significant change in PD-L1 mRNA. Furthermore, a time-course showed that overexpression 
of miR-155 controlled the kinetics of miR-155 induction between 8 and 48 h (Figure 3.24). 
Whereas, the effects of inhibiting miR-155 activity were also seen as early as 8 h on PD-L1 
expression. Altogether, these results suggest that miR-155-mediated suppression of PD-L1 is 
not limited to HDLECs and is observed in other primary dermal cells reacting to 
inflammatory stimuli.  
 
Figure 3.19. PD-L1 is expressed in HFFs and can be synergistically induced by IFN- 
and TNF-. Human foreskin fibroblasts (HFFs) were assessed for expression of PD-L1 at 
both total and surface protein level using two different analytical techniques. A) Western 
blot analysis following 24 h stimulation of HFFs with IFN- and TNF-. B) Flow cytometric 
analysis showing PD-L1 surface expression (MFI) after stimulation (24 h) on live HFFs. 
MFI of PD-L1 staining: IFN- + TNF- = 5301, IFN- = 1583, UT = 255, iso = 25.7. 
74 
 
 
Figure 3.20. Effect of IFN- and TNF- activation on PD-L1 and IL-1 transcription. 
A) PD-L1 and B) IL-1 mRNA levels in HFFs were measured by qRT-PCR after 
stimulation (24 h), data is normalized to untreated. One-way ANOVA was calculated with 
Tukey's multiple comparisons test for (A), n = average of 3 independent experiments. (B), n 
= average of 2 independent experiments. **, p < 0.01.    
 
Figure 3.21. Effect of IFN- and TNF- activation on miR-155 expression levels.  A) 
miR-155 expression was measured by qRT-PCR following stimulation (24 h) in HFFs and 
normalized to untreated. Statistical test used was one-way ANOVA using Tukey's multiple 
comparisons test. B) Time course of miR-155 expression after IFN-γ and TNF- stimulation 
(8, 24, and 48 h) and normalized to untreated (24 h), n = 3 independent samples. 
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Figure 3.22. miR-155 regulates PD-L1 expression in response to IFN- and TNF- in 
HFFs. A) Protein expression following IFN-γ and TNF- stimulation (24 h) in HFFs 
transfected with miR-155 mimics (48 h). Western blot quantification of PD-L1 normalized 
to IFN-γ and TNF- treated NTC with average expression and standard deviation stated 
below (n = 2 independent experiments). B and C) PD-L1 mRNA expression in (B) untreated 
or (C) IFN-γ and TNF--stimulated (24 h) HFFs transfected with miR-155 mimics (48 h).  
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Figure 3.23. Inhibition of miR-155 increases PD-L1 expression following IFN- and 
TNF- activation in HFFs. A) Protein expression following IFN-γ and TNF- stimulation 
(24 h) in HFFs transfected with miR-155 inhibitors (48 h). Western blot quantification of 
PD-L1 normalized to IFN-γ and TNF- treated NTC with average expression and standard 
deviation stated underneath (n = 2 independent experiments). B and C) PD-L1 mRNA 
expression in (B) untreated or (C) IFN-γ and TNF--stimulated (24 h) HFFs transfected with 
miR-155 inhibitors (48 h).    
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Figure 3.24. Time-course to show effect of overexpression/inhibition of miR-155 on PD-
L1 expression following IFN- and TNF- activation in HFFs. Protein expression 
following IFN-γ and TNF- stimulation (8, 24, 48 h) in HFFs transfected with miR-155 
mimics (left side) or miR-155 inhibitors (right side) (48 h). n =1 experiment.  
3.9 Overexpression of miR-218 alters constitutive and induced PD-L1 
expression 
From the small RNA sequencing, I identified other miRNAs that are regulated by IFN- and 
TNF- stimulation including the expression of miR-218-5p (referred to as miR-218) (Figure 
3.10B). Validation of miR-218 showed that this was on average the second highest miRNA 
induced by IFN- and TNF- (~3 fold) (Figure 3.10C). Furthermore, miR-218 is strongly 
induced by TNF- and to a lesser extent by IFN-, however, there seemed to be no 
synergistic activation of miR-218 with both cytokines (Figure 3.25A). Similar to 
experiments with miR-155, I transfected miR-218 mimics into HDLECs to determine its 
functional relevance (Figure 3.25B). Although, Targetscan did not predict any binding sites 
for PD-L1, overexpression of miR-218 resulted in an increase to constitutive and induced 
PD-L1 protein expression HDLECs (Figure 3.26A). Levels of PD-L1 mRNA expression 
were also increased with miR-218 overexpression compared to NTC but in a similar manner 
to miR-155 (Figure 3.26B). In addition, there was an increase to phosphorylated levels of 
STAT1. The 3’-UTR of PROX1 was predicted to have miRNA binding sites for miR-155 
and miR-218, however, protein expression of PROX1 remained unchanged after 
overexpression of either miRNA (Figure 3.26A). 
To test miR-218 regulation of PD-L1 expression in other cell types, I found that miR-218 is 
also induced in HFFs by IFN- and TNF- (Figure 3.27A). Overexpression of miR-218 
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using mimics elevated PD-L1 expression in both untreated and treated cells and similarly 
PD-L1 mRNA expression was increased compared to NTC (Figure 3.27B and C). These 
data suggest that there may be a form of regulation of PD-L1 by miR-218, however, the 
mechanism of action remains unclear since there are no predicted miR-218 binding sites on 
the 3’-UTR of PD-L1. Other possibilities could include miR-218-mediated activation of PD-
L1 translation via the 5’-UTR or relief of repression by suppressing a negative regulator of 
PD-L1 (Vasudevan 2012).                 
 
Figure 3.25. miR-218 expression is regulated by IFN- and TNF-. A) miR-218 
expression was measured by qRT-PCR following stimulation (24 h) in HDLECs and 
normalized to untreated. Statistical test used was one-way ANOVA using Tukey's multiple 
comparisons test. n = 3 independent experiments. B) HDLECs were transfected with miR-
218 mimics (48 h) and treated with IFN- and TNF- (24 h). The expression of miR-218 
was measured by qRT-PCR and normalised to untreated NTC.  *, p < 0.05.  
79 
 
 
Figure 3.26. Overexpression of miR-218 induces expression of PD-L1 in HDLECs. 
HDLECs were analysed following IFN-γ and TNF- stimulation (24 h) in cells transfected 
with miR-155 or miR-218 mimics (48 h). A) Protein expression assessed by western blot 
and B) PD-L1 mRNA expression measured by qRT-PCR. n = 2 independent experiments. 
 
Figure 3.27. Overexpression of miR-218 induces expression of PD-L1 in HFFs. A) miR-
218 expression was measured by qRT-PCR in HFFs treated with IFN- and TNF- (24 h). B 
and C) HFFs were analysed following IFN-γ and TNF- stimulation (24 h) in cells 
transfected with miR-155 or miR-218 mimics (48 h). B) Protein expression assessed by 
western blot and C) PD-L1 mRNA expression measured by qRT-PCR. n = 2 independent 
experiments. 
3.10 Dicer knockdown does not affect PD-L1 protein expression in LECs 
Having demonstrated that PD-L1 protein expression is regulated at the posttranscriptional 
level by miRNAs, I further investigated whether Dicer activity had the capacity to modulate 
PD-L1. Dicer is essential for the majority of miRNA biogenesis and silencing (Kim et al. 
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2016), and has been shown in HUVECs to regulate a subset of miRNA profiles including 
miR-126 and angiogenesis (Kuehbacher et al. 2007; Suárez et al. 2007). By silencing Dicer, 
this would potentially provide information on the larger effect of miRNA regulation of PD-
L1. These experiments analysed the knockdown of Dicer in untreated and IFN- and TNF--
stimulated LECs. I confirmed loss of Dicer expression after cells were transfected with 
siRNAs targeting Dicer (Figure 3.28A). PD-L1 protein expression remained largely 
unaffected in cells with Dicer knockdown, compared to control, and there was some 
decrease in PD-L1 mRNA expression (Figure 3.28B). In addition, Dicer knockdown had a 
modest decrease in the expression of miR-126, miR-155 and miR-218 in untreated cells but 
did not have any effect in the induced expression of miR-155 or miR-218 (Figure 3.28C). 
Altogether, these data show that Dicer knockdown in LECs result in an incomplete 
inhibition of miRNAs, and that Dicer does not directly affect PD-L1 protein expression. 
Kuehbacher et al. also reported that a subset of miRNAs were reduced after Drosha and 
Dicer silencing, which may be due to insufficient knockdown of protein or a higher stability 
of some miRNAs (Kuehbacher et al. 2007). This could suggest that some miRNAs have a 
longer half-life and a time-course experiment to observe the effects of Dicer knockdown 
could be performed (Rüegger & Großhans 2012). An alternative method would be to 
knockdown AGO2, which is reported to be the most critical of all AGO in the miRNA 
pathway and can significantly affect both protein activity and mRNA levels (Schmitter et al. 
2006).  
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Figure 3.28. Dicer knockdown does not affect PD-L1 protein expression in LECs. 
Transfection of LECs with siRNAs targeting non-targeting control (NTC), Dicer and PD-L1 
(48 h) was followed by IFN-γ and TNF- stimulation (24 h). A) Protein expression in 
untreated and IFN-γ and TNF--stimulated LECs. B) PD-L1 mRNA expression was 
measured by qRT-PCR. C) miR-126, miR-155 and miR-218 expression were analysed by 
qRT-PCR. n = 3 independent experiments.     
3.11 Chapter discussion 
In this chapter, I assessed PD-L1 expression, the miRNA landscape and lineage commitment 
markers of primary cells in response to pro-inflammatory cytokines IFN- and TNF-. The 
main finding in this chapter reveals an incoherent feed-forward loop that is initiated by IFN-
 and TNF- which induces PD-L1 expression (Figure 3.29). Concurrently, IFN- and TNF-
 promotes the induction of PD-L1 targeting miRNAs. I identified miR-155 as a 
posttranscriptional regulator of PD-L1 that fine-tunes the kinetics and maximal levels of PD-
L1 induction in primary dermal cells responding to inflammation. This is in contrast to miR-
513 which blocks the induction of PD-L1 but is suppressed by IFN- signalling (Gong et al. 
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2009). In addition, miR-218 is also induced by IFN- and TNF- in primary cells and acts to 
increase PD-L1 expression. Overall, the data reveal that miRNAs induced in response to 
inflammation are critical components of regulatory loops that can control the expression of 
immune checkpoint molecules and thereby mediate a functional role in immunosuppression. 
 
Figure 3.29. The IFN-/TNF-/miR-155/PD-L1 incoherent feed-forward loop. Cartoon 
depicting the inflammatory activation of cells by IFN- and TNF-, which leads to the 
production of both PD-L1 and miR-155. PD-L1 expression mediates immune tolerance, 
whereas the effect of miR-155 is to directly inhibit the induced expression of PD-L1 protein 
to promote inflammation. IFN- and TNF- regulates the initial induction of PD-L1 and 
fine-tunes the expression of PD-L1 via miR-155 in a balance between inflammation and 
tolerance. 
miR-155 regulates PD-L1 protein expression 
The finding that miR-155 regulates PD-L1 expression is significant. As briefly mentioned, 
miR-155 is a known multifunctional modulator of immune system and primary component 
of the inflammatory response (Chapter 1.2.4). The mechanism of this regulatory loop is 
presumed to be the blocking of PD-L1 translation or protein synthesis rather than affecting 
the degradation of PD-L1 mRNA. In addition, the effects of miR-155 on the JAK/STAT 
pathway cannot be ruled out and may contribute towards overall PD-L1 protein expression.  
miR-155 is described in many aspects of the immune system, where it has a crucial role 
towards to the development and maintenance of the immune response. miR-155 was first 
described as B-cell integration cluster (bic) in chickens (Tam et al. 1997). The precursor of 
miR-155 in chickens is encoded within bic exon 2 and that miR-155 is also expressed in 
mice and humans (Lagos-Quintana et al. 2002). The stem-loop sequence of pre-miR-155 has 
high evolutionary conservation in the region that corresponds to mature miR-155. In several 
types of B cell lymphomas and solid tumours, miR-155 expression is abnormally expressed, 
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where it is regarded as an oncomir and associated with unfavourable prognosis (Eis et al. 
2005; Volinia et al. 2006; Yanaihara et al. 2006). In the mammalian immune system, miR-
155 is responsible for regulating a broad range of immune cell types including subsets of T 
cells, B cells and DCs. Mice with mutant miR-155 have normal numbers of most lymphoid 
and myeloid subsets (Vigorito et al. 2013). However, the importance of miR-155 is shown 
upon activation of cells, where mutant bic/miR-155 mice are found to be immune-deficient 
and have impaired lymphocyte responses, including failure of DCs to efficiently activate T 
cells (Rodriguez et al. 2007). In response to B cell receptor (BCR) activation, miR-155 is 
induced where it directly inhibits the transcription factor PU.1 (Lu et al. 2014). This enables 
plasma cell commitment in the germinal centre due to downregulation of PAX5. If the miR-
155 binding site on PU.1 mRNA is mutated, this leads to increased PU.1 expression during 
B cell activation with defective class-switch recombination and plasma cell differentiation. 
Moreover, activation-induced deaminase (AID), required for class-switch recombination and 
somatic hypermutation, is upregulated in response to BCR signalling and the expression of 
AID can be repressed by miR-155 affecting B cell immune function (Teng et al. 2008). In 
addition, miR-155 is required for production of immunoglobulin class-switch differentiation 
of B cells by targeting transcription factor PU.1 (Vigorito et al. 2007). Upon T cell 
activation, miR-155 is induced and promotes Th1 differentiation by targeting IFN-R in 
Th1 cells (Thai et al. 2007; Banerjee et al. 2010). Given that miR-155 regulates several 
processes in immune cells, my results show an additional mechanism that miR-155 can 
potentially regulate the activation of the immune response through immune checkpoint 
expression.    
A broad range of inflammatory cytokines induce the activation of miR-155 including LPS, 
poly I:C and TNF- (O’Connell et al. 2007; Tili et al. 2007; Stanczyk et al. 2008; Ceppi et al. 
2009). Induction of miR-155 was found to be dependent on  TNFR1 and JNK signalling in 
macrophages (O’Connell et al. 2007). Both IFN- and TNF- were shown to induce miR-
155 expression in mesangial cells and cells of the retinal pigment epithelium (Imaizumi et al. 
2010; Villarino et al. 2017). Here, I identified a consistent finding in primary dermal cells 
that miR-155 is synergistically enhanced by IFN- and TNF-. Up to now, TNF- was 
associated with stabilisation of PD-L1 through NF-B signalling (Lim et al. 2016). I show 
here that TNF- is required for maximal induction of PD-L1 where it may also regulate the 
localisation of PD-L1 to the cell surface.         
The association between inflammatory activation, miR-155 and PD-L1 reveals the existence 
of an incoherent feed-forward loop in primary stromal fibroblasts/vascular cells. Moreover, a 
regulatory loop involving miR-155 was found in macrophages where TLR4 signalling is 
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activated by LPS (Androulidaki et al. 2009). This led to differential expression of miRNAs 
such as miR-155 which enhanced TLR4 signalling. Stimulation of LPS also induced 
expression of Akt, which was found to regulate miR-155 expression and response of 
macrophages to LPS. My findings show that at least the phosphorylation of Akt S473 is 
downregulated at 16 and 24 h which may affect the expression of miR-155.  
SOCS1 is a regulatory negative feedback mechanism of several cytokine signalling 
pathways including IFN-/STAT1 signalling which inhibits the activity of JAK 
phosphorylation and has been demonstrated to be a direct target of miR-155 in human and 
mice (Androulidaki et al. 2009; Lu et al. 2009). In some cases, miR-155 expression is 
inversely correlated with SOCS1, as shown in breast cancer (Jiang et al. 2010). 
Overexpression of miR-155 has been shown to decrease SOCS1 and increase 
phosphorylation levels of JAK2 and phospho-STAT3 (Jiang et al. 2010; Zhao et al. 2013; 
Rasmussen et al. 2015). Furthermore, disrupting miR-155 regulation of SOCS1 in T regs, 
CD8+ T cells and NK cells was shown to affect the immune response during autoimmunity 
and infection (Lu et al. 2015).     
Interestingly, miR-155 suppresses expression of SOCS1 leading to enhanced STAT1 
phosphorylation in macrophages (Wang et al. 2010), miR-155-deficient CD8+ T cells 
display enhanced levels of STAT1 phosphorylation (Gracias et al. 2013). I observed that 
inhibition of miR-155 increased SOCS1 expression although overexpression of miR-155 did 
not affect SOCS1 levels in HDLECs. Moreover, we found no increase in STAT3 after miR-
155 overexpression but rather an increase in phospho-STAT3 at 8 h after inhibiting miR-155. 
Additionally, I found that overexpression and inhibition of miR-155 both increased the 
levels of STAT1 indicating the existence of dose-dependent effects, in agreement with 
previous reports (Gracias et al. 2013; Lin et al. 2015). Inflammatory conditions promote the 
expression of miR-155, which through the regulation of SOCS1 and PD-L1 in different cell 
types, can have potential pro-inflammatory effects. 
Overexpression of miR-218 regulates PD-L1 protein expression 
Of the validated miRNAs that were selected from small RNA sequencing, miR-93-5p as part 
of the miR-25-93-106b cluster (Cioffi et al. 2017) and miR-217 (Miao et al. 2017) were later 
shown to regulate PD-L1 in cancer cells. I also identified that miR-218 is induced by IFN- 
and TNF-. miR-218 has been shown to affect endothelial cell angiogenesis and migration 
(Small et al. 2010) and LPS-induced inflammation (H. Zhao et al. 2014) through targeting of 
the Slit-Robo pathway. Slit2 upregulates miR-218 expression which in turn inhibits Robo1 
protein expression and produces an anti-inflammatory effect by suppressing LPS-induced 
signalling of the NF-B pathway. In some cancers, miR-218 is downregulated suggesting 
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miR-218 acts as a tumour suppressor (Venkataraman et al. 2013; Mathew et al. 2014). An 
indirect target of miR-218 was found to be HIF-2 through its activity on multiple 
components of receptor tyrosine kinase signalling pathways such as EGF (Mathew et al. 
2014). My findings show that overexpression of miR-218 increases the expression of PD-L1, 
while not a direct 3’-UTR target of miR-218. Although HIF-2 has been shown to regulate 
PD-L1 in hypoxic conditions (Messai et al. 2016), it is unlikely that primary dermal cells 
would produce much HIF-2 to affect PD-L1 expression. In untreated cells, overexpression 
of miR-218 increased some PD-L1 expression suggesting this may not be due to the anti-
inflammatory effects of miR-218. This mechanism of miR-218 regulation of PD-L1 
expression remains unexplained. RNA-binding proteins such as Pumilio (PUM1, PUM2) 
bind to the 3’-UTR of certain mRNAs and can act on mRNA stability or repression of 
translation (Vasudevan 2012). Using TargetScan, miR-218 has conserved binding sites for 
both PUM1 and PUM2 that could relief repression of PD-L1 mRNA translation. Overall, I 
showed that IFN- and TNF- activation of miRNAs can lead to up- and downregulation of 
PD-L1 expression. 
Loss of LEC lineage commitment markers in response to IFN- and TNF- treatment 
There was a significant decrease in all tested LEC lineage commitment markers (PROX1, 
VEGFR3, COUP-TFII and LYVE1) after IFN- and TNF- activation. PROX1 and 
VEGFR3 regulate LEC differentiation and maintenance of lineage and downregulation of 
these molecules suggests that the integrity or growth of LECs was affected. Several reports 
have indicated that inflammation or TNF- stimulation can lead to reduced PROX1 and 
LYVE-1 expression (Vigl et al. 2011; Huggenberger et al. 2011; Johnson et al. 2007; Oka et 
al. 2008). Activation of lymphatic vasculature can limit skin inflammation through 
promotion of fluid drainage and reduction of edema formation (Huggenberger et al. 2011). 
In addition, T cells can suppress growth of lymphatic vasculature through the production of 
IFN-, whereas B cells do not in vivo (Kataru et al. 2011). In T cell deficient models, there is 
an increase of LN lymphatic vasculature accompanied with higher levels of antigen-carrying 
DCs. T cells moderate immune responses through the lymphatic vasculature which respond 
to IFN- in order to maintain homeostasis (Kataru et al. 2011). A further study using a 
mouse melanoma model (K14-VEGFR3-Ig) that lacked LYVE-1+ dermal lymphatic vessels 
found that lymphatic vessel remodelling and drainage was key for tumour-associated 
inflammation and immunity (Lund et al. 2016). There was a decrease in the number of 
infiltrating immune cells (CD8+ T cells) and reduced trafficking of DCs from the tumour to 
the LN. 
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IL-3 has been reported to upregulate PROX1 through NF-B activation and both IL-3 and 
LPS can upregulate VEGFR3 expression, indicating inflammatory factors can also induce 
LEC commitment markers (Gröger et al. 2004; Flister et al. 2010). PROX1 synergises with 
the p50 subunit but not p65 of NF-B to induce VEGFR3 expression (Flister et al. 2010). 
Since NF-B is also an effector of downstream TNF- signalling, my results support that 
NF-B regulates PROX1 expression. However, the stimulus may affect how the expression 
of PROX1 is regulated. Another explanation for the loss of lineage commitment markers 
could be due to the de-differentiation of LECs to BEC-like cells in response to physiological 
challenge (Srinivasan et al. 2007; Johnson et al. 2008). The plasticity of endothelial cells has 
been demonstrated from the switch between BEC to LEC in Kaposi’s sarcoma (Hong et al. 
2004; Wang et al. 2004).         
Conclusion 
Based on the above, I propose that miR-155 affects the JAK/STAT pathway through 
multiple mechanisms, likely in a cell type-specific manner. The observed effects of miR-155 
mimics and inhibitors on PD-L1 protein expression in combination with the direct binding of 
the miRNA to the PD-L1 3’-UTR, demonstrate that direct targeting of PD-L1 by miR-155 is 
a crucial component of the cytokine receptor (IFNGR or TNFR)/miR-155/PD-L1 network. 
Overall, this study provides a novel perspective on the posttranscriptional regulation of PD-
L1 during inflammation. I reveal a number of potentially PD-L1-targeting miRNAs as 
responsive to inflammatory challenge. These include miR-155, a multifunctional miRNA 
which plays a primary role in inflammation and can be induced by a broad range of 
inflammatory mediators. Concomitantly, I show that PD-L1 is induced in HDLECs upon 
inflammation and contributes towards immune suppression which is in line with previous 
findings in macrovascular endothelial cells (Mazanet & Hughes 2002; Rodig et al. 2003). 
Having shown that both IFN- and TNF- are required for miR-155 regulation of PD-L1 in 
vitro, it would be unlikely in this context that either IFN- or TNF- stimulation alone could 
induce this regulation. A limitation of this study would be that inflammatory environments 
are more complex than two cytokines and further experiments would be required to test this 
mechanism in pathological contexts such as in chronic inflammation. I show that in dermal 
vascular and stromal cells, miR-155 acts to suppress PD-L1 induction to potentially fine-
tune the immune response. Moreover, miR-155 is expressed by a variety of immune cells 
and frequently overexpressed in cancer and chronic inflammatory diseases. miR-155 was 
shown to regulate the expression of CTLA-4, a negative regulator of T cell activation, in 
atopic dermatitis suggesting miR-155 contributes to chronic inflammation (Sonkoly et al. 
2010). My findings contribute to the overall understanding of PD-L1 regulation in 
physiological and pathological contexts. 
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4. miRNA regulation of PD-L1 in in cancer cells 
4.1. Introduction 
From Chapter 1, I outlined the regulation of PD-L1 in cancer and in Chapter 3, identified 
miRNAs that regulate PD-L1 protein expression with a focus on miR-155. Both PD-L1 and 
miR-155 can have aberrant expression in several types of cancer (X. Wang et al. 2016; 
Bayraktar & Van Roosbroeck 2018). PD-L1 is expression is associated with poor clinical 
outcome in multiple cancers including renal cell carcinoma, bladder cancer (X. Wang et al. 
2016). However, the expression of PD-L1 in lung cancer and melanoma can have both 
positive and negative prediction values suggesting using PD-L1 as a predictive biomarker 
can be limited. The expression of PD-L1 is heterogeneous which can be affected by a 
number of factors as described in Chapter 1, including miRNAs. Additional biomarkers 
could be used to facilitate those patients that can benefit from immunotherapy such as using 
miRNA biomarkers. Levels of miR-155 are often overexpressed in a variety of cancers such 
as B cell lymphoma, acute myeloid leukaemia, and solid tumours (breast, colon, lung 
cancers), frequently associated with poor prognosis (Eis et al. 2005; Faraoni et al. 2012). 
There are multiple cellular processes that miR-155 can affect which include tumour growth, 
migration and invasion of cells and EMT (Bayraktar & Van Roosbroeck 2018). Additionally, 
miR-155 has been associated with resistance to systemic chemotherapy and radiotherapy in 
different types of cancer. There is a requirement for more understanding in the function and 
immunoregulatory role of miR-155 in cancer cells. The findings of this chapter characterise 
the levels of PD-L1 and miR-155 found in a selection of cancer cell lines and indicate that 
miR-155 could regulate PD-L1 expression in cancer cells. 
To extend my findings from primary cells, I investigated whether the mechanism of PD-L1 
regulation by miR-155 is similar in cancer cells. The Cancer Genome Atlas (TCGA) 
Research Network has produced a large amount of data that is publicly available (The 
Cancer Genome Atlas Research Network et al. 2013). The data was accrued from 
characterisation of 33 different cancer types including 10 rare cancers (see Table 4.1 for 
specific details) which were selected for their poor prognosis and overall public health 
impact. The TCGA aimed to generate and interpret, quality-controlled molecular profiles at 
the DNA, RNA, protein and epigenetic levels for several hundreds of clinical tumours. The 
Pan-Cancer analysis project was a collaboration between many researchers of the TCGA 
research network that coordinated a collection of data at the Broad Institute’s Firehose and 
the Memorial Sloan-Kettering Cancer Centre’s cBioPortal for automated analysis. 
Sequencing data included miRNA and mRNA sequencing data. The TCGA data for miRNA 
sequencing were then analysed by Chu and colleagues using a computational pipeline as to 
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allow for consistent comparison with other TCGA sequencing datasets (Chu et al. 2016). I 
used the normalised data (available at https://gdc.cancer.gov/about-
data/publications/pancanatlas) to understand the different levels of tumour expression of PD-
L1 and miR-155 in cancer cells that I would be experimenting with. I matched the 
corresponding RNA or miRNA value (these are obtained from two separate files named 
‘RNA (Final)’ and ‘miRNA (Batch Effects Normalised miRNA data’) with the patient and 
type of cancer (which can be found in the ‘Merged_sample-quality_annotations’ and 
‘sample list’ files) found in the supplemental data section.    
Overall, there is a large variation of PD-L1 and miR-155 expression in the different tumour 
types analysed. There is no clear positive or negative correlation between miR-155 and PD-
L1 suggesting the possibility of tumour-specific posttranscriptional regulation. 
4.2. RNA expression of miR-155 and PD-L1 in 33 tumour types 
Using publicly available sequencing data from TCGA, the median expression of miR-155 
could be presented to show comparisons between 33 different tumour types. Of note, the 
data does not draw comparisons between non-transformed or cancer cells and in addition 
there were a low quantity of glioblastoma multiforme (GBM) samples analysed for miRNA 
sequencing. miR-155 is associated with the pathogenesis of various types of haematological 
malignancies. The data showed that the levels of miR-155 were highest in diffuse large B 
cell lymphoma (DLBC), acute myeloid leukaemia (LAML) and in skin cutaneous 
melanomas (SKCM) (Figure 4.1 and Figure 4.2). Moreover, miR-155 expression was lowest 
in cancers of the CNS and endocrine as determined by the median expression of these cancer 
types. In terms of PD-L1, mRNA expression was also highest in a rare haematological 
cancer, thymoma, followed closely by two types of lung cancer, lung squamous cell 
carcinoma and lung adenocarcinoma, and head and neck squamous cell carcinoma (HNSC) 
(Figure 4.3). Lowest expression of PD-L1 was found in rare cancers uterine carcinosarcoma 
(UCS) and adrenocortical carcinoma (ACC). By comparing both miR-155 and PD-L1 
together, DLBC express high levels of both miR-155 and PD-L1, whereas LAML only 
expresses high levels of miR-155 (Figure 4.3). Relatively, both lung cancer types and head 
and neck cancers express high levels of PD-L1 and above global median levels of miR-155. 
Although there is high expression of PD-L1, low expression of miR-155 is found in 
pheochromocytoma and paraganglioma (PCPG), kidney chromophobe (KICH) and prostate 
adenocarcinoma (PRAD). These data show that miR-155 and PD-L1 expression differ in 
many types of cancer, including within the same broad category of cancer and there is no 
clear correlation between the two factors, across the 33 tumour types analysed (Pearson r 
correlation coefficient = +0.1523). 
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Table 4.1. 33 tumour types were sampled by the TCGA network. Table shows details of 
acquired sequencing data from TCGA (see Figure 4.1 for full details), showing number of 
samples for all 33 tumour types, with abbreviations described. CNS = central nervous 
system; GI = gastrointestinal. *denotes rare cancers, 10 of which were characterised in the 
study. Sample size was determined by the number of data available from supplementary files 
found on the NCI Genomic Data Commons data portal (https://gdc.cancer.gov/about-
data/publications/pancanatlas). Note: not all samples had both values for miR-155 and PD-
L1 (i.e. see GBM).  
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Figure 4.1. The expression of miR-155 and PD-L1 across 33 tumour types. Pre-
normalised sequencing data from The Cancer Genome Atlas (TCGA) comparing 33 tumour 
types gathered by the Pan-Cancer Atlas initiative was acquired from the NCI Genomic Data 
Commons data portal (https://gdc.cancer.gov/about-data/publications/pancanatlas). A) 
miRNA-seq analysis showing expression of miR-155 (normalised to reads per million 
mapped reads, RPM), data was originally generated by the Michael Smith Genome Sciences 
Centre and normalised using a computational pipeline (Chu et al. 2016). Tumour type and 
expression miR-155 of samples were then paired and sorted from low to high expression. A 
global median (271.7422 RPM) across all tumour types was calculated (red dotted line). B) 
RNA-seq analysis showing expression of PD-L1 mRNA expression (data was normalised 
using two related methods: fragments per kilobase of transcript per million mapped reads, 
FPKM, and FPKM upper quartile methods). Tumour type and expression PD-L1 mRNA of 
samples were also paired and sorted from low to high expression. A global median (24.5025 
FPKM) across all tumour types was calculated (red line). Abbreviations for tumour types 
detailed in Table 4.1. For sample size, see Table 4.1.            
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Figure 4.2. Expression of miR-155 (blue) and PD-L1 mRNA (red) in different types of 
tumours. Different cancers were grouped based on location and the median value of PD-L1 
mRNA (red) and miR-155 (blue) expression for each tumour type was calculated and plotted 
on the above graph. The global median value taking into consideration all 33 tumour types 
was then calculated to allow comparison for each tumour type: miR-155 (blue line; 
271.7422 RPM) and PD-L1 (red line; 24.5025 FPKM). CNS = central nervous system; GI = 
gastrointestinal. For sample size, see Table 4.1. 
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Figure 4.3. Tumour types sorted for increasing expression of either miR-155 (blue) or 
PD-L1 mRNA (red). The median value of PD-L1 mRNA (red) and miR-155 (blue) 
expression for each tumour type was sorted in terms of increasing expression. Expression of 
miR-155 (blue) with PD-L1 mRNA (red), A) where miR-155 expression is sorted from low 
to high-expressing tumour types and PD-L1 expression is unsorted. B) Where PD-L1 mRNA 
expression is sorted from low to high-expressing tumour types and miR-155 levels are 
unsorted. Data shown represents the median expression for each tumour type based on the 
sample size from Table 4.1. Global medians, calculated across all tumour types, are 
displayed for miR-155 (blue line; 271.7422 RPM) and PD-L1 (red line; 24.5025 FPKM).    
4.3. Expression and kinetics of miR-155 and PD-L1 in human cancer cell lines 
Next, I investigated PD-L1 expression in a series of human cancer cell lines, including a 
renal cell carcinoma line (RCC4), a metastatic breast adenocarcinoma cell line (MDA-MB-
231) and a lung adenocarcinoma cell line (A549). All three cancer cell lines expressed 
differing levels of PD-L1 and miR-155 upon induction by inflammatory stimuli which could 
be used to test whether miR-155 regulation of PD-L1 was a general mechanism in different 
cancer cell types. I aimed to characterise PD-L1 and miR-155 expression in the available 
cancer cell lines and investigate the interaction between miR-155 and PD-L1 in this context.   
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4.3.1. miR-155 regulates PD-L1 in a renal cell cancer line 
Renal cell carcinoma (RCC) accounts for up to ~85% of kidney cancer diagnoses, of which 
the clear cell renal cancer subtypes form around ~75% of renal cell cancers. RCC subtypes 
are generally characterised by loss-of-function mutations of the tumour suppressor von 
Hippel-Lindau (VHL) gene in up to 90% of clear cell RCC (Brodaczewska et al. 2016). 
VHL is associated with regulation of HIF, acting as an E3 ubiquitin ligase which targets HIF 
for proteasomal degradation. HIF is involved in a number of cellular processes such as 
growth, apoptosis, angiogenesis and metabolism (Brodaczewska et al. 2016). HIF-1 has 
been shown to upregulate PD-L1 expression in various types of cancer cells (Noman et al. 
2014; Barsoum et al. 2014). Furthermore, VHL mutation status was demonstrated to 
correlate with PD-L1 expression in clear cell renal tumours (Messai et al. 2016; Kammerer-
Jacquet et al. 2017).  
The RCC4 line is a clear cell renal cancer that has mutated VHL and the cell line is often 
used to model VHL-dependent mechanisms in comparison to RCC4 cells that have been 
transfected with VHL to restore this function. Suppression of HIF-1 or HIF-2 caused a 
significant decrease in PD-L1 mRNA and protein expression in RCC4 cells (Messai et al. 
2016). Moreover, VHL was reported to be involved in regulation of miRNAs in renal cancer 
including miR-155 (Neal et al. 2010). It was demonstrated that in RCC4 cells without VHL, 
miR-155 was upregulated compared to RCC4 cells with transfected VHL. Induction of miR-
155 was determined to be a HIF-dependent mechanism. Furthermore, miR-155 is expressed 
significantly higher in renal tumours than in normal tissue. Herein this chapter, I used the 
RCC4 cell line to investigate the levels of PD-L1 and miR-155 expression.       
According to TCGA data (Figures 4.1, 4.2 and 4.3), kidney renal clear cell carcinoma (KIRC) 
displays above median expression of miR-155 and PD-L1, which places it in the top third of 
all tumour types characterised. Compared to other renal cancers (KICH and kidney renal 
papillary cell carcinoma (KIRP), KIRC has similar expression of PD-L1 but displays higher 
miR-155 levels based on median expression. RCC4 cells were used as an in vitro model of 
clear cell renal carcinoma to characterise PD-L1 expression, RCC4 cells that have stably 
transfected empty vector (RCC4-EV), restored VHL (RCC4 +VHL) and wild-type were also 
tested. Treatment of RCC4-EV with IFN- and TNF- induced higher PD-L1 expression 
compared to treated RCC4 +VHL cells (Figure 4.4A). Two bands of HIF-1 were detected 
(~120 kDa), where presumably the upper band is phosphorylated HIF-1, which has been 
attributed previously (Minet et al. 2000). The upper band was present in RCC4-EV cells but 
not in RCC4 +VHL. Furthermore, total STAT1 levels were higher in RCC4-EV than RCC4 
+VHL cells. Analysis of PD-L1 surface expression by flow cytometry corroborated the 
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results of western blot (Figure 4.4B). RCC4-EV cells displayed higher levels of PD-L1 in 
both IFN- and TNF--treated and untreated conditions. Similar results were shown by 
measuring PD-L1 mRNA expression (Figure 4.5A). Altogether, the results validate previous 
reports (Noman et al. 2014; Barsoum et al. 2014; Messai et al. 2016) that restoration of VHL 
in RCC4 cells suppresses PD-L1 expression. 
 
Figure 4.4. Expression of VHL regulates the levels of PD-L1. A) Protein expression 
analysis of renal cell carcinoma line (RCC4) cells with stable transfection of empty vector 
(EV) or von Hippel-Lindau (VHL), transfected with siRNA targeting PD-L1 or control 
(NTC) (48 h) and treated with IFN- and TNF- (24 h). B) Surface expression of PD-L1 
was measured in RCC4-EV or +VHL cells treated with IFN- and TNF- (24 h) or left 
untreated (UT) in comparison to isotype (iso). MFI of PD-L1 staining: RCC4-EV (IFN- + 
TNF-) = 2274, RCC4 +VHL (IFN- + TNF-) = 1304, RCC4-EV (UT) = 452, RCC4 
+VHL (UT) = 210, iso = 8.60. n = 1 experiment.   
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Next, I determined that VHL also regulates miR-155 expression with and without 
inflammatory stimulation (Figure 4.5B). RCC4-EV cells displayed higher levels of miR-155 
than RCC4 +VHL cells. Overexpression of miR-155 in RCC4 wild-type cells showed 
suppression of PD-L1 protein levels notably after 24 h of treatment with IFN- and TNF- 
(Figure 4.6). In contrast, inhibition of endogenous miR-155 resulted in an increase in PD-L1 
at 24 h post-stimulation. This suggests that miR-155 regulates PD-L1 expression in renal 
cancer cells. 
 
Figure 4.5. Expression of PD-L1 and miR-155 in RCC4 cells. A) PD-L1 mRNA 
expression was analysed by qRT-PCR in RCC4-EV or +VHL cells treated with IFN- and 
TNF- (24 h) or untreated (UT). B) miR-155 expression was analysed by qRT-PCR in 
RCC4 wild-type, RCC4-EV or +VHL cells treated with IFN- and TNF- (24 h) or left 
untreated (UT). n = mean of 2 independent experiments.     
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Figure 4.6. miR-155 expression regulates PD-L1 in RCC4 cells. RCC4 cells were tested to 
understand whether miR-155 could regulate the expression of PD-L1 in a renal cancer cell 
line. Protein expression following IFN-γ and TNF- stimulation (8, 24, 32 h) in RCC4 wild-
type cells transfected with miR-155 mimics (left side) or miR-155 inhibitors (right side) (48 
h). n = 1 experiment. 
4.3.2. miR-155 regulates PD-L1 in a metastatic breast cancer cell line 
The MDA-MB-231 cell line represents a mesenchymal-like breast cancer type. These are 
triple negative for receptors of the hormones oestrogen, progesterone and human epidermal 
growth factor receptor 2 (HER2), a member of the EGFR family, representing 10-20% of 
breast cancers. MDA-MB-231 cells are highly invasive and metastatic-derived from a 
pleural effusion, the excess fluid that is accumulated in the fluid-filled space surrounding the 
lungs. MDA-MB-231 cells have been shown to express PD-L1 which can be induced further 
by knockdown of PTEN (Mittendorf et al. 2014). Levels of miR-155 can be increased by 
inflammatory cytokines TNF- or LPS in MDA-MB-231 at 24 h post-stimulation (Tili et al. 
2011).   
TCGA data suggested that participants with breast invasive carcinoma (BRCA) had levels of 
miR-155 and PD-L1 that were close to the global median of all tumour types (Figures 4.1, 
4.2 and 4.3). Similar to RCC4 cells, both PD-L1 mRNA and miR-155 levels are induced by 
IFN- and TNF- (Figure 4.7). Overexpression of miR-155 in MDA-MB-231 cells led to 
decreased PD-L1 protein expression at 24 h (Figure 4.8). Conversely, when endogenous 
expression of miR-155 was inhibited this led to an increase in PD-L1 expression. These 
results suggest the capacity of miR-155 to regulate induction of PD-L1 expression in a 
metastatic breast cancer cell line.          
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Figure 4.7. Expression of PD-L1 and miR-155 in MDA-MB-231 cells. A) PD-L1 mRNA 
expression was analysed by qRT-PCR in MDA-MB-231 cells treated with IFN- and TNF- 
(24 h) or untreated (UT). n = 1 experiment. B) miR-155 expression was analysed by qRT-
PCR in MDA-MB-231 cells treated with IFN- and TNF- (24 h) or left untreated (UT). n = 
3 independent experiments.     
 
Figure 4.8. miR-155 expression regulates PD-L1 in MDA-MB-231 cells. MDA-MB-231 
cells were tested to understand whether miR-155 could regulate the expression of PD-L1 in 
a breast cancer cell line. Protein expression following IFN-γ and TNF- stimulation (8, 24, 
32 h) in MDA-MB-231 cells transfected with miR-155 mimics (left side) or miR-155 
inhibitors (right side) (48 h). n = 1 experiment. 
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4.3.3. Different regulation of PD-L1 by miR-155 in a lung adenocarcinoma cell line 
Alveolar type II cells have a compact shape that cover 5% of the alveolar surface, as 
compared to alveolar type I cells that cover 95% (Mason 2006). These type II cells 
restructure the alveolar epithelium after damage has occurred to type I cells. A characteristic 
of type II cells is the lamellar bodies that produce and secrete pulmonary surfactant to 
prevent the collapse of lungs during breathing out. Human A549 lung adenocarcinoma cells 
fall within the range of NSCLC tissues, originating from the basal epithelium of alveoli and 
are considered alveolar type II cells. A549s have weak PD-L1 signal at basal levels (Chen et 
al. 2015; Hong et al. 2016) but were shown to upregulate PD-L1 following IFN- treatment 
(24 h) (Anantharaman et al. 2016). Expression of miR-155 is higher expressed in lung 
cancer tissues (adenocarcinoma and squamous carcinoma) than para-cancerous and  normal 
tissues (Zang et al. 2012). However, A549 cells express almost undetectable miR-155 levels 
(Rather et al. 2013).  
TCGA data analysis (Figure 4.3) indicated that lung adenocarcinoma (LUAD) and lung 
squamous cell carcinoma (LUSC) express levels of PD-L1 and miR-155 above the global 
median, compared to other tumour types. Further characterisation in A549 cells saw that 
IFN- and TNF- synergise to induce PD-L1 mRNA expression (Figure 4.9A). Similarly, 
miR-155 is induced in A549 cells by the same inflammatory cytokines (Figure 4.9B). 
Moreover, the synergistic induction of PD-L1 translated to cell surface expression (Figure 
4.9C). Untreated A549s displayed very low levels of PD-L1 which were elevated upon 
stimulation. Upon overexpression of miR-155 using mimics, PD-L1 expression was 
increased and not suppressed as seen in the RCC4 and MDA-MB-231 cell lines at all time-
points (Figure 4.10). The increase in protein expression was observed in western blot in an 
upper band of PD-L1 that was noticeable after 24 h post-stimulation. The lower band of PD-
L1 did not change. In contrast, inhibition of miR-155 did not affect PD-L1 expression. 
Phosphorylation of STAT1 was increased after overexpression of miR-155 compared to 
NTC. No increase was seen after inhibition of miR-155. This suggests that miR-155 may 
affect PD-L1 protein expression in A549 cells by a different mechanism that could be cell-
type specific.  
4.4.  Regulation of PD-L1 by miR-155 in lung cancer cell lines 
Next, I validated that all tested cancer cell lines have an intact PD-L1 3’-UTR to indicate 
that the regulatory mechanism of miRNAs can occur in these cells, since in some cancers the 
3’-UTR of PD-L1 is truncated (Kataoka et al. 2016). The average length of a human 3’-UTR 
is ~950 bp long (Sood et al. 2006). The PD-L1 gene is 3691 bp long, containing a 5’-UTR 
sequence (108 bp), an open reading frame (ORF) (873 bp) which encodes the functional 
protein and a long 3’-UTR (2710 bp). The two miR-155 binding sites are situated in the 
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latter half of the 3’-UTR. First, I designed primer pairs that enclosed the whole 3’-UTR 
(‘F1:R1’) and the latter half (‘F2:R1’) containing the miR-155 binding sites, based on the 
dominant PD-L1 mRNA isoform that represents the longest transcript (NM_014143.3) 
(Figure 4.11A). I tested RCC4, MDA-MB-231, A549 and HFF cells and confirmed the 
presence of the full length (F1:R1) PD-L1 3’-UTR in all cell types (Figure 4.11B and C), 
including the regions where miR-155 binding sites are situated. This suggests that all of the 
tested cell types express the dominant mRNA isoform of PD-L1. However, this does not test 
whether other isoforms are expressed such as truncated forms. In addition, the PCR products 
require further sequencing to investigate whether the miR-155 binding sites are not mutated 
and therefore expected to have functional capability. By examining miR-155 expression in 
the tested cell types, I determined that HFFs and RCC4s expressed higher levels of miR-155 
than A549 or MDA-MB-231 (Figure 4.11D). As described before, all cell types induce miR-
155 upon inflammatory activation.  
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Figure 4.9. Expression of PD-L1 and miR-155 in A549 cells. A) PD-L1 mRNA expression 
was analysed by qRT-PCR in A549 cells treated with IFN- and TNF- (24 h) or untreated 
(UT). B) miR-155 expression was analysed by qRT-PCR in A549 cells treated with IFN- 
and TNF- (24 h) or left untreated (UT). C) Surface expression of PD-L1 in A549 cells 
untreated or treated with IFN-, or both IFN- and TNF- (24 h). MFI of PD-L1 staining: 
IFN- + TNF- = 2236, IFN- = 421, UT = 48.9, iso = 7.92. n = 2 independent experiments.       
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Figure 4.10. Different regulation of PD-L1 by miR-155 in A549 cells. A549 cells were 
tested to understand whether miR-155 could regulate the expression of PD-L1 in a lung 
cancer cell line.  Protein expression following IFN-γ and TNF- stimulation (8, 24, 48 h) in 
A549 cells transfected with miR-155 mimics (left side) or miR-155 inhibitors (right side) 
(48 h). n = 1 experiment. 
The low levels of miR-155 expressed in A549 cells suggest that in general this cell type 
deviates from the median expression of lung cancers that were analysed by the TCGA 
(Figure 4.12A). As described before, lung cancer cells express above median levels of both 
miR-155 and PD-L1 based on the data from the TCGA (Figure 4.12B). I found no 
correlation of miR-155 levels with PD-L1 in either LUAD or LUSC cell types (Figure 4.12C 
and D). Since it was found that PD-L1 was suppressed by overexpressing miR-155 in RCC4 
and MDA-MB-231, two cell types that express different levels of miR-155, this indicated 
that cell-specific effects may contribute to the regulation of PD-L1 by miR-155. Furthermore, 
to investigate potentially different regulatory mechanisms of PD-L1 by miR-155 in lung 
cancer cells I characterized five additional lung cancer cell lines. These included NSCLC 
lines: H838, HCC193, H1299, H358M and Hop62 of various stages of cancer. H838, H1299 
and H358M are all metastatic-derived. H838 and H1299 cells are derived from the lymph 
node while H358M was isolated from a primary bronchioalveolar carcinoma of the lung. 
Moreover, all three cancer types are sourced from a male whereas HCC193 and Hop62 come 
from females. Both H1299 and H358M do not express the tumour suppressor p53 protein. 
All lung cancer cell types including A549 were transfected with miR-155 mimics and treated 
with IFN- and TNF- (Figure 4.13A). These lung cancer cell lines displayed different 
expression levels and glycosylation patterns of PD-L1. miR-155 mimic suppressed PD-L1 
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expression in H838, H1299 and H358M but not HCC193, Hop62 and A549 cell lines. It was 
observed that overexpression of miR-155 in HCC193 and A549 appeared to increase upper 
glycosylated bands of PD-L1. 
I found that all lung cancer cell lines contain the 3’-UTR of PD-L1 at a similar level to that 
of expressed PD-L1 protein (Figure 4.13B). As described before, sequencing would be 
required for further analysis of the miR-155 binding sites and PD-L1 3’-UTR. The 
expression of miR-155 was characterised in all lung cancer cells with variability in the levels 
that were detected (Figure 4.13C). Hop62 cells expressed the most miR-155 of all tested 
lung lines, which were similar levels to that of HFFs. A549 cells expressed the lowest 
amount of endogenous miR-155 and do not follow the previously described mechanism of 
PD-L1 expression by miR-155 (Chapter 3). These data propose that miR-155 regulation of 
PD-L1 is not correlative to the levels of miR-155 or the pattern of PD-L1 expression. Instead, 
this refers back to cell-type specific events within cancer subtypes of similar origin that may 
affect miRNA-mediated regulation of mRNAs.    
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Figure 4.11. Expression of PD-L1 3’-UTR and miR-155 in cancer cells. A) The 3’-UTR 
of PD-L1 covers 2710 bp of the whole length of the PD-L1 gene (3691 bp). Within the 3’-
UTR of PD-L1, there are two binding sites for miR-155 of PD-L1, Site 1 (1335-1341) and 
Site 2 (2587-2593). PCR primers were designed to amplify a product that covers the 
majority of the 3’-UTR (F1:R1, 2671 bp) or the latter half of the 3’-UTR (F2:R1, 1446 bp), 
inclusive of the two miR-155 binding sites. B) cDNA synthesised from HFFs and various 
cancer cells (A549, MDA-MB-231 and RCC4) were amplified using PCR and the product 
(F1:R1) was analysed by agar gel electrophoresis. C) Similar to (B) using primers to amplify 
PCR product (F2:R1) from cDNA and analysed by agar gel electrophoresis. F = Forward, R 
= Reverse primer. D) miR-155 expression was analysed by qRT-PCR in HFFs and various 
cancer cells treated with IFN- and TNF- (24 h) or left untreated (UT). ORF = open 
reading frame. n = 1 experiment.     
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Figure 4.12. Normalised lung cancer sequencing data obtained from TCGA for LUAD 
and LUSC (see Figure 4.1 for details). A) Expression of miR-155 with whiskers showing 
minimum and maximum for both LUAD and LUSC tumour types. The red line represents 
the global median (271.7422 RPM) of all 33 tumour types. B) Expression of PD-L1 mRNA 
in both LUAD and LUSC tumour types, the red line represents the global median (24.5025 
FPKM). C) Scatter plot showing both expression of PD-L1 mRNA and miR-155 for each 
individual sample in LUSC (Pearson r correlation coefficient = +0.05542) and D) LUAD 
(Pearson r correlation coefficient = +0.07275) to observe any correlation. LUSC = lung 
squamous cell carcinoma; LUAD = lung adenocarcinoma.  
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Figure 4.13. miR-155 expression and regulation of PD-L1 in lung cancer cell lines. A) 
Protein expression following IFN-γ and TNF- stimulation (24 h) in lung cancer cell lines 
(H838, HCC193, H1299, H358M, Hop62 and A549) transfected with miR-155 mimics (48 
h) and analysed by western blot. B) PCR product (F2:R1) from cDNA synthesised from lung 
cancer cell lines (see above) and analysed by agar gel electrophoresis. C) miR-155 
expression was analysed by qRT-PCR in HFFs and in lung cancer cell lines treated with 
IFN- and TNF- (24 h) or left untreated (UT). n = 1 experiment. 
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4.5. miR-218 regulation of PD-L1 in cancer cell lines 
In Chapter 3, I first looked at miR-218 regulation of PD-L1 in primary cells. Here, I 
continued investigating the effect of miR-218 on PD-L1 in cancer cell lines. I compared 
overexpression of miR-218 in A549, MDA-MB-231 and RCC4 cell lines with HFFs (Figure 
4.14). All cells were stimulated with IFN- and TNF- and analysed for protein expression 
of PD-L1 after 24 h. In line with previous results, overexpression of miR-218 in HFFs 
induces the expression of PD-L1 more so than IFN- and TNF- alone. There was no 
noticeable increase in PD-L1 expression in the tested cancer cell lines, apart from a small 
increase in A549 cells. Upon measuring miR-218, both HFF and MDA-MB-231 expressed 
the higher levels of miR-218 and A549 expressed the lowest (Figure 4.15A). IFN- and 
TNF- induced miR-218 in all cells except in RCC4. Moreover, testing the additional lung 
cancer cell lines showed that miR-218 was suppressed following IFN- and TNF- 
activation in H838, HCC193, H358M (Figure 4.15B). These data suggested a differential 
regulation of miR-218 induction in cancer cells as opposed to HDLECs/HFFs cells which 
may account for the mechanism by which PD-L1 is affected by miR-218 overexpression in 
non-transformed cells.   
 
Figure 4.14. The effect of miR-218 overexpression in cancer cell lines. Protein expression 
following IFN-γ and TNF- stimulation (24 h) in A549, MDA-MB-231, RCC4 and HFF 
cells transfected with miR-218 mimics (48 h). n = 1 experiment. 
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Figure 4.15. miR-218 expression in HFFs and cancer cell lines. A) miR-218 expression 
was analysed by qRT-PCR in HFFs and various cancer cells (A549, MDA-MB-231 and 
RCC4) treated with IFN- and TNF- (24 h) or left untreated (UT). B) Similar to (A), miR-
218 expression analysed in lung cancer cell lines. Both sets of data were normalised to 
expression of miR-218 in untreated HFFs.  n = 1 experiment. 
4.6. Chapter discussion 
This chapter primarily addresses miRNA-mediated regulation of PD-L1 and in some cases, 
specifically whether the mechanism by which PD-L1 is regulated by miR-155 in 
HDLECs/HFFs could be extended to cancer cell lines. The tested cancer cell lines align 
within the categories of renal (RCC4), breast (MDA-MB-231) and lung cancer (A549). 
Regulation of PD-L1 by miR-155 extended in a similar pattern in inflammatory-activated 
RCC4 and MDA-MB-231 cells. However, in A549 cells, miR-155 had the opposite effect on 
PD-L1 expression. Upon testing of additional lung cancer cell lines, I identified a subset 
following the initial finding that miR-155 suppresses PD-L1 expression. These preliminary 
findings identify a larger scope of miR-155 regulation of PD-L1 beyond healthy cells, which 
could be studied in further detail in a disease context.  
In the beginning, I analysed expression of PD-L1 and miR-155 in multiple tumour types 
using clinical data from the TCGA Research Network. This provided an overview to 
understanding any potential relationships between PD-L1 and miR-155 in different cancer 
subtypes. Between various cancer subtypes, the expression of PD-L1 and miR-155 is varied 
especially in haematological cancers such as DLBC and LAML. B cell lymphomas were 
found to have up to 10- to 30-fold higher copy numbers of miR-155 than normal circulating 
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B cells (Eis et al. 2005). Patients with the activated B cell (ABC) phenotype of DLBC have 
increased levels (2- to 3-fold) of miR-155 compared to a non-germinal centre B cell (GCB) 
phenotype. In a study where 1253 DLBC samples were analysed, PD-L1 expression was 
significantly associated with the GCB phenotype and had poor prognosis (Kiyasu et al. 
2015). It would be interesting to establish whether miR-155 regulates PD-L1 expression in 
DLBC samples due to the high expression of both molecules. Moreover, I analysed that 
miR-155 expression was high in LAML compared to other tumour types but expressed PD-
L1 at a lower level. Similar findings on PD-L1 expression were reported where a study 
found 18% of patients expressing PD-L1 (Berthon et al. 2010). However, these studies 
showed that LAML cells were inducible by IFN- and upregulated PD-L1 upon stimulation 
(Berthon et al. 2010; Krönig et al. 2014). miR-155 is overexpressed and repeatedly linked 
with poor prognosis in LAML (Narayan et al. 2018). The levels of miR-155 (intermediate or 
high) in LAML can affect the targeting of genes, such that intermediate miR-155 expression 
will target lowly expressed genes and as the levels of miR-155 rise this allows more highly 
expressed mRNAs to be regulated. This is another possible context to explore the miR-
155/PD-L1 interaction in more detail.    
In the present work, I demonstrated that miR-155 and PD-L1 were differentially expressed 
at basal levels and induced by IFN- and TNF- in diverse orders of magnitude. In RCC4, I 
confirmed previous reports (Messai et al. 2016; Kammerer-Jacquet et al. 2017) that VHL is 
a crucial regulator of PD-L1 and miR-155 expression. It has also been demonstrated 
previously that upregulation of miR-155 can target VHL in breast cancer and therefore there 
may be an add-on effect on PD-L1 expression in RCC4 cells from regulation of VHL (Kong 
et al. 2014). 
Both RCC4 and MDA-MB-231 cells displayed similar regulation of PD-L1 using miR-155 
mimics in line with results from primary cells as described (Chapter 3). Only three of six 
tested lung cancer cell lines demonstrated a similar regulatory pattern despite overexpression 
of miR-155. There was also no distinct correlation between endogenous miR-155 and PD-L1 
expression in individual lung cancer tissues. Despite the differences in miR-155 expression 
between the cancer cell lines, the miR-155/PD-L1 mechanism can occur in selected cell 
types. This suggests that for the interaction to occur, there are more factors to understand 
than the expression of miR-155 or PD-L1. This may explain the lack of correlation between 
PD-L1 and miR-155 from the lung cancer data. My experiments so far cannot rule out 
indirect regulation by miR-155 on signalling pathways that can affect PD-L1 expression, 
such as the JAK/STAT cascade. Moreover, conducting luciferase assays (similar to that in 
Chapter 3) to demonstrate that miR-155 can bind directly to the 3’-UTR of PD-L1 in all 
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tested lung cancer cell lines would provide further knowledge on the accessibility of the 
binding site.    
All lung cancer cell lines had an intact 3’-UTR of PD-L1 inclusive of miR-155 binding sites 
which suggests against the incidence of a shortened 3’-UTR in cancer cells caused by 
alternative cleavage or polyadenylation (Mayr & Bartel 2009). Sequencing of the 3’-UTR 
would be required to determine whether there are alterations of the miR-155 binding sites 
and/or surrounding sequences. The site accessibility is reported to be as important as the 
matching of the seed sequence in miRNA-mediated translational repression (Kertesz et al. 
2007). It would be important to know whether the binding sites are functionally accessible 
for binding of miR-155 to sites on PD-L1 3’-UTR in lung cancer cells (discussed below).  
The 3’-UTR of PD-L1 is twice as long as the average human 3’-UTR. This opens up the 
possibility that PD-L1 is heavily regulated by factors that affect the stability, translation, 
localisation, transport and polyadenylation/deadenylation of the mRNA (Hu & Coller 2012). 
Although miRNAs can functionally cleave target mRNAs, the majority of mechanisms are 
not and require the role of mRNA decay factors that contribute towards mRNA 
deadenylation (Huntzinger & Izaurralde 2011). How does miR-155 exert its regulation on 
PD-L1 and why does this mechanism not occur in some cell types? It has been reported that 
translational repression can precede mRNA deadenylation and decay, such as repression of 
translation initiation (Djuranovic et al. 2012; Bazzini et al. 2012). A genome-wide scale 
study found that there was poor correlation between the changes in protein production and 
mRNA fold change at a time-scale of 8 h and 32 h after miR-1 transfection (Selbach et al. 
2008). Many of the miRNA targets were regulated at the protein level at 8 h and at a later 
time-point protein and mRNA levels were similarly suppressed. In contrast, other studies 
have suggested that the majority of miRNA targets are repressed at the mRNA level (Baek et 
al. 2008; Guo et al. 2010; Eichhorn et al. 2014). A small number of targets (10-25% of 
overall repression) are repressed at the translational level without change to mRNA 
expression. Additionally, depletion of decapping factors can relieve miRNA-mediated 
silencing of mRNAs (Eulalio et al. 2007).    
In Chapter 3, overexpression of miR-155 did not reduce PD-L1 mRNA levels and in some 
cases increased the amount of mRNA in primary cells. In spite of this, the protein expression 
of PD-L1 was suppressed. Generally, this indicates that miR-155-mediated gene silencing of 
PD-L1 in primary cells occurs through translational repression. PD-L1 mRNA levels were 
not measured after overexpression of miR-155 in cancer cell lines to confirm whether this 
was the case in these particular cells. In addition, regulation of PD-L1 by miR-155 occurs in 
cells responding to inflammatory stimuli rather than in untreated cells.  
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Some mechanisms have been proposed that explain how miRNAs in animals might repress 
translation. These include involvement of GW182 family of proteins that interact directly 
with Argonaute (AGO) proteins and are involved in mRNA decay (Iwakawa & Tomari 
2015). GW182-mediated dissociation of eukaryotic initiation factor 4F (eIF4F) from poly 
(A)-binding protein (PABP) compromises translation initiation and contributes to overall 
miRNA-mediated translational repression. Furthermore, GW182 recruits downstream 
translational repressors such as DEAD-box RNA helicase 6 (DDX6) to target mRNAs 
(Iwakawa & Tomari 2015). Dissociation of the RNA helicase eIF4A from target mRNAs 
can abolish ribosome binding (Iwakawa & Tomari 2015). In zebrafish embryos, injection of 
miR-155 duplexes caused mostly translational repression at an early stage of miR-155 
targets but shifted towards mRNA destabilisation at a later phase due to the length of the 
poly (A)-tail (Subtelny et al. 2014). Tail lengths in early zebrafish were associated with 
translational efficiency which was diminished in non-embryonic samples.      
The mechanism by which miR-155 affects PD-L1 in the 3’-UTR could be cell-type specific 
depending on the accessibility of the 3’-UTR and other factors that may regulate PD-L1 in 
the 3’-UTR such as RNA-binding proteins. RISC proteins can hinder base-pairing 
interactions between miRNA and the target site (Kertesz et al. 2007). Control of protein 
levels via the 3’-UTR and is not only regulated by miRNAs but also by adenylate-uridylate 
(AU)-rich elements (AREs) which also lead to rapid mRNA decay (Mayr 2017). ARE-
mediated degradation of mRNA has been shown to require cooperation between miRNAs 
and ARE-binding proteins (Jing et al. 2005). Moreover, the ARE-binding protein, HuR was 
shown to de-repress the 3’-UTR of cationic amino acid transporter 1 (CAT-1) mRNA from 
miR-122-induced inhibition (Bhattacharyya et al. 2006). Additionally, RNA-binding 
proteins (RBPs) can bind to the mRNA and modify its translatability. Binding of Pumilio to 
the 3’-UTR of p27 can alter the secondary structure and accessibility of miR-221 and miR-
222 to their binding sites (Kedde et al. 2010). In contrast, expression of dead end 1 (Dnd1) 
can bind mRNAs and inhibit the association of miRNAs to their target sites (Kedde et al. 
2007). Recently, RAS-MEK signalling was demonstrated to stabilise the expression of PD-
L1 by enhancing the phosphorylation of the ARE-binding protein TTP (ZFP36) (Coelho et 
al. 2017). TTP negatively regulates PD-L1 expression and inhibition of MEK increased TTP 
expression. In addition, restoration of TTP expression increased the effectiveness of anti-
tumour immunity which was dependent on the regulation of PD-L1 mRNA (Coelho et al. 
2017). From these studies, there is a possibility that the activity of RNA-binding proteins or 
ARE-binding proteins could affect miR-155 regulation of PD-L1 expression. Using TCGA 
data, low levels of TTP found in lung adenocarcinoma patients were observed to correspond 
to high levels of PD-L1 (Figure 4.16). No similar relationship with PD-L1 is observed with 
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Pumilio or DND1 regardless of expression suggesting the relationship between TTP and 
miR-155 regulation of PD-L1 expression could be further investigated. 
 
Figure 4.16. Low expression of ZPF36 correlates with high expression of PD-L1 mRNA. 
Scatter plots showing TCGA data from LUAD of the expression of A) PUM1 B) DND1 C) 
ZFP36 (TTP) against the expression of CD274 (PD-L1). Comparing the top 25% and the 
bottom 25% values of each gene on the y-axis (PUM1, DND1, ZFP36) with its 
corresponding/matching CD274 value in each tumour sample. LUAD = lung 
adenocarcinoma. 
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Additionally, results in this chapter have suggested miR-155 affects posttranslational 
modification of PD-L1. I saw that miR-155 decreased the intensity of all glycosylated PD-
L1 bands (Figure 4.13A). However, in some cases where miR-155 increased PD-L1 
expression (HCC193 and A549), these were associated with glycosylated bands at a higher 
size than the main PD-L1 band. In contrast, H1299 cells expressed PD-L1 with a primary 
intensity on the upper bands which were suppressed following overexpression of miR-155. 
The stability of PD-L1 is associated with N-glycosylation, which prevents ubiquitination of 
the protein, and is important for the immunosuppressive function of PD-L1 upon 
engagement to PD-1 (Li et al. 2016; C. W. Li et al. 2018). In addition, EGF signalling was 
shown to induce PD-L1 glycosylation which is mediated at the posttranslational level. EGF 
upregulates the β-1,3-N-acetylglucosaminyl transferase (B3GNT3) glycosyltransferase to 
facilitate glycosylation of PD-L1 in triple-negative breast cancer cells (C. W. Li et al. 2018). 
Monoclonal antibodies targeting the glycosylated version of PD-L1 blocked interaction with 
PD-1 and promoted internalisation and degradation of PD-L1. Lung cancer cell lines, 
including HCC193, display different levels of signalling complexes associated with the 
EGFR pathway (Toki et al. 2016). Moreover, glycosylation has been shown to be affected 
by miRNAs (Vaiana et al. 2016). GSK3β was shown to mediate destabilisation of 
unglycosylated PD-L1 (Li et al. 2016). Interestingly, there is one predicted conserved miR-
155 binding site in the 3’-UTR of GSK3β (4794-4800) among mammals. Furthermore, miR-
155 was reported to inhibit the activity of GSK3β directly or indirectly by affecting -
arrestin-2 in mice (J. Zhao et al. 2014). This suggests that within my subset of lung cancer 
cell lines there exists different forms of glycosylated PD-L1. There is some possibility that 
miR-155 activity, either directly via GSK3β or indirectly, could affect the glycosylation of 
PD-L1. 
In the subset of lung cancer cells where miR-155 suppressed PD-L1 expression, these 
belonged to cells that were derived from metastatic sites such as the lymph node. Thus, this 
could affect responses to PD-L1 treatment. A comparative study between primary and 
metastatic pulmonary adenocarcinomas observed a number of cases where the majority had 
regional nodal metastasis (Kim et al. 2017). There was a high concordance of PD-L1 
expression between primary and metastatic pulmonary adenocarcinomas. This was based on 
the proportion of tumour cells expressing PD-L1. This high concordance was observed in 
both low expressing (<1%) and high expressing (>50%) PD-L1+ tumour cells. However, 
there was a low concordance in cases with >1% and <50% PD-L1 expression between 
primary and metastatic tumours. This was suggested by the authors to be due to the 
vulnerability of tumour cells to extrinsic regulation (Kim et al. 2017). Furthermore, lymph 
node metastases of triple-negative breast cancer were found to have higher PD-L1 
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expression (59.41%) than paired primary tumours (38.61%) (M. Li et al. 2018). Similar 
reports of weak correlation in PD-L1 expression between primary and metastatic tumours 
have been reported in RCC (Jilaveanu et al. 2014) and bladder cancer (Mukherji et al. 2016). 
Although, it appears that higher expression of PD-L1 is found in metastatic tumours 
compared to primary tumours, the effect of miR-155 activity has not been detailed in PD-
1/PD-L1 immunotherapy.     
Overall, the implication of these findings demonstrate that the mechanism by which miR-
155 regulates PD-L1 expression in HDLECs/HFFs can be found in cancer cell lines after 
treatment with IFN- and TNF-. Overexpression of miR-155 in several cancer cell lines 
suppressed the levels of PD-L1. In some lung cancer cell lines, the type of miR-155 
regulation of PD-L1 was different. I speculate that this is either due to how miR-155 
specifically binds and regulates PD-L1 expression, whether the 3’-UTR of PD-L1 is altered 
in terms of accessibility to miRNAs in different cancer cell types or the effect of 
posttranslational regulation of PD-L1. The regulation of PD-L1 by miR-155, now found, in 
cancer cells adds to the possibility that miR-155 can potentially influence tumour response 
to anti-PD-1/PD-L1 therapeutic agents, in addition to its regulatory effect in 
stromal/vascular cells.  
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5. Development of a co-culture assay to 
determine the PD-L1 interaction from primary 
stromal fibroblast/vascular cells   
5.1. Introduction 
The effects of miRNA regulation can affect several mRNA targets but the downregulation of 
mRNA or protein expression is typically modest (Lim et al. 2005; Selbach et al. 2008). For 
example, knockdown of miR-223 which is highly expressed in mouse neutrophils, resulted 
in hundreds of repressed genes although to a modest degree (<33%) at the protein level 
(Baek et al. 2008). Targets that underwent further repression also showed de-stabilisation at 
the mRNA level (Baek et al. 2008). My results in Chapter 3 did not demonstrate that PD-L1 
mRNA levels were repressed after miR-155 regulation of PD-L1. However, the protein 
expression of PD-L1 was regulated by miR-155 to a mild extent. To further understand the 
significance of this regulatory loop, the functional relevance of these effects should be tested 
in stromal fibroblasts/vascular cells. Here, I investigated whether surface expression of PD-
L1 on stromal fibroblasts/vascular cells suppresses T cell activation via PD-1 engagement 
using an in vitro co-culture system.  
The Jurkat cell line is a widely known model of cultured human CD4+ T cell suspension 
from leukemic origin (Abraham & Weiss 2004). Jurkat cells release large amounts of IL-2 
upon stimulation which can be used as a marker of T cell activation for in vitro model 
systems. IL-2 is crucial for maintenance of antigen-activated T cells where it controls 
proliferation, development and survival (Boyman & Sprent 2012). In addition, transcription 
of IL-2 is mediated by transcription factors including nuclear factor of activated T cells 
(NFAT) and activator protein-1 (AP-1) (Boyman & Sprent 2012). Jurkat cells could be 
activated with phytohaemagglutinin (PHA) to produce IL-2 (Abraham & Weiss 2004). PHA 
is a lectin that binds and crosslinks sugars on glycosylated surface proteins, including the 
-heterodimer of the TCR and the CD3 co-receptors, and in doing so indirectly activates 
the TCR. An additional signal is required which can be fulfilled by phorbol 12-myristate 13-
acetate (PMA). PMA diffuses through to the cytoplasm where it directly activates protein 
kinase C, leading to activation of NF-κB, NFAT and AP-1. Other known combinations that 
have been used to activate T cells include ionomycin and PMA as well as anti-CD3/CD28 
stimulation (Abraham & Weiss 2004). Upon ligation, the CD3 chains of the TCR 
cluster/aggregate and a conformational change is induced (Minguet et al. 2007). A second 
co-stimulatory signal can be provided by ligation of CD28. This type of stimulation 
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represents a more physiologically relevant activation of T cells than with pharmacological 
agents. 
Co-culture techniques allow us to observe cell-cell interactions in a closed environment 
(Goers et al. 2014). Previously, a co-culture assay was used to determine the effect of PD-L1 
on uveal melanoma cells (Yang et al. 2008). PHA and PMA were added to induce PD-1 
expression on Jurkat T cells which do not express PD-1 unless activated. IFN-γ-treated 
melanoma cells were co-cultured with Jurkat cells and supernatants were harvested and 
assessed for IL-2 by ELISA. Co-culture resulted in significant reduction of IL-2 production 
which was demonstrated to be in a cell contact-dependent manner. Blockade of PD-1 or PD-
L1 resulted in a restoration of IL-2 production by Jurkat cells (Yang et al. 2008). Measuring 
IL-2 expression on activated Jurkat cells has also been used to demonstrate GSK3 
regulation of PD-L1 on tumour cells (Li et al. 2016). Moreover, Jurkat cells were found to 
enhance PD-1/PD-L1-mediated drug resistance in tumour cells (Black et al. 2016). Jurkat 
cells cannot fully replace primary T cell biology and harbour mutations that make it an 
unique transformed T cell line (Abraham & Weiss 2004). Jurkat cells lack expression of 
PTEN, which can lead to constitutive activation of the PI3K pathway that could alter T cell 
signal transduction (Gioia et al. 2018). In addition, Jurkat cells do not express SHIP1, Syk or 
CTLA-4, which are associated with T cell receptor signalling.  
However, these co-culture models provide in vitro testing of T-like cells that are ease of use 
and low expense that can supplement the data generated from in vivo approaches. By using 
co-culture assays, this would enable me to test the PD-L1-expressing cells in conjunction 
with the Jurkat T cell line to study the effect of PD-L1 regulation on T cell activation. First, 
this would involve testing the interaction of PD-L1 on HFFs or HDLECs with Jurkat cells to 
see whether there is suppression of T cell activation via the PD-1/PD-L1 pathway. Further, 
to investigate whether miRNA regulation of PD-L1 affects the PD-1/PD-L1 interaction and 
consequently activation of T cells. This chapter describes the development of two co-culture 
assays using wild-type or engineered Jurkat T cells and techniques including ELISA to 
measure IL-2 production and luciferase assays to measure NFAT activation. 
5.2. IL-2 secretion upon activation of wild-type Jurkat cells with PHA/PMA 
5.2.1. Activation of Jurkat cells with PHA and PMA induces PD-1 expression 
For this first co-culture assay, I characterised wild-type Jurkat T cells (E6-1) using the 
pharmacological agents PHA and PMA to induce the expression of PD-1. I also measured 
CD69 expression, an independent marker of T cell activation by flow cytometry. Of the two 
agents, PHA had a prominent role in PD-1 induction whereas PMA alone had no effect on 
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PD-1 expression (Figure 5.1A and B). PD-1 expression did not increase with the addition of 
PMA to PHA (Figure 5.1B). Although, Jurkat cells activated with both PHA and PMA 
generated the highest CD69 levels indicating higher activation of T cells than with PHA 
alone (Figure 5.1C). PHA and PMA activation led to a decrease in the number of live cells 
(~43%), compared to PHA (64% live) and PMA (80% live). Furthermore, activation of 
Jurkat cells found that the production of IL-2 was higher at 48 h compared to 24 h or 6 h 
post-activation (Figure 5.2A). The initial co-culture setup was based on the previously 
described report (Yang et al. 2008), replacing the uveal melanoma cells with HFFs. The 
reason for using HFFs was due to having a sustainable supply of cells to test and optimise 
the co-culture assay, whereas HDLECs are slower growing and can only be used up to a 
limited number of passages. HFFs were pre-treated with IFN- and TNF- stimulation to 
increase PD-L1 expression or left untreated (Figure 5.2B). Jurkat T cells were added on top 
of the HFFs and the cells were treated with PHA/PMA to increase PD-1 expression for 48 h. 
Jurkat cells were titrated between ratios of 1:2, 1:4, 1:8 and 1:20 (i.e. 20 Jurkat cells to 1 
HFF) in order to optimise the co-culture setup. IL-2 was measured by ELISA to study 
changes to T cell activation. I found that at ratios 1:2 and 1:8, that IFN- and TNF- 
stimulated HFFs significantly decreased the amount of IL-2 detected compared to untreated 
HFFs (~20% reduction). This suggested that activated HFFs could affect the production of 
IL-2 from Jurkat T cells.   
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Figure 5.1. PHA and PMA induce PD-1 on Jurkat T cells. A) Jurkat cells were treated 
with PHA, PMA or both (48 h) and analysed for surface expression of PD-1 (x-axis) and the 
T cell activation marker CD69 (y-axis) by flow cytometry. B and C) Histograms showing 
overlaid data from (A), MFI (median fluorescence intensity) of PD-1 (PHA+PMA = 319, 
PHA = 560, PMA = 8.18, UT = 6.46, isotype = 2.37) and CD69 = (PHA+PMA = 2450, PHA 
= 1096, PMA = 734, UT = 27.9, isotype = 20.0). n = 3 independent experiments.      
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Figure 5.2 IL-2 levels as a marker of Jurkat T cell activation. A) Jurkat T cells were 
treated with PHA and PMA or left untreated (UT) for 6, 24 and 48 h and IL-2 production 
was measured by ELISA. n = 1 experiment. B) Co-culture of HFFs with Jurkat cells. In this 
particular case, IFN- and TNF- pre-treated (24 h) HFFs were co-cultured with Jurkat cells 
in the presence of PHA and PMA (48 h) and supernatants were measured for IL-2 levels by 
ELISA. Unpaired Student's t test was used to compare ‘UT HFF + PHA/PMA Jurkat’ and 
‘IFN- and TNF- HFF + PHA/PMA Jurkat’ in each ratio. Ratio means HFF: Jurkat cells. *, 
p < 0.05. n = 4 samples in quadruplicate. 
Since PHA/PMA could possibly introduce external factors that may affect the co-culture 
assay such as activation of signalling pathways in HFFs, I separated the activation of Jurkat 
cells with PHA/PMA from the co-culture with HFFs. Therefore, pre-activated Jurkat T cells 
(48 h) were placed on top of pre-treated HFFs and co-cultured for 24 h (Figure 5.3). Both 
untreated and treated HFFs increased IL-2 expression of Jurkat T cells in co-culture 
compared to the levels observed with Jurkat cells alone. Similarly, pre-treated HFFs 
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prevented secretion of IL-2 at 1:4 and 1:8 ratios. Following this, I sought to investigate the 
effect of cell-cell contact compared to the secretion of chemokines and cytokines by HFFs 
on Jurkat cells. I utilised Transwell inserts that prevent cell-cell contact meanwhile 
maintaining the transfer of media across a 0.4 m pore (Figure 5.4). The increase of IL-2 
production of Jurkat T cells during co-culture was reduced but remained above Jurkat only 
controls, and this was more noticeable with untreated HFFs, suggesting HFFs secrete pro-
inflammatory mediators that induce T cell activation. Moreover, there was a significant 
increase in IL-2 secretion observed with the co-culture of treated HFFs compared to 
untreated HFFs in Transwell. This suggests anti-inflammatory cell-cell interactions that 
occur between treated HFFs and Jurkat cells were suppressed. These data indicate that HFFs 
differentially affect the amount of IL-2 produced by Jurkat cells via cell-cell contact or by 
the secretion of chemokines/cytokines where this response can depend on inflammatory 
activation of HFFs.  
 
Figure 5.3. Experimental procedure for IL-2 ELISA co-culture assays. Jurkat T cells 
were pre-activated with PHA/PMA (48 h) which produce IL-2 upon activation. Meanwhile, 
human foreskin fibroblasts (HFFs) were plated on 24-well plates and stimulated with IFN-γ 
and TNF-α (24 h) the following day to increase PD-L1 expression. After pre-activation, 
Jurkat T cells were co-cultured with HFFs in a ratio such as 1:4 or 1:8 (HFF: Jurkat) in a 
volume of 500 to 1000 l fresh media per well. Supernatants of each co-culture were 
harvested 24 h later for analysis by IL-2 ELISA to determine the change in levels of secreted 
IL-2.   
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Figure 5.4. HFFs affect the production of IL-2 by Jurkat T cells. Jurkat T cells pre-
treated with PHA/PMA (48 h) were added to UT or IFN-γ and TNF-α-treated (24 h) HFFs 
and co-cultured for 24 h. Data marked with ‘Transwell’ used 0.4 μm pore Transwell inserts 
to separate from cell-cell contact. Whereas the label ‘cell-cell contact’ did not restrict any 
interaction between the two cell types. Wells designated with Jurkat only were used as 
controls for IL-2 levels. IL-2 production was assessed by ELISA. Unpaired Student's t test 
was used to compare ‘UT HFF + PHA/PMA Jurkat’ and ‘IFN- and TNF- HFF + 
PHA/PMA Jurkat’ for the same ratio in each condition. Ratio means HFF: Jurkat cells. *, p 
< 0.05. n = 3 independent experiments run in triplicate. 
5.2.2. Blockade of PD-L1 interaction does not affect IL-2 expression 
To investigate the effect of PD-L1 on IL-2 expression, I investigated whether the levels of 
IL-2 were affected by blockade of PD-L1 expression. In several reports, anti-PD-L1 clone 
29E.2A3 has been used to block the expression of PD-L1 which has led to restoration of T 
cell function (Butte et al. 2008; Haile et al. 2014; Black et al. 2016; Watanabe et al. 2017). 
IFN- and TNF- induces PD-L1 surface expression which was partially blocked by anti-
PD-L1 antibody (29E.2A3) (Figure 5.5). Of note, the same antibody was used to block the 
PD-L1 site and to measure the surface expression by flow cytometry. PD-L1 expression was 
reduced compared to blockade with an isotype control with increasing concentration of 
blocking antibody (~85% reduction with the highest concentration). No difference was 
observed with the effect of anti-PD-L1 blockade on IL-2 levels compared to the isotype 
control (Figure 5.6). To test the effect of PD-L1 in the co-culture system in an alternative 
approach, I used siRNA to target PD-L1 (Figure 5.7 and 5.8). No difference in IL-2 levels 
was observed between knockdown of PD-L1 and non-targeting control in HFFs (Figure 5.7), 
although, there was an 80% knockdown in PD-L1 expression that was maintained 
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throughout co-culture (Figure 5.8). In addition, there was no difference observed with PD-1 
or CD69 expression in Jurkat T cells following co-culture (Figures 5.9A and B). These data 
showed that the loss of PD-L1 on HFFs did not affect T cell activation as observed by levels 
of IL-2. These findings indicated that the lack of effect from PD-L1 disruption suggested the 
possibility of some limiting factors such as the expression of PD-1. In addition, the effect of 
PHA/PMA activation on Jurkat cells which resulted in a high proportion of cell death; using 
PHA alone to increase PD-1 expression would have not generated sufficient IL-2 to measure. 
The approach could be optimised by engineering PD-1 expression on Jurkat cells and using 
a different form of T cell activation.  
 
Figure 5.5. Induced PD-L1 expression is partially blocked by antibody blockade. HFFs 
were treated with IFN-γ and TNF-α for 24 h. Next, HFFs were harvested and incubated with 
unconjugated anti-PD-L1 antibody (29E.2A3, 5, 10 and 20 μg/ml) for 30 min on ice to block 
the PD-L1 site. Then, cells were incubated with PE-conjugated anti-PD-L1 (29E.2A3, 2 
μg/ml) for 30 min on ice to determine the surface expression of PD-L1 by flow cytometry. n 
= 1 experiment. 
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Figure 5.6. Co-culture with antibody blockade of PD-L1. HFFs were pre-stimulated with 
IFN- and TNF- (24 h) and co-cultured with pre-treated Jurkat T cells (PHA and PMA, 48 
h) with either anti-PD-L1 antibody (29E.2A3, 5 μg/ml per well) or isotype control (24 h). 
Supernatants were harvested for IL-2 ELISA 24 h later. Unpaired Student's t test was used to 
compare ‘UT HFF + PHA/PMA Jurkat’ and ‘IFN- and TNF- HFF + PHA/PMA Jurkat’ 
for the same ratio in each condition. Ratio means HFF: Jurkat cells. *, p < 0.05. n = 3 
samples run in triplicate. 
   
Figure 5.7. IL-2 levels secreted by Jurkat T cells following co-culture are not affected 
by PD-L1 knockdown of HFFs. HFFs were transfected with PD-L1 siRNA (48 h) and 
treated with IFN- and TNF- (24 h). In parallel, Jurkat T cells were pre-treated with PHA 
and PMA (48 h), prior to co-culture with HFFs (24 h). Supernatants were collected 
following co-culture incubation period and IL-2 levels were determined by ELISA. 
Unpaired Student's t test was used to compare ‘UT HFF + PHA/PMA Jurkat’ and ‘IFN- and 
TNF- HFF + PHA/PMA Jurkat’ for the same ratio in each condition. Ratio means HFF: 
Jurkat cells. *, p < 0.05. n = 3 samples run in triplicate.   
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Figure 5.8. HFF PD-L1 surface expression following co-culture with Jurkat T cells. 
HFFs were transfected with siRNAs targeting PD-L1 (48 h) or non-targeting control (NTC) 
and subsequently treated with IFN-γ and TNF-α for 24 h or left untreated (UT). HFFs were 
co-cultured with pre-treated Jurkats (PHA and PMA, 48 h) for 24 h and collected for 
analysis by flow cytometry. Average MFI of PD-L1 staining: siNTC IFN- + TNF- = 
3486, siPD-L1 IFN- + TNF- = 631, siNTC UT = 582, siPD-L1 UT = 115. Black = isotype 
control (MFI = 16.0). n = 2-3 samples run in triplicate.  
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Figure 5.9. PD-1 and CD69 expression of Jurkat T cells following co-culture with HFFs. 
Jurkat cells were pre-treated with PHA and PMA (48 h) prior to co-culture with PD-L1 
siRNA transfected HFFs (24 h), see Figure 5.8 for further details. Levels of PD-1 and CD69 
in Jurkat T cells were measured by flow cytometry. Average MFI of PD-1 staining when co-
cultured with HFFs: siNTC IFN- + TNF- = 112, siPD-L1 IFN- + TNF- = 119, siNTC 
UT = 91, siPD-L1 UT = 91, PHA and PMA Jurkat control = 128. Black = isotype control 
(MFI = 6.5). Average MFI of CD69 staining when co-cultured with HFFs: siNTC IFN- + 
TNF- = 3012, siPD-L1 IFN- + TNF- = 3090, siNTC UT = 2742, siPD-L1 UT = 2742, 
PHA and PMA Jurkat control = 3048. Black = isotype control (MFI = 20.7). n = 2-3 samples 
run in triplicate.    
5.3. NFAT activation upon stimulation of engineered Jurkat cells with anti-
CD3/CD28 antibodies  
A second co-culture assay was set up in order to overcome the potential limiting factors such 
as PD-1 expression on T cells and the high proportion of activation-induced cell death. This 
approach used an engineered Jurkat T cell line (PD-1/NFAT-Luc Jurkat, defined as PD-1 
Jurkat from here onwards) that overexpress CD3, PD-1 and carry a luciferase reporter tagged 
to the promoter of NFAT, similar to a previously published report (Skalniak et al. 2017). 
This would enable the quantification of T cell activation such that NFAT-responsive cells 
would express a higher level of luciferase upon activation. Downstream signalling from the 
TCR can lead to NFAT activation through the mobilisation of calcium from the plasma 
membrane to the cytoplasm (Smith-Garvin et al. 2009). This involves the activity of 
phospholipase C (PLC) to catalyse the hydrolysis of phosphatidylinositol-4,5-bisphosphate 
(PIP2) to inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG) (Smith-Garvin et al. 
2009). The build-up in cytosolic calcium concentration leads to activation of calcineurin 
which dephosphorylates NFAT via a calcineurin-binding domain. This enables nuclear 
translocation of NFAT to associate with its nuclear component, AP-1, to promote 
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transcription of genes such as IL-2 via a Rel-homology DNA binding domain that is 
required for regulation of T cell differentiation, proliferation and survival. In addition, 
NFAT is also activated through downstream co-stimulatory CD28 signalling. PI3K 
(phosphoinositide 3-kinase) is an effector of CD28 signalling, which converts PIP2 to PIP3, 
where PIP3 can serve as a docking site for PDK1 (phosphoinositide-dependent kinase 1). 
PDK1 precedes activation of Akt which can indirectly increase NFAT activation through 
NF-κB signalling and also regulate the inhibitory effects of GSK3 on NFAT (Smith-Garvin 
et al. 2009). Overall, the increase in intracellular free Ca2+ represents a triggering signal for 
T cell activation.  
The co-culture model has been previously used for antibody screening to test anti-PD-1 and 
anti-PD-L1 antibodies (Skalniak et al. 2017). This consisted of the PD-1 Jurkat cell line and 
a Chinese hamster ovary (CHO) cell line (PD-L1+ aAPC/CHO-K1), which overexpresses 
PD-L1 and an engineered ligand to activate the TCR, simulating an APC. These were two of 
the factors to overcome in order to implement HFFs/HDLECs into the set up. IFN- and 
TNF- were used to stimulate PD-L1 expression and anti-CD3 and/or anti-CD28 antibodies 
to activate the PD-1 Jurkat cells (Figure 5.10) (Trickett & Kwan 2003). The co-culture 
would allow the two types of cells to interact and to determine the effect of PD-1/PD-L1 
interaction on T cell activation, which is linked to NFAT response. Of note, this approach 
differs because the PD-L1 expressing cells do not provide an antigenic stimulus. 
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Figure 5.10. Experimental pathway for PD-1 engineered Jurkat T cell luciferase assay. 
PD-1 Jurkat T cells are engineered to constutively to express PD-1. These cells also have a 
luciferase reporter that is coupled to the transcriptional activity of nuclear factor of activated 
T cells (NFAT, response element (RE)) which is upregulated upon T cell activation and 
thereby represents a measurable form of T cell activation response. 1) The assay consists of 
PD-L1-expressing cells that are treated with IFN- and TNF- to induce maximal PD-L1 
expression that would interact with PD-1 expressed by modified Jurkat cells. 2) PD-1 
expression is increased upon T cell activation which can be induced by using antibodies 
against CD3 and CD28 to stimulate the T cell receptor (TCR) and co-stimulatory pathways, 
respectively. This is used due to the lack of antigen presentation or TCR-activating ligand by 
the primary cells in this assay. 3) Activation of both of these pathways increase the amount 
of intracellular calcium levels that further facilitate the translocation and expression of 
NFAT in the nucleus which acts to promote transcription of cytokines such as IL-2. Overall, 
binding of PD-L1 to PD-1 prevents activation of T cells which would decrease the levels of 
NFAT and can be measured by luciferase assay to determine the effect of co-culture between 
PD-L1 expressing and Jurkat cells.    
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5.3.1. Activation of PD-1 Jurkat cells with anti-CD3 and anti-CD28  
To activate the PD-1 Jurkat cells with anti-CD3 and/or anti-CD28, I used either plate-bound, 
soluble (Figure 5.11) or coated beads. Plate-bound activation of T cells provides a better 
crosslinking effect than soluble activation, the idea that receptor or ligands are brought 
closer in a specific area which would enable prolonged engagement of the TCR and 
sustained signalling. In addition, PD-1 expression is induced following TCR crosslinking of 
CD4+ CD8+ double positive T cells using plate-bound anti-CD3 antibodies (Keir et al. 2005). 
In contrast, the soluble activating format would be in alignment with the previous co-culture 
format, allowing the PD-L1-expressing cells to adhere to the bottom of the well prior to the 
addition of Jurkat cells and stimulating factors.  
 
Figure 5.11. Plate-bound versus soluble T cell activation: crosslinking difference. 
Crosslinking means to bring receptors or ligands together in a specific area of the cell 
membrane leading to a strong point signal. In vitro method of activation of T cells can 
determine the response of T cells. A) Plate-bound or immobilised antibodies are coated on 
96-well plates and can send a strong proliferative signal to T cells, allowing gradual 
accumulation of signalling events over time. B) Soluble antibodies in the media can also 
activate T cells where there is uniform distribution of antibody on the cell surface and 
engagement of most receptors. However, there is no continuous receptor triggering or 
sustained signalling. Therefore plate-bound activation provides better activation of T cells.   
I tested both the plate-bound and soluble format. Although, these cells were engineered to 
overexpress PD-1, I determined that at basal level these PD-1 Jurkat cells expressed a 
modest level of surface PD-1 expression (~50-60%) (Figure 5.12A). Plate-bound or 
immobilised anti-CD3 coated at the bottom of the well generated a strong increase to both 
PD-1 and CD69 signal after 24 h compared to the modest increases generated from soluble, 
free-floating antibodies (Figure 5.12A-C). Live-stained cell count was ~70-85% in both 
untreated and anti-CD3-treated cells (Figure 5.12B-C). Similar findings were observed using 
the luciferase assay, NFAT activity was higher with plate-bound activation (Figure 5.12D). 
In addition, there was a further increase in the activation of PD-1 Jurkat T cells by using 
media with lower serum content (1%) (Figure 5.12D). To determine the effect of PD-L1 Fc 
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on PD-1 Jurkat cells, recombinant PD-L1 Fc was added at the same time as anti-CD3 
(Figure 5.12A-D). There was a decrease in detectable PD-1 expression and a modest 
reduction in CD69 signal from flow cytometry analysis. However, there was no difference in 
NFAT signal when quantified through the luciferase assay. Soluble anti-CD3 activation of 
NFAT activity in PD-1 Jurkat cells could be enhanced in combination with anti-CD28 
(Figure 5.13A-B). In addition, levels of NFAT activation were higher at 6 h compared to 24 
h activation. There was a decrease in PD-1 signal and a small rise in NFAT activation after 
applying PD-L1 Fc, suggesting that PD-L1 Fc partially blocks the PD-1 site rather than 
mitigating the activation of T cells. Moreover, the number of live-stained cells was ~80-90% 
in both untreated and anti-CD3/CD28-treated cells (Figure 5.13B). Overall, these data 
indicate that both plate-bound and soluble anti-CD3 and/or anti-CD28 application can 
activate PD-1 Jurkat cells to increase PD-1, CD69 and NFAT expression. Although, the 
effect of soluble activation is noticeably weaker. This allows some flexibility with the setup 
of the co-culture with the aim to optimise a system that can determine the effect of PD-
1/PD-L1 interaction on the initialisation and maintenance of T cell activation.    
   
129 
 
 
Figure 5.12. Effect of plate-bound or soluble antibody activation of NFAT expression in T cells. 
PD-1 Jurkat T cells were treated with 1 or 5 μg/ml anti-CD3 for 24 h in RPMI 1% FCS either in wells 
that have been coated with anti-CD3 (plate-bound) or anti-CD3 that was soluble in the media. If 
applicable, recombinant PD-L1 Fc was added at the same time as anti-CD3 to attempt to block the 
PD-L1 binding site. A) Cells were analysed for surface expression of PD-1 and CD69 by flow 
cytometry. B and C) Histograms showing intensity of PD-1 and CD69 expression, D) NFAT 
activation was subsequently analysed for luminescence following addition of luciferase substrate 
(Bio-Glo). n = 3 samples run in triplicate. iCD3 = immobilised anti-CD3, sCD3 = soluble anti-CD3 
and PBS = no activating factors. Average MFI of PD-1: iCD3 [5] = 11220, iCD3 [5] + PD-L1 Fc = 
908, iCD3 [1] = 4763, sCD3 [5] = 2513, sCD3 [5] + PD-L1 Fc = 492, sCD3 [1] = 2063 and PBS = 
130. Average MFI of CD69: iCD3 [5] = 1001, iCD3 [5] + PD-L1 Fc = 655, iCD3 [1] = 357, sCD3 [5] 
= 232, sCD3 [5] + PD-L1 Fc = 142, sCD3 [1] = 217 and PBS = 23.7.  
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Figure 5.13. NFAT Activation of Jurkat T cells with soluble CD3/CD28. PD-1 Jurkat T 
cells were treated with 5 μg/ml anti-CD3 and either 0, 1 or 3 μg/ml anti-CD28 for 6 or 24 h 
in RPMI 1% FCS. A) NFAT activation was subsequently analysed for luminescence 
following addition of luciferase substrate (Bio-Glo). Striped bars = 6 h time-point and bars 
with no pattern = 24 h time-point. n = 3 samples in triplicate. B) Cells were analysed by flow 
cytometry for surface PD-1 expression after 24 h. Average MFI of PD-1: sCD3 + sCD28 [3] 
= 1038, : sCD3 + sCD28 [3] + PD-L1 Fc = 385, sCD3 + sCD28 [1] = 983, sCD3 + sCD28 
[1] + PD-L1 Fc = 392, sCD3 [3] = 565, sCD3 + PD-L1 Fc = 297, sCD28 [3] = 104, sCD28 
[1] = 96.2, RPMI = 78.7.   
131 
 
5.3.2. Co-culture of primary cells with plate-bound activated PD-1 Jurkat cells  
Having determined two forms of activation of PD-1 Jurkat cells, the next step was to 
establish a protocol for the co-culture. Plate-bound antibody activation of PD-1 Jurkat cells 
gave the higher level of activation and PD-1 expression compared to using soluble 
antibodies. PD-1 Jurkat cells were pre-activated on anti-CD3/CD28 coated wells for ~4 h 
prior to the addition of pre-stimulated HFFs on top of the PD-1 Jurkat cells (IFN- and TNF-
, 24 h) (Figure 5.14A). This meant that additional time was required for the HFFs to adhere. 
Following co-culture for ~16 h, activation of NFAT in PD-1 Jurkat cells were analysed by 
luciferase assay. For this co-culture method, I tested HFFs transfected with siRNAs for non-
targeting control (siNTC) or PD-L1 (siPD-L1) as well as two anti-PD-1 antibodies 
(EH12.2H7, Figure 5.14B and nivolumab, Figure 5.14C) to determine PD-1/PD-L1 
interaction. It was expected that knockdown of PD-L1 would increase activation of NFAT in 
PD-1 Jurkat cells. Co-culture had a modest decrease to NFAT signal in PD-1 Jurkat cells, 
which was also not affected by the depletion of PD-L1. As activation of NFAT in samples 
treated with non-targeting control were higher than samples where PD-L1 was knockdown. 
Addition of HFFs to Jurkat T cells decreased T cell activation. In addition, samples with 
Jurkat only controls had increased NFAT signal compared to counterpart isotype controls 
and was more noticeable in samples treated with nivolumab. These results suggest that the 
protocol with plate-bound activation above does not demonstrate that PD-1/PD-L1 
interaction affects the activation of NFAT in PD-1 Jurkat cells. Although, plate-bound 
activation of PD-1 Jurkat cells generates the higher form of activation, it is complicated by 
other factors such as the addition of HFFs to the well, such as the suspension of PD-1 Jurkat 
cells that may be displaced from the bottom of the well due to this movement and thereby 
detach from plate-bound anti-CD3/CD28. 
132 
 
 
Figure 5.14. Effect of co-culture on plate-bound activated PD-1 Jurkat cells. A) Jurkat T 
cells were incubated with plate-bound anti-CD3/CD28 with anti-PD-1 (panel B, EH12.2H7, 
red), anti-PD-1/nivolumab (panel C, blue) or isotype IgG control in a 96-well plate. After 4 
h, pre-stimulated HFFs which were either siRNA transfected with non-targeting control 
(NTC) or PD-L1, were added and cells were co-cultured for 16 h. For Jurkat control, the 
same volume in media was added. This means the Jurkat cells were pre-activated prior to 
addition of HFFs and anti-CD3/CD28 remained in the media during co-culture. Cells were 
subsequently analysed for luminescence following addition of luciferase substrate (Bio-
Glo). % Jurkat cell activation is calculated from normalisation of all luciferase readings to 
the average of the relevant Jurkat isotype control. n = 3 samples run in triplicate. 
5.3.3. Co-culture of primary cells with soluble activated PD-1 Jurkat cells  
As an alternative, soluble anti-CD3/CD28 antibodies were used for activation of PD-1 Jurkat 
cells (Figure 5.15). HFFs were adhered and stimulated with IFN- and TNF- (24 h) to 
increase PD-L1 expression. I tested the addition of PD-1 Jurkat cells, overlaying these cells 
on top of HFFs for different periods (Figure 5.16A). I also adjusted the times before anti-
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CD3/CD28 antibodies were applied to start the activation of T cells, as there may be a pre-
incubation time required for the HFFs and PD-1 Jurkat cells to form an interface or 
immunological synapse (Figure 5.16A). Suppression of NFAT activation was more evident 
with 3-4 h of pre-incubation. Upon further testing, I activated the PD-1 Jurkat cells for a 
lesser time and found that as early as 3 h activation there was a decrease in NFAT signal 
with 3 h pre-incubation (Figure 5.16B). Activation times of 1-2 h for PD-1 Jurkat cells may 
be too short to see a difference. Further 3 h pre-incubation periods with longer activation (up 
to 9 h) yielded a similar decrease in NFAT activity (Figure 5.17A). This suggested that for 
HFFs, a pre-incubation period is required to suppress T cell activity. By titrating the starting 
number of HFFs versus PD-1 Jurkat cells, there was a significant amount of suppression of 
NFAT activity with increasing density of IFN- and TNF- stimulated HFFs (Figure 5.17B). 
Untreated HFFs can also suppress T cell activation which is then further decreased when 
HFFs were treated with IFN- and TNF- (Figure 5.18A). There was no disparities between 
using fresh media or conditioned media that was collected from HFFs treated with IFN- and 
TNF- to test for possible factors in the media that affected the activation of T cells, 
indicating that the suppression was primarily mediated by cell-cell contact. 
 
Figure 5.15. Effect of co-culture on soluble activated PD-1 Jurkat cells. In the final 
version of this assay. HFFs were seeded in 96-well plate format for up to 24 h.  Untreated 
PD-1 Jurkat T cells were added to IFN- and TNF- stimulated (24 h) HFFs and co-cultured 
without activating antibodies for up to 3 or 4 h to establish cell-cell interactions. 
Subsequently, anti-CD3, anti-CD28 and anti-PD-1 (if applicable) were added to the well to 
initialise activation of PD-1 Jurkat cells whilst in contact with HFFs for up to a total of 8 to 
24 h co-culture.  
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Figure 5.16. Pre-incubation prior to anti-CD3/CD28 activation is required for 
suppression of Jurkat cell activation. Untreated PD-1 Jurkat T cells were added to IFN- 
and TNF- stimulated (24 h) HFFs and co-cultured without activating antibodies (defined as 
pre-incubation) for the time-period indicated. Subsequently, anti-CD3 and anti-CD28 were 
added to activate the Jurkat cells that are in co-culture with HFFs. Total co-culture time is 
notified by the number on the top row; bottom row indicates the pre-incubation time. A) 
Total co-culture up to 16 h with pre-incubation between 0-4 h, Jurkat cells were analysed by 
luciferase assay to assess NFAT activation. B) Total co-culture up to 6 h with pre-incubation 
between 0-5 h. Jurkat cells were analysed by luciferase assay to assess NFAT activation. % 
Jurkat cell activation is calculated from normalisation of all luciferase readings to the 
average of the anti-CD3/CD28-treated Jurkat only control. n = 3 samples run in triplicate. 
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Figure 5.17. HFFs inhibit activation of PD-1 Jurkat T cells. A) Untreated PD-1 Jurkat T 
cells were added to IFN- and TNF- stimulated (24 h) HFFs and pre-incubated initially 
without activating antibodies (3 h). Subsequently, anti-CD3 and anti-CD28 were added to 
activate the Jurkat cells that were in co-culture with HFFs, length of activation is indicated 
on the x-axis. Following co-culture, Jurkat cells were analysed by luciferase assay to assess 
NFAT activation.  B) Similar preliminary setup to A) but with titration of number of HFFs 
per well (i.e. this is the starting number of HFFs in the well). Pre-incubation of Jurkat and 
HFFs occurred for 3 h before activation of Jurkat with anti-CD3 and CD28 for the time 
indicated on the x-axis. % Jurkat cell activation is calculated from normalisation of all 
luciferase readings to the average of the anti-CD3/CD28-treated Jurkat only control. Two-
way analysis of variance (ANOVA) was calculated with Tukey's multiple comparisons test, 
here showing the difference between Jurkat control and HFF (1x104/well). **, p < 0.01. n = 
3 samples run in triplicate. 
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Next, I transfected HFFs with siRNAs for NTC and PD-L1 (Figure 5.18B). There was no 
noticeable difference apart from a small increase from the knockdown of PD-L1 on NFAT 
activity. I also transfected miR-155 mimics, which previously described to decrease PD-L1 
expression, generated a small decrease on T cell activation (Figure 5.18B). Previously, 
nivolumab (anti-PD-1 antibody) was shown to affect the activation of PD-1 engineered 
Jurkat T cells (Skalniak et al. 2017). Blockade of PD-1 using nivolumab partially restored 
NFAT signal but there were some technical difficulties since nivolumab affected the 
luciferase signal given by PD-1 Jurkat cells (Figure 5.19A). Specifically, the PD-1 Jurkat 
control cells were generating decreased luciferase signal after nivolumab was added to the 
co-culture compared to the isotype control, suggesting nivolumab was affecting the PD-1 
Jurkat cells themselves. The reason for this is unknown and testing for cell viability using 
the Alamar Blue assay did not indicate that the PD-1 Jurkat cells were dying (Figure 5.19B).     
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Figure 5.18. IFN- + TNF- treated HFFs suppress Jurkat T cell activation but is not 
restored by blocking PD-1/PD-L1 interaction. A) Conditioned media was collected from 
IFN- and TNF- stimulated HFFs (2 h) and added at the same time as untreated PD-1 
Jurkat T cells were added to HFFs and co-cultured initially without activating antibodies (3 
h). Percentage indicates the ratio of conditioned to fresh media. Subsequently, anti-CD3 and 
anti-CD28 were added to activate the PD-1 Jurkat cells that are in co-culture with HFFs (3 
h). B) HFFs were transfected with miR-155 mimic or PD-L1 siRNA (48 h) and treated with 
IFN- and TNF- (24 h). PD-1 Jurkat cells were co-cultured with HFFs for 3 h without 
activating factors and then anti-CD3 and anti-CD28 were added to activate the Jurkats (3 h). 
Following co-culture, Jurkat cells were analysed by luciferase assay to assess NFAT 
activation. % Jurkat cell activation is calculated from normalisation of all luciferase readings 
to the average of the anti-CD3/CD28-treated Jurkat only control. n = 3 samples run in 
triplicate. Unpaired Student's t test was used to compare ‘HFF UT/Jurkat’ and ‘HFF IFN- + 
TNF-/Jurkat’. *, p < 0.05. n = 3 samples run in triplicate.   
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Figure 5.19. Effect of nivolumab on the blockade of PD-1/PD-L1 interaction in this 
assay. A) Jurkat T cells were incubated with pre-treated HFFs (IFN- and TNF-, 24 h) and 
anti-PD-1/nivolumab or isotype IgG control for 3 h and then activated with anti-CD3/CD28 
were for 3 or 4 h. Cells were subsequently analysed for luminescence following addition of 
luciferase substrate (Bio-Glo). % Jurkat cell activation is calculated from normalisation of 
all luciferase readings to the average of the relevant anti-CD3/CD28-treated Jurkat isotype 
control. B) In a parallel setup to A), Alamar Blue was added to wells at the final step 
(instead of the luciferase substrate) to determine cell viability and the fluorescence was 
measured. HFF only controls were used to determine the contribution of Jurkat cells within 
the co-culture to the fluorescence reading. [1] denotes 1 g/ml. n = 3 samples run in 
triplicate. 
To investigate the effect of HDLECs on PD-1 Jurkat cell activation, a similar approach was 
undertaken whereby HDLECs were titrated versus Jurkat cells (Figure 5.20). Untreated 
HDLECs did not display any difference, in contrast, IFN- and TNF- treated HDLECs 
significantly suppressed PD-1 Jurkat cell activation. The highest density of HDLECs used 
had the most suppressive effect. These data indicate that both IFN- and TNF- activated 
HFFs and HDLECs can suppress NFAT activity in PD-1 Jurkat cells.     
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Figure 5.20. HDLECs inhibit activation of PD-1 Jurkat T cells. Untreated PD-1 Jurkat T 
cells were added to IFN- and TNF- stimulated (24 h) HDLECs (number per well is shown 
on x-axis) and co-cultured initially without activating factors (3 h). Subsequently, anti-CD3 
and anti-CD28 were added (3 h) to activate the Jurkat cells that were in co-culture with 
HDLECs. Following co-culture, Jurkat cells were analysed by luciferase assay to assess 
NFAT activation. % Jurkat cell activation is calculated from normalisation of all luciferase 
readings to the average of the anti-CD3/CD28-treated Jurkat only control. n = 3 samples run 
in triplicate. Unpaired Student's t test was used to compare ‘LEC UT/Jurkat’ and ‘LEC IFN-
 + TNF-/Jurkat’. *, p < 0.05. n = 3 samples run in triplicate.   
5.3.4. PD-L1 knockdown does not affect T cell activation in PD-1hi-sorted Jurkat cells  
To assess whether the weak effect of PD-1 blockade (or PD-L1 siRNA knockdown) on 
NFAT activity was dependent on PD-1 expression, PD-1 Jurkat cells were FACS sorted 
based on high expression of PD-1 (Figure 5.21). Untreated pre-sorted PD-1 Jurkat cells were 
gated on the higher expressing PD-L1 population of cells (based on MFI) and were sorted 
into a new population defined as PD-1hi Jurkat cells (Figure 5.21A and C). Activation of PD-
1hi Jurkat cells with soluble anti-CD3/CD28 (3 h) increased the expression of PD-1 from 
untreated levels (84.5% to 93.8% of cells) and gained 2-fold MFI over activated pre-sorted 
Jurkat cells (Figure 5.21B and D). Co-culture experiments were repeated with the sorted PD-
1hi Jurkat cells using soluble anti-CD3/CD28 activation similarly to the previous setup 
(Figure 5.22A). Compared to previous results (Figure 5.17B), the addition of HFFs to PD-1hi 
Jurkat cells resulted in reduced suppression of NFAT activation with both untreated or IFN- 
and TNF- treated HFFs. There was no noticeable difference in the activation of PD-1hi 
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Jurkat cells when co-cultured with HFFs that were depleted of PD-L1 (Figure 5.22B). 
However, there was further decrease in activation of PD-1hi Jurkat cells when IFN- and 
TNF- stimulated HFFs were transfected with miR-155 mimics but not with untreated HFFs 
(Figure 5.22B). Similar to HFFs, co-culture of PD-1hi Jurkat cells with IFN- and TNF- 
treated HDLECs resulted in a reduced effect of suppression (Figure 5.23A). Neither 
knockdown of PD-L1 or transfection of miR-155 mimics in HDLECs affected NFAT 
activation in PD-1hi Jurkat cells (Figure 5.23B). Overall, stimulation of HFFs or HDLECs 
with IFN- and TNF- induced a suppressive effect on NFAT activation. However, blocking 
PD-1/PD-L1 interaction did not affect NFAT activation. 
 
Figure 5.21. PD-1 expression on pre- and post-sort of PD-1 Jurkat T cells. PD-1 Jurkat T 
cells were sorted for high expression of PD-1 by FACS and compared to pre-sorted Jurkat T 
cells. A) and B) Pre-sorted Jurkat cells were activated with anti-CD3 and anti-CD28 (3 h) or 
left untreated and analysed by flow cytometry for surface PD-1 expression. C and D) Post-
sorted Jurkat cells were activated with anti-CD3 and anti-CD28 (3 h) or left untreated. PD-1 
MFI: untreated pre-sorted PD-1 Jurkat cells = 67, soluble anti-CD3/CD28 activated pre-
sorted PD-1 Jurkat cells = 1188, untreated post-sorted PD-1hi Jurkat cells = 767, soluble anti-
CD3/CD28 activated post-sorted PD-1hi Jurkat cells = 2356. n = 1 experiment.      
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Figure 5.22. PD-L1 knockdown in HFFs has no effect in the co-culture model. A) Sorted 
PD-1hi Jurkat T cells were co-cultured with titrated number of IFN- and TNF- stimulated 
HFFs (3 h) prior to addition of anti-CD3 and anti-CD28 (3 h). B) HFFs were transfected 
with miR-155 mimic or PD-L1 siRNA (48 h) and treated with IFN- and TNF- (24 h). 
Sorted PD-1hi Jurkat cells were co-cultured with HFFs for 3 h without activating factors and 
then anti-CD3 and anti-CD28 were added to activate the Jurkats (3 h). Following co-culture, 
Jurkat cells were analysed by luciferase assay to assess NFAT activation. % Jurkat cell 
activation is calculated from normalisation of all luciferase readings to the average of the 
anti-CD3/CD28-treated Jurkat only control. Unpaired Student's t test was used to compare 
‘HFF UT/Jurkat’ and ‘HFF IFN- + TNF-/Jurkat’. *, p < 0.05. n = 3 samples run in 
triplicate.   
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Figure 5.23. PD-L1 knockdown in HDLECs has no effect in the co-culture model. A) 
Sorted PD-1hi Jurkat T cells were co-cultured with titrated number of IFN- and TNF- 
stimulated HDLECs (3 h) prior to addition of anti-CD3 and anti-CD28 (3 h). B) HDLECs 
were transfected with miR-155 mimic or PD-L1 siRNA (48 h) and treated with IFN- and 
TNF- (24 h). Sorted PD-1hi Jurkat cells were co-cultured with HDLECs for 3 h without 
activating factors and then anti-CD3 and anti-CD28 were added to activate the Jurkats (3 h). 
Following co-culture, Jurkat cells were analysed by luciferase assay to assess NFAT 
activation. % Jurkat cell activation is calculated from normalisation of all luciferase readings 
to the average of the anti-CD3/CD28-treated Jurkat only control. Unpaired Student's t test 
was used to compare ‘LEC UT/Jurkat’ and ‘LEC IFN- + TNF-/Jurkat’. *, p < 0.05. n = 3 
samples run in triplicate.   
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5.4. Chapter discussion 
This chapter focused on the development of co-culture assays to study the effect of PD-L1 
expression and regulation on T cell activation, using both wild-type and engineered Jurkat 
cells as a model for T cells. Both co-culture models were developed off previously reported 
systems (Yang et al. 2008; Skalniak et al. 2017) to test PD-1/PD-L1 interaction with primary 
stromal fibroblasts/vascular cells that have been used in previous chapters. The experimental 
setup required extensive optimisation and was far more complex than first thought. Both 
NFAT and IL-2 were used as measures of Jurkat T cell activation of which NFAT is an 
essential component that contributes towards IL-2 expression (Chow et al. 1999) and both 
factors have been used to characterise PD-1/PD-L1 interaction (Yang et al. 2008; Skalniak et 
al. 2017). In addition, surface levels of CD69 were used, which serves as an independent 
early activation marker (Sancho et al. 2005). There was a noticeable and reproducible 
difference in IL-2 or NFAT after co-culture with HFFs or HDLECs (Figures 5.4, 5.17B, 
Figure 5.20), suggesting that HFFs/HDLECs did interact with the activation of Jurkat cells 
in both co-culture models. In contrast, neither of the two co-culture models which utilised 
different measures of T cell activation showed an effect that was dependent on PD-1/PD-L1 
interaction since depletion of PD-L1 by siRNA or blockade of PD-1 with antibodies made 
no difference to the described markers of T cell activation.  
Presentation of specific antigen activates T cells and upregulates PD-1 expression, which is 
dependent on the concentration of antigen and duration of antigen stimulation (Xu-Monette 
et al. 2017). The importance of antigen expression on the PD-L1-expressing cell may 
influence whether PD-1/PD-L1 interaction occurs as co-localisation of PD-1 with CD3 
and/or CD28 is required for suppression of T cell activation (Chemnitz et al. 2004). Purified 
primary CD4+ T cells were coated with artificial APCs that were constructed using magnetic 
beads comprised of anti-CD3, anti-CD28, anti-MHC class I and anti-PD-1. T cells were 
activated with anti-CD3/CD28-coated beads in the production of IL-2 mRNA, compared to 
using anti-MHC class I which served as the negative control. CD28 stimulation was required 
for rapid increase of PD-1 mRNA. Moreover, SHP2 was recruited to the cytoplasmic tail of 
PD-1 upon TCR-induced cell activation but only upon PD-1 engagement can SHP2 mediate 
inhibition of T cell activation. In addition, low levels of PD-1 surface expression on CD4+ T 
cells were sufficient for inhibitory effects and SHIP1 did not bind to PD-1 cytoplasmic tail 
(Chemnitz et al. 2004). These findings suggest that for further optimisation of the PD-1 
Jurkat co-culture assay, anti-MHC class I antibodies could be used to test whether antigen-
dependent stimulation is required for PD-1/PD-L1 interaction to occur.  
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In co-culture assays using Jurkat cells to investigate PD-1/PD-L1 interaction, Raji B cells 
were pre-incubated with the superantigen staphylococcal enterotoxin E (SEE) that binds to 
MHC class II molecules and the TCR (Tian et al. 2015; Zhao et al. 2018; Fraser et al. 1992). 
This would enable Jurkat cells to recognise antigen-loaded Raji B cells and become 
activated upon interaction. The advantage of using superantigens is that it only requires 
binding to the TCR to induce acute inflammatory responses (Pinchuk et al. 2008) and SEE 
has been shown to activate NFAT and IL-2 in wild-type Jurkat cells (Antón et al. 2008). In 
addition, superantigens can be used to bind to a diverse number of cell types via MHC class 
II molecules. I have shown that IFN- and TNF--activated HDLECs can express MHC 
class II molecules, and fibroblasts have been demonstrated in a previous paper to express 
MHC class II upon activation (Ilangumaran et al. 2002). To further optimise the co-culture 
assay, primary stromal fibroblasts/vascular cells could be pre-loaded with superantigen SEE 
(or similar) prior to co-culture (Brogan et al. 2004), instead of using anti-CD3/CD28 
antibodies to activate Jurkat cells. In some studies, PD-1/PD-L1 interaction has been 
demonstrated between wild-type Jurkat cells and human melanoma or breast cancer cells 
without the use of superantigen or antigen presentation on PD-L1-expressing cells (Yang et 
al. 2008; Black et al. 2016; Li et al. 2016). This may be due to the level of immunogenicity 
of these tumour cells as a result of mutations that give rise to tumour-associated antigens, 
enabling further interactions between cancer cells and Jurkat cells (Escors 2014). Overall, 
the use of pre-loaded antigens on PD-L1-expressing cells can enable these cells to function 
as non-professional APCs in order to analyse PD-1/PD-L1 interaction in a physiological 
manner. 
For the first co-culture model involving IL-2, which was based on a previously described 
system, uveal melanoma cells overall decreased the amount of IL-2 produced by Jurkat cells 
(Yang et al. 2008). In addition to IL-2, the production of IFN-, TNF- and IL-10 have been 
characterised after PD-1 blockade in T cell co-cultures with lymphoma cell lines, to 
determine the activation of T cells (Quan et al. 2015). In contrast to the report that this co-
culture procedure was based on (Yang et al. 2008), Jurkat cells were pre-treated with PHA 
and PMA instead of this addition at the co-culture step. This meant that HFFs were 
unaffected by PHA and PMA treatment, where PMA has been shown to affect the growth of 
fibroblasts and induce cyclooxygenase-2 (COX-2) expression, an inflammatory mediator 
(Ning & Mamrack 1994; Cheng et al. 2014). An additional reason was that PD-1 expression 
induced by PHA and PMA treatment on Jurkat cells requires up to 48 h to reach maximal 
levels. This meant that the measurement of IL-2 production from Jurkat cells took place at a 
different stage of T cell activation compared to the previous report (Yang et al. 2008). 
Overall, HFFs induced IL-2 secretion of pre-treated Jurkat cells and this induction was 
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suppressed with IFN- and TNF- stimulated HFFs. By eliminating cell-cell contact using a 
Transwell system, the induction of IL-2 by untreated HFFs was suppressed but not with 
treated HFFs suggesting the presence of anti-inflammatory cell-contact-dependent 
interactions that are induced by IFN- and TNF-. A titration of increasing density of HFFs 
to Jurkat cells could have shown a range of effect on T cell activation with and without 
Transwell inserts. Furthermore, PHA stimulation can induce apoptosis of Jurkat cells in a 
concentration-dependent manner, a process termed activation-induced cell death (Zhang et al. 
2017). I found some similarity in the number of live-stained cells (~43% PHA/PMA treated) 
in my results comparing to PHA stimulation in the previously described report (Zhang et al. 
2017), indicating that there were fewer Jurkat cells to interact with HFFs which may 
decrease any effect of PD-1/PD-L1 interaction that could be observed.       
Therefore, I investigated whether a second co-culture model could demonstrate PD-1/PD-L1 
interaction using PD-1 engineered Jurkat cells. In this second approach, the limiting factors 
that were thought to be associated with the first approach (i.e. PD-1 expression, live number 
of cells) could be taken into consideration in order to observe PD-1/PD-L1 interaction. This 
method utilised PD-1 engineered Jurkat cells with a luciferase reporter linked to NFAT, 
which can be used to measure luminescence and improve the sensitivity of the assay. 
Activation of PD-1 Jurkat cells with anti-CD3/CD28 antibodies expressed more levels of 
PD-1 than PHA/PMA activated wild-type Jurkat cells without requiring a longer period of 
stimulation that could cause activation-induced cell death. This was demonstrated by a 
difference of ~43% live-stained cells with PHA/PMA-treated Jurkat cells compared with 
~70-80% live cells using anti-CD3/CD28 with PD-1 engineered Jurkat cells. There were two 
different developments of this assay that deviated from the previously described method that 
presented a challenge (Skalniak et al. 2017), involving the use of plate-bound or soluble 
activation to stimulate PD-1 Jurkat cells. As this was to replace engineered CHO cells that 
overexpressed PD-L1 and a ligand to activate the TCR (Skalniak et al. 2017). In another 
report that showed a similar PD-1 NFAT system, a membrane-anchored anti-CD3 antibody 
(OKT3) fragment was engineered onto CHO cells (L. Wang et al. 2017). The difference 
between my experimental procedure and the previously described reports (Skalniak et al. 
2017; L. Wang et al. 2017) is there are two specific interactions, such that an APC can 
activate and inhibit the same Jurkat cell. In my setup, anti-CD3/CD28 antibodies were used 
to activate PD-1 Jurkat cells and IFN- and TNF- to induce PD-L1 expression on 
HFFs/HDLECs. Thus, this represents only one interaction from the PD-L1-expressing cell 
and increases the variability of the type of interactions that can occur. For example, an IFN- 
and TNF- stimulated HFF could make contact with an unstimulated PD-1 Jurkat cell. The 
pre-incubation of both Jurkat and PD-L1-expressing cells was essential in demonstrating an 
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effect on PD-1 Jurkat cell activation. The idea was to facilitate the assembly of an interface 
between the two cell types or the immunological synapse where PD-1 can be recruited upon 
TCR engagement (Pentcheva-Hoang et al. 2007; Yokosuka et al. 2012). The interaction 
between PD-1/PD-L1 is characterised as entropy-driven and relies on relatively weaker 
interactions, compared to CD28/CTLA-4 (Cheng et al. 2013; Parry et al. 2005). The 
suppressive effect mediating by HFFs/HDLECs was not found to be dependent on PD-1/PD-
L1 interaction and suggests a lack of MHC-peptide antigen may be the issue. Antigenic 
peptide-MHC binding can induce restructuring of the actin cytoskeleton that leads to PD-1 
accumulation at the immunological synapse, which can be stabilised by PD-L1 (Pentcheva-
Hoang et al. 2007). The formation of PD-1/PD-L1 checkpoint interaction may have been 
prevented between HFFs/HDLECs and PD-1 Jurkat cells, or there was a lack of downstream 
effector signalling if the two molecules did engage (Pentcheva-Hoang et al. 2007). A 
positive control for this co-culture procedure would be to use the CHO-K1 cells that express 
a TCR ligand and PD-L1 to determine whether the same PD-1 Jurkat T cells require the 
interaction at the TCR to initiate the PD-1/PD-L1 interaction that is described in published 
reports (Skalniak et al. 2017; L. Wang et al. 2017).  
The role of miR-155 in CD4+ T cells has been shown to be important for influencing IFN- 
signalling and generating a bias for Th1 differentiation (Rodriguez et al. 2007; Lu et al. 2009; 
Banerjee et al. 2010). Moreover, miR-155 is required for optimal responses of CD8+ T cells 
by enhancing cytokine signalling through the targeting of SOCS1 (Dudda et al. 2013; 
Gracias et al. 2013). The expression of miR-155 was shown to regulate LCMV-mediated 
CD8+ T cell exhaustion (Stelekati et al. 2018). miR-155 was shown to influence T cell 
differentiation through the balance of AP-1 family members where overexpression of miR-
155 resulted in decreased expression of NFAT1 and Fosl2. Of note, the overexpression of 
miR-155 did not complement the efficacy of anti-PD-L1 blocking antibody treatments in 
exhausted CD8+ T cells (Stelekati et al. 2018). What effect may miR-155 expression in 
stromal fibroblasts/vascular cells have on the inflammatory response, in particular on T cell 
activation in a paracrine manner? Previously, miR-155 expression was demonstrated to 
decrease PD-L1 expression (Chapter 3) which suggested that using miR-155 mimics in 
HFFs/HDLECs may lead to an increase in Jurkat cell activation. In contrast, the addition of 
miR-155 mimics to IFN- and TNF--stimulated but not untreated HFFs was found to have 
a modest decrease on NFAT activation in PD-1hi Jurkat cells, suggesting the overall effect of 
miR-155 in HFFs may have a suppressive effect on T cell activation. However, the findings 
are limited because it was not possible to observe whether miR-155-dependent regulation of 
PD-L1 expression affects T cell activation.  
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In sum, I aimed to investigate the functional relevance of the effects of miRNA regulation of 
PD-L1 protein expression on the activation of T cells using stromal fibroblasts/vascular cells. 
I can determine that HFFs/HDLECs affect markers of T cell activation (NFAT, IL-2) and 
that IFN- and TNF- stimulation of HFFs/HDLECs suppresses activation of Jurkat cells. 
The experimental setups of these co-cultures are influenced and interlinked by a number of 
limitations and variables that include: the type of cells used (with/without genetic 
engineering of antigen or PD-L1 expression), the activation of Jurkat cells, the type of PD-
1/PD-L1 blockade used, the period of co-culture, the concentration of cells per co-culture 
and the controls that are used for normalisation of IL-2 or NFAT signal (Goers et al. 2014). 
A “small” adjustment in the system could widely affect the results of the co-culture. These 
setups have generated reproducible results using IL-2 or NFAT expression upon repeated 
experiments but have yet to show an effect on T cell activation that is dependent on PD-
1/PD-L1 interaction in their current state. Further optimisation is required for the co-culture 
assays as these will determine whether regulatory effects of PD-L1 expression on 
HFFs/HDLECs can affect T cell activation. 
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6. PD-L1 silencing in primary cells 
6.1. Introduction 
Previously, I showed that inflammatory cytokines and inflammatory-regulated miRNAs can 
affect the expression of PD-L1. At the time of those experiments it was relatively weakly 
understood whether PD-L1 had any forward signalling or feedback mechanisms to the 
effects on its expression in a cell-intrinsic manner. This chapter explored the capabilities of 
PD-L1 by silencing its expression and investigating the resulting effects specifically on key 
STAT proteins and miRNA levels in an exploratory fashion.    
The cytoplasmic region of human PD-L1 is short (30 aa) and relatively conserved in pigs, 
cattle, mice and rats (Figure 6.1A) (Keir et al. 2008). Human PD-L2 also has a short 
intracellular tail (30 aa) but in mice and rats there are a loss of amino acid residues towards 
the end of the PD-L2 tail sequence (Figure 6.1B) (Latchman et al. 2001). Initially, PD-L1 
was thought to have no signalling motifs or any known signalling function. Emerging 
evidence have shown that PD-L1 may indeed have a role in intracellular signalling (Azuma 
et al. 2008; Jin et al. 2011; Chang et al. 2015; Clark et al. 2016; Gato-Cañas et al. 2017; 
Lucas et al. 2018). In studies using mouse tumour models, tumour expression of PD-L1 was 
demonstrated to regulate mTOR activity and glycolytic metabolism in tumour cells as 
blockade of PD-L1 decreased phosphorylation of Akt (S473) and mTOR target proteins and 
glycolysis enzymes (Chang et al. 2015). These findings were supported by another study that 
found tumour expression of PD-L1 regulated cell proliferation, mTOR signalling and 
autophagy without the need for engagement of PD-1 (Clark et al. 2016).  
PD-L1 was indicated to have a functional role in corneal angiogenesis (Jin et al. 2011). 
Knockdown of PD-L1 by siRNA transfection was demonstrated to increase VEGFR2 and 
proliferative levels of MS1 pancreatic islet endothelial cells (obtained from a C57BL/6 
mouse). A higher level of angiogenesis was observed in PD-L1 knockout mice compared to 
wild-type mice but there was no change in expression of inflammatory cytokines after 
induction of inflammation. This suggests that PD-L1 expression limits endothelial cell 
division. Additionally, inhibition of a potential binding partner of PD-L1, CD80 affected 
similar targets including VEGFR2 which may be addressed by possible interaction between 
PD-L1 and CD80 (Jin et al. 2011). Typically, CD80 provides a co-stimulatory signal for 
activation of T cells by binding to CD28 on the surface of T cells but can also interact with 
the immune checkpoint CTLA-4 to attenuate T cell immune responses. Moreover, PD-L1 
was reported to receive a signal from PD-1 which allowed cancer cells to resist T cell-
mediated apoptosis (Azuma et al. 2008). These experiments involved engineered PD-1 and 
PD-L1 with normal binding but impaired ability to transmit signals to tumour cells or T cells. 
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Truncation of the intracellular domain of PD-L1 but not PD-1 suppressed lysis of cancer 
cells. Replacing the extracellular domain of PD-L1 with the corresponding region from PD-
L2 did not affect the lysis of cancer cells (Azuma et al. 2008).  
Three sequence motifs in the intracellular domain of PD-L1 were linked with tumour 
progression (Gato-Cañas et al. 2017). Expression of IFN- was linked to lethality of murine 
melanoma cells (B16) when PD-L1 expression was silenced or the cytoplasmic domain was 
deleted. “RMLDVEKC” and “DTSSK” were identified to be associated with a 
posttranslational modification mechanism that leads to ubiquitination and destabilisation 
(Lim et al. 2016) through mutation of these sequences (Gato-Cañas et al. 2017). Moreover, a 
third sequence motif “QFEET” was found to protect against the effects of IFN--mediated 
cytotoxicity, whereas deletion of “RMLDVEKC” and “DTSSK” enhanced resistance to 
IFN- toxicity. Silencing of PD-L1 using PD-L1 knockout B16 cells increased STAT3 
phosphorylation (Y705), and caspase 7 after IFN- stimulation. Moreover, mutation of the 
human homolog of the “DTSSK” motif also enhanced resistance to type I and type II IFN-
induced toxicity (IFN-, IFN- and IFN-). These findings indicate that signalling motifs in 
the intracellular domain of PD-L1 confer resistance against IFN-induced cytotoxicity in 
order to protect cancer cells (Gato-Cañas et al. 2017).       
A recent study highlighted a role of PD-L1 in promoting survival of LECs (Lucas et al. 
2018). Type I IFN-/ receptor signalling was demonstrated to induce PD-L1 expression in 
human and mouse LECs of the LN, particularly on the subcapsular sinus. This was observed 
during early time points following immunisation (polyI:C) and infection (vaccinia virus, and 
chikungunya). Of importance was the level of PD-L1 expression which was shown to 
negatively correlate with the division of LECs and the expression of caspase-3/7 in response 
to type I IFN-inducing stimuli. In response to an acute inflammatory response, there was 
more LEC division and apoptosis in PD-L1-low expressing mice during expansion and 
contraction of the LN. In addition, LECs with high PD-L1 expression had elevated levels of 
CXCL4, a known inhibitor of endothelial cell division. This report demonstrates that type I 
IFN stimulation leads to PD-L1 upregulation on LN-LECs, which could determine apoptosis 
of LECs and the growth of lymphatic vasculature (Lucas et al. 2018). 
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Figure 6.1. Alignments of PD-L1 and PD-L2 protein sequences in mammals. A) PD-L1 
compared between human, pig, cow, mouse and rat. B) Similar for PD-L2. Red (90% 
consensus) and blue (50%) represent conserved residues. The consensus sequence is 
presented below the species. Note: “RM$DVEKC”, “D.nsk”, “qfEET” consensus sequences 
in the cytoplasmic tail of PD-L1 of which the mouse sequences (“RMLDVEKC”, “DTSSK”, 
“QFEET”) have been characterised (Gato-Cañas et al. 2017). 
6.2. Effects of PD-L1 knockdown on intracellular signalling and miRNAs 
Since, I identified that miRNA-mediated regulation of PD-L1 occurs in HDLECs. I 
investigated whether PD-L1 expression could affect the expression of miRNAs or had any 
role on intrinsic signalling in HDLECs. I aimed to do this by transfecting siRNAs targeting 
PD-L1 and confirmed knockdown at the protein level by approximately 80% after 48 hours 
(Figure 6.2A). In IFN- and TNF--stimulated cells with PD-L1 knockdown, p-STAT3 
levels were increased compared to the control at 8 and 24 h post-stimulation (Figure 6.2A 
and Figure 3.9A). In addition, p-STAT5 was increased in both IFN-, and IFN- and TNF--
stimulated cells following PD-L1 knockdown (Figure 6.2B). No difference in p-STAT1 
expression was observed. These results suggest that in activated cells, PD-L1 can affect 
specific components of the STAT pathway. However, the mechanism or any downstream 
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effects remain to be clarified. Moreover, there was a modest decrease in the phosphorylation 
of Akt (S473) in IFN- and TNF--stimulated cells with PD-L1 knockdown, compared to no 
knockdown. 
 
Figure 6.2. PD-L1 knockdown has modest effects on the STAT and AKT pathway. A 
and B) Protein expression in HDLECs transfected (48 h) with siRNAs targeting PD-L1 or 
non-targeting control and subsequently stimulated with IFN- and TNF- (24 h). For (A) 
HDLEC experiments were run in parallel with the samples collected for small RNA 
sequencing and used for validation of knockdown. n = 2 independent experiments. 
Next, I studied the effect of PD-L1 knockdown on mRNA expression in HDLECs. CD80 
expression was induced by IFN- and TNF- stimulation, although CD80 is lowly expressed 
in HDLECs determined by the cycle threshold value when analysed by qRT-PCR (Figure 
6.3). This finding provides low signal to noise ratio and difficulty determining the results 
where CD80 is increased or decreased following PD-L1 knockdown. In addition, I detected 
very low levels of CD80 surface expression in HDLECs by flow cytometry analysis, 
compared to secondary antibody staining only, indicating that CD80 surface expression is 
under posttranscriptional control (Figure 6.4). The mRNA expression of angiogenic factors 
VEGFR1, VEGFR2, ANG1 and ANG2 were next analysed. I found that VEGFR1 
expression was increased following PD-L1 knockdown in IFN- and TNF--activated cells 
but not with IFN- stimulation alone. VEGFR2 was suppressed regardless of knockdown in 
IFN- and TNF--activated cells. I also observed that VEGFR2 is upregulated only in 
untreated cells after inhibition of PD-L1 and not with stimulated cells. Moreover, IFN- and 
TNF--stimulated cells suppressed the expression of ANG2. PD-L1 did not affect the 
expression of ANG1 or ANG2. The addition of TNF- to IFN- suppressed VEGFR2, 
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ANG1 and ANG2 but not VEGFR1. These data show that inflammatory signalling affect 
key angiogenic factors and suggest that PD-L1 may be associated with VEGFR1 and 
VEGFR2 expression.    
 
Figure 6.3. The effect of PD-L1 knockdown on angiogenic factors and CD80. HDLECs 
transfected with siRNAs targeting PD-L1 or non-targeting control (48 h) and stimulated with 
IFN-γ and TNF-α (24 h) were collected for RNA. mRNA expression of angiogenic factors 
and the co-stimulatory molecules CD80 was analysed by qRT-PCR. 
 
Figure 6.4. CD80 surface expression in HDLECS. Flow cytometric analysis showing 
CD80 surface expression (MFI) after stimulation (24 h) on live HDLECs. A) Untreated (UT) 
levels of CD80. B) IFN- stimulated (24 h) levels of CD80. MFI of CD80 staining: IFN- 
(green) = 15.4,  UT (blue) = 11.0, secondary antibody only (red) = 10.2 and unstained = 
1.90. n = 2 experiments.  
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As described in previous chapters (Chapter 3 and 4) that miRNAs including miR-155 can 
determine the expression of PD-L1 in inflammatory-activated cells, I determined whether 
PD-L1 may have any feedback mechanism that can affect miRNA expression (Figure 6.5). 
No difference was observed with miR-155 expression following PD-L1 knockdown 
suggesting a lack of negative feedback from miRNA modulation of PD-L1 expression. The 
other miRNAs studied were tested previously to determine the effect of IFN- and TNF- 
(Chapter 3). I did not observe any changes due to PD-L1 knockdown on any of these 
miRNAs (Figure 6.5). However, this was a limited selection of miRNAs and to widely 
explore this I continued to investigate whether the expression of other miRNAs could be 
affected by PD-L1 using small RNA sequencing.   
 
Figure 6.5. The effect of PD-L1 knockdown on miRNA levels. miRNA expression as 
analysed by qRT-PCR in HDLECs transfected (48 h) with siRNAs targeting PD-L1 or non-
targeting control and subsequently stimulated with IFN- and TNF- (24 h). n = 2 
independent experiments. 
6.3. Identification of potential miRNAs affected by PD-L1 using small RNA 
sequencing 
To this aim, HDLECs with siRNAs targeting PD-L1 or non-targeting control were set up in 
parallel and treated with IFN- and TNF-. No untreated sample was set up with PD-L1 
knockdown because it was thought that there would be a greater effect due to the difference 
in expression in activated cells. Samples were set up alongside those shown (Figure 6.2) to 
confirm knockdown of PD-L1 expression. Sequencing of these samples were also performed 
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in parallel as those described and simultaneously statistically analysed (Chapter 3). Deletion 
of PD-L1 resulted in differentially expressed miRNAs (Figure 6.6) but less than those 
analysed with or without IFN- and TNF--stimulation (Chapter 3). Sequencing analysis 
identified that miRNAs that were significantly different between samples with PD-L1 
knockdown compared to control were predicted by TargetScan to target PD-L1 including 
miR-20a-5p and miR-576-3p. There is no known resource like TargetScan to predict 
whether miRNA targets can affect the expression of miRNAs themselves. However, low 
stability of miRNAs can lead to changes in response to altered transcription or processing 
(Rüegger & Großhans 2012). It could be possible that upon miRNA-mRNA interaction that 
a feedback mechanism be applied on the miRNA as part of a miRNA-mRNA network, such 
that target mRNAs can modulate miRNA stability in a reciprocal regulation (Rüegger & 
Großhans 2012). Candidate miRNAs were selected for validation based on the following 
criteria: significant fold-change in expression (p < 0.05), known relevant targets in the 
literature, predicted site-binding on PD-L1 3’UTR and predicted targets using TargetScan 
(Agarwal et al. 2015) and Search Tool for the Retrieval of Interacting Genes/Proteins 
database (STRING) (Szklarczyk et al. 2015). For validation of sequencing, both the most 
upregulated (miR-223-3p) and downregulated miRNAs (miR-15b-5p) were selected. In 
addition, the miR-23-27-24 cluster was shown to be linked to the regulation of Th2 
immunity (Cho et al. 2016). I used qRT-PCR to analyse the expression of these miRNAs 
following PD-L1 deletion in HDLECs (Figure 6.7). There were discrepancies between the 
sequencing and qRT-PCR analysis. Firstly, miR-223-3p was suggested to be very lowly 
expressed in activated cells but highly upregulated after knockdown of PD-L1. This was not 
observed with qRT-PCR where miR-223-3p is detectable in activated cells with no 
knockdown. Similarly, no downregulation of miR-15b-5p was found in qRT-PCR but an 
increase to levels of the miRNA following deletion of PD-L1. miR-20a-5p and miR-23b-3p 
were indicated by analysis of sequencing to increase by approximately ~2 fold after 
knockdown of PD-L1 of which only a modest increase was observed in qRT-PCR. 
Sequencing indicated that IFN- and TNF- stimulation downregulates miR-576-3p (~0.5 
fold decrease), seen with qRT-PCR, but there was no further downregulation of miR-576-3p 
in cells with PD-L1 knockdown that was suggested by sequencing. Additionally, the list of 
candidate miRNAs included miR-302c-3p and miR-6865-3p which were undetectable in 
qRT-PCR. Overall, I could not convincingly conclude any of the candidate miRNAs to be 
affected by PD-L1 knockdown using two different techniques to measure miRNA 
expression. This may be due to the sensitivity of each technique although previous miRNAs 
were validated using both techniques (Chapter 3). 
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Figure 6.6. The effect of PD-L1 deletion on miRNA expression. Heat map showing fold-
change in expression of miRNAs from small RNA sequencing (adjusted p < 0.1). HDLECs 
were transfected with PD-L1 siRNA or non-targeting control (48 h) and then stimulated with 
IFN-γ and TNF-α (24 h). Row Z-score represents mean ± S.D., n = 3 independent samples 
performed in triplicate. 
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Figure 6.7. Validation of miRNAs identified through small RNA sequencing. HDLECs 
were transfected (48 h) with siRNAs targeting PD-L1 or non-targeting control and 
subsequently stimulated with IFN- and TNF- (24 h). Total RNA was isolated from 
HDLECs and analysed by qRT-PCR for miRNA expression. 
6.4. Chapter discussion 
This chapter aimed to address the possibility that PD-L1 has intrinsic signalling in primary 
vascular cells. Previous studies using murine or tumour cells have highlighted that 
knockdown of PD-L1 affects cell proliferation, glycolytic metabolism, autophagy, 
angiogenesis as well as confer protection against IFN--mediated cytotoxicity or T cell-
mediated apoptosis (Azuma et al. 2008; Jin et al. 2011; Chang et al. 2015; Clark et al. 2016; 
Gato-Cañas et al. 2017). Here, I describe preliminary findings following the effect of PD-L1 
siRNA knockdown in primary HDLECs. I show that knockdown of PD-L1 in has a modest 
increase on phosphorylation of STAT3 and STAT5 in IFN- and TNF--activated cells (8 
and 24 h). The period of stimulation of cells may be important since the kinetics of p-STAT3 
activation are observed at 4 h and does not appear gradually increase at 8 or 24 h, compared 
to phosphorylation of STAT1 (Figure 3.9). An effect was similarly reported in IFN--
stimulated PD-L1 knockout B16 cells where phosphorylation of STAT3 was increased after 
10-20 min stimulation (Gato-Cañas et al. 2017). In addition, there was an increase in STAT3 
levels after 24 h stimulation and there was no difference in upregulation of STAT1 or 
STAT2 compared to control B16 cells. These findings were linked to lethality of B16 cells 
caused by the combination of IFN-/mutated PD-L1 as deletion of IFNAR1, JAK1, STAT3 
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and CASP7 reduced these effects (Gato-Cañas et al. 2017). Moreover, the blockade or 
deletion of PD-L1 sensitised murine and human cancer cells to IFN- in vitro and affected 
tumour growth and survival in vivo. Overexpression of PD-L1 in B16 cells that were 
administered into mice significantly offset the inhibitory effects of intratumoural IFN- and 
improved tumour progression (Gato-Cañas et al. 2017). This protective effect requires non-
classical regulatory sequence motifs found in the cytoplasmic domain of PD-L1 (see 
introduction of this chapter) that are not similar to any classical signalling motif. 
Furthermore, this report could indicate that upregulation of PD-L1 expression on cancer 
cells acts as an additional protective response against IFNs in the tumour microenvironment 
upon PD-1 engagement. The production of IFN- by fibroblasts, tissue resident 
macrophages and DCs, or IFN- secreted from Th1 CD4+ cells and CD8+ promote anti-
tumour activity including inducing apoptosis (Parker et al. 2016). Additionally, cancer 
patients with JAK1/2 loss-of-function mutations can be resistant to IFN-induced toxicity 
(Shin et al. 2017). It would be interesting to investigate whether the IFN-induced anti-
apoptotic effect observed in described reports (Gato-Cañas et al. 2017; Lucas et al. 2018) is 
similar in HDLECs. This includes overexpressing PD-L1 in IFN- and TNF- activated 
HDLECs to determine whether the phosphorylation of STAT3 or STAT5 are as a 
consequence downregulated and further measuring the expression of apoptotic markers such 
as caspase-3 or 7 and membrane integrity via 4’,6-diamidino-2-phenylindole (DAPI). 
Overexpression could be achieved through lentiviral transduction of a plasmid expressing 
PD-L1, generated using HEK293T cells.   
My preliminary findings showed similar results to a previous report in mouse endothelial 
cells (Jin et al. 2011) that PD-L1 knockdown increases VEGFR2 mRNA expression in 
untreated HDLECs. In contrast, I detected very low levels of CD80 on the surface which 
suggests that PD-L1/CD80 interaction between HDLECs is unlikely. In addition, I observed 
upregulated VEGFR1 expression in IFN- and TNF--activated cells that had PD-L1 
knockdown. VEGFR1/2 expression were dependent on the inflammatory stimulus, 
particularly TNF-. Both VEGFR1 and VEGFR2 are similarly connected receptor tyrosine 
kinases with shared ligands (Rahimi 2006). TNF- modulates the expression of both 
VEGFR1 and VEGFR2 in human endothelial cells (Patterson et al. 1996; Giraudo et al. 
1998). In my study, the function of PD-L1 on VEGFR1/2 signalling pathways may lead to 
downstream effects towards development or angiogenesis in HDLECs. However, this 
requires further investigation including measuring proliferative levels of HDLECs. 
Overexpression of PD-L1 could determine whether the effects on VEGFR1 or VEGFR2 are 
dependent on PD-L1 regardless of inflammatory stimulus.     
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Target RNAs can stabilise or de-stabilise partially complementary miRNAs in different 
systems (Rüegger & Großhans 2012), suggesting a potential mechanism for negative 
feedback. In a situation where target RNAs can de-stabilise miRNAs, a study showed that 
high complementarity between target RNA (egfp) and the miRNA (miR-277) caused a 
significant decrease in the levels of the miRNA in drosophila (Ameres et al. 2010). This was 
shown to be effective against AGO1-bound miR-277 but not AGO2-associated miR-277. 
Small RNAs bound to AGO2 can be protected by the addition 2’-O-methyl groups mediated 
by Hen1 in the final step of AGO2 loading that prevents tailing or trimming of the miRNA. 
Moreover, there is also the mechanism of target-mediated miRNA protection that can be 
induced by the expression of mRNAs which correlates with the abundance of cognate 
miRNAs (Chatterjee et al. 2011; Haas et al. 2016). Here, I investigated whether there is a 
reverse mechanism by which PD-L1 expression regulates the abundance of certain miRNAs. 
There have been no reports that suggest PD-L1 signalling can affect miRNA expression. It is 
also not known to be linked to any miRNA degrading enzymes. Small RNA sequencing and 
qRT-PCR analysis did not coherently reveal any miRNAs from the candidate list that were 
affected by PD-L1 knockdown. Those miRNAs that have been reported or predicted to 
target PD-L1 and that were tested included miR-15b (Kao et al. 2017), miR-20a, miR-576 
and miR-155. As described (Chapter 3), miR-155 targets PD-L1 but silencing of PD-L1 does 
not lead to any effect on the expression of miR-155. This suggests a lack of a regulatory 
feedback loop from PD-L1 back to miRNA expression and that PD-L1 does not modulate 
the regulatory effect of miR-155. The modest effect of PD-L1 knockdown on phospho-
STAT3 or -STAT5 may have not generated any noticeable miRNA profile changes. 
However, the identification of miR-20a may be relevant since miR-20a has been 
demonstrated to regulate STAT3 mRNA expression during MDSC-mediated suppression 
(Zhang et al. 2011; Haghikia et al. 2012).  
The effect on PD-L1 on miR-15b is left open and additional techniques would be required to 
determine a possible feedback loop. Such as validation of miR-15b targeting of PD-L1 in 
primary cells as well as overexpression of PD-L1 with and without the cytoplasmic domain 
to determine the effect on miRNAs in the opposite direction. Although as previously 
reported (Chapter 3) that I validated several miRNAs using both techniques, the discrepancy 
between small RNA sequencing and qRT-PCR analysis is not novel. Sequencing is used to 
generate a global outlook on the number of targets that could be complementary investigated 
by qRT-PCR (Costa et al. 2013). Both techniques assess gene expression in a different 
experiment setup which can introduce bias in the final analysis as well as the quality of the 
sample used. However, it is recommended to test whether both techniques determine a 
consistent and reproducible analysis of gene expression for further experimentation. Indeed, 
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I only investigated a small number of miRNAs from a larger list that were revealed to be 
significant from the sequencing analysis. In fact, a number of factors are needed to take into 
consideration (Git et al. 2010). Firstly, how strict the analysis and normalisation of the 
sequencing is performed such as the number mismatches that are tolerated which would not 
be the same with the TaqMan primers that are designed for qRT-PCR. In addition, the 
expression of the miRNA is important and both techniques use different values and 
normalisation for gene expression. This is the RPKM for sequencing which is using absolute 
values, as opposed to the relative expression of qRT-PCR products to the reference gene. 
The candidate list did take into consideration a range of miRNAs with differential 
expression above the arbitrary threshold to filter possible low expressing miRNAs. Some of 
these miRNAs from the list were not detectable with qRT-PCR suggesting a discrepancy in 
the sensitivity of these techniques and that the sequencing technique may be more affected 
by this. It also seems that normalised fold change from the sequencing analysis of ~2 fold is 
not picked up as strongly when using qRT-PCR in these results and that fold change should 
not be strictly expected to be the same for both methods. Also for genes that are identified in 
sequencing to be lowly expressed can exaggerate the fold change greatly. Overall, even 
though there was a lack of validation between small RNA sequencing and qRT-PCR 
analysis. There are still a lack of understanding of potential signalling mechanisms from PD-
L1 which may suggest that the likelihood of PD-L1 affecting miRNA expression may be 
small. The next experimental setup would be to overexpress PD-L1 in HDLECs and to 
observe whether the JAK/STAT pathway or miRNA expression are affected to provide 
clarity on the above findings. 
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7. General discussion 
7.1  Review of aims and summary of findings  
This study aimed to address the significance of PD-L1 expression and function, and the 
miRNA mechanisms that regulate and fine-tune its expression in human stromal and 
endothelial cells. I used a variety of techniques including western blot, flow cytometry, qRT-
PCR to address my aims. Here, I review the main outcomes of the study and revisit the list 
of aims, described in the introduction of this thesis (Chapter 1). I further reflect on the 
significance of miR-155-mediated posttranscriptional regulation of PD-L1, potential future 
research and the implications of this study on miR-155 therapeutic options and PD-1/PD-L1 
immunotherapy.  
Hypothesis: Expression and function of PD-L1 in stromal, vascular and cancer cells is 
posttranscriptionally regulated by inflammatory-driven microRNAs.  
Aim 1: To characterise PD-L1 expression under inflammatory conditions, using 
inflammatory mediators IFN- and TNF- (Chapter 3).  
Here, I demonstrated why HDLECs/HFFs are a good model for investigating regulatory 
mechanisms behind PD-L1 expression in primary cells, partly due to their responsiveness to 
IFN- and TNF-. 
Main outcomes: 
 Th1 cytokines IFN- and TNF- synergistically induce high levels of PD-L1 in 
HDLECs and HFFs.  
 The JAK/STAT pathway which is a primary target of IFN- signalling is activated as 
demonstrated by increased levels of STAT1 phosphorylation in correlation with PD-L1 
expression.  
 IFN- and TNF- upregulate MHC class I and class II molecules on HDLECs. 
 IFN- and TNF- downregulate lineage commitment markers PROX1, VEGFR1, 
COUP-TFII and LYVE1 in HDLECs. 
Aim 2: To determine the dynamics of the microRNA landscape in vascular and stromal 
cells exposed to inflammatory stimuli (Chapter 3). 
The outcome from small RNA sequencing provided a mass of data that showed several 
dysregulated miRNAs under inflammatory conditions and led to a number of candidates to 
investigate miRNA regulation of PD-L1 expression. 
Main outcomes: 
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 Small RNA sequencing of IFN- and TNF--stimulated HDLECs showed several up- 
(19) and downregulated (29) miRNAs (p < 0.01).  
 Validated upregulated miRNAs: miR-155-5p, miR-4485-3p, miR-218-5p, miR-146a-5p 
 Validated downregulated miRNAs: miR-582-5p, miR-582-3p, miR-93-5p, miR-217 and 
miR-125bp-5p 
 Knockdown of Dicer did not affect PD-L1 protein expression in HDLECs. 
Aim 3: To investigate the effect of dysregulated microRNAs on regulation of PD-L1 
expression (Chapter 3). 
I determined that IFN- and TNF- induce both PD-L1 and miR-155 expression, in which a 
role of miR-155 is to regulate and fine-tune the levels of PD-L1 in stromal/vascular cells. 
Main outcomes: 
 49 out of 631 miRNAs detected in HDLECs were predicted to target PD-L1. 
 Determined that miR-155 binds directly to PD-L1 via two binding sites on the 3’-UTR. 
 Overexpression and inhibition of miR-155 down- or upregulates PD-L1 protein 
expression, respectively, in IFN- and TNF--activated HDLECs/HFFs. 
 Overexpression of miR-218 induces PD-L1 protein expression in untreated and IFN- 
and TNF--activated HDLECs/HFFs.  
Aim 4: To compare microRNA-mediated mechanisms of PD-L1 expression between 
primary stromal cells and human cancer cell lines (Chapter 4). 
Here, I showed that miR-155 regulation of PD-L1 expression is not limited to 
stromal/vascular cells and can be found in renal, breast and lung cancer cell lines. There was 
also evidence of differential miR-155 regulatory mechanisms of PD-L1 in a subset of cancer 
cell lines.  
Main outcomes: 
 In many tumour types analysed from TCGA data, miR-155 and/or PD-L1 expression are 
overexpressed. However, there is no obvious correlation in terms of expression. 
 Demonstrated that miR-155 regulates PD-L1 protein expression in RCC4 and MDA-
MB-231 cells. 
 In a subset of lung cancer cells, miR-155 regulates PD-L1 protein expression. 
Differences in regulation may be accounted by accessibility to the 3’-UTR e.g. 
obstructed by other RNA-binding proteins or posttranslational regulation e.g. 
glycosylation. 
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 In cancer cell lines, overexpression of miR-218 has a subtle effect in A549s but there is 
no effect in RCC4 or MDA-MB-231. 
Aim 5: To develop a co-culture model that can be used to functionally test the 
relevance of the above findings, particularly the mechanism of a miRNA/PD-L1 
regulatory loop (Chapter 5). 
I developed two co-culture models with an output of measuring T cell activation (IL-2 
ELISA, NFAT luciferase) to understand the biological relevance of PD-L1 
posttranscriptional regulation on stromal fibroblast/vascular cells on the activation of T cells. 
This work was met with some challenging aspects and would need to be followed up in the 
future. I could not suitably show that PD-1/PD-L1 interaction was a factor to the effects on T 
cell activation when HFFs/HDLECs were co-cultured with Jurkat T cells.  
Main outcomes: 
 Both assays showed some effect (activation/suppression) on T cell activation when 
HFFs/HDLECs were co-cultured with Jurkat cells. 
 However, blockade of PD-1/PD-L1 with antibodies or siRNA knockdown of PD-L1 did 
not affect the activation of Jurkat cells, suggesting these assays were not suitable to test 
PD-1/PD-L1 interaction in the current state.  
Aim 6: To determine whether PD-L1 expression or signalling affects miRNA 
regulatory loops (Chapter 6). 
I showed that silencing of PD-L1 does not broadly affect miRNA expression in HDLECs, 
inclusive of miR-155. However there is some data that suggest deletion of PD-L1 may affect 
the JAK/STAT pathway.      
Main outcomes: 
 PD-L1 has a short cytoplasmic domain with no known signalling motifs, however, 
knockdown of PD-L1 increased the phosphorylation levels of STAT3 and STAT5. 
 Small RNA sequencing indicated some miRNAs that were dsyregulated after deletion of 
PD-L1, although this could not be validated using qRT-PCR. 
 Silencing of PD-L1 did not affect expression of miR-155 suggesting the IFN-/TNF-
/miR-155/PD-L1 mechanism is an incoherent feed-forward loop and not a negative 
feedback mechanism. 
7.2  Reflections on miRNA-mediated regulation of PD-L1 expression 
The PD-1/PD-L1 checkpoint is an important determinant of immune homeostasis and 
tolerance that regulates T cell activity (Sun et al. 2018). Our knowledge of PD-L1 regulation 
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has expanded to understand that the dynamic expression of PD-L1 is regulated at the 
transcriptional, posttranscriptional and posttranslational level, leading to heterogeneity in the 
clinical response to PD-1/PD-L1 immunotherapy (Sun et al. 2018). Posttranscriptional 
regulation of protein-coding genes by miRNAs is an important mechanism that controls a 
diverse number of cellular processes through the degradation of mRNA targets or inhibition 
of translation (Ha & Kim 2014). The 3’-UTR of PD-L1 is long and serves as a negative 
regulatory role (Kataoka et al. 2016; Mezzadra et al. 2017), facilitating an interface for 
posttranscriptional regulation by RNA-binding proteins (Coelho et al. 2017) and miRNAs 
(Sun et al. 2018). 
Here in this thesis, I demonstrated that inflammation-induced miRNAs can be critical 
regulators of immune checkpoint (PD-L1) expression in HDLECs and that an IFN-/TNF--
mediated incoherent feed-forward loop mechanism can also be found in HFFs and cancer 
cells in vitro. Overall, this study contributes towards to the systemic understanding of PD-L1 
regulation in an inflammatory environment that would be of interest to other investigators 
(Table 7.1). The strength of these findings fills an important knowledge gap in primary 
human cell types (HDLECs/HFFs) and highlights the importance of PD-L1 expression on 
non-immune or non-transformed cells. The setup of co-culture assays to answer whether the 
effect of miR-155 regulation of PD-L1 expression alters the activation of T cells remains to 
be completed, and would inevitably support the significant findings of this study. It would 
also be important to further understand the physiological role of miR-155/PD-L1 interaction 
and the immunological significance of this interaction in vivo. Host-derived PD-L1 
expression in DCs and macrophages can impact the effectiveness of PD-L1 blockade (Lin et 
al. 2018; Tang et al. 2018). It is unknown whether miR-155 can regulate PD-L1 expression 
in DCs or macrophages. However, there is wide-spread expression of miR-155 in myeloid 
cells, which can act as a critical regulator of cytokine production in DCs (O’Connell, Rao, et 
al. 2010; Smyth et al. 2015) and macrophages (O’Connell et al. 2007; Tili et al. 2007).  
The role of miR-155/PD-L1 regulation is in line with the overarching miR-155 regulation of 
inflammatory responses in addition to its functions in the development and maintenance of 
the immune system (Table 7.2). The miR-155/PD-L1 mechanism demonstrates that 
inflammatory responses elevate high levels of miR-155 to regulate the induction of PD-L1, 
indicating that miR-155 acts as a pro-inflammatory mediator or amplifier of the immune 
response through the modulation of peripheral tolerance. Similarly, high levels of miR-155 
found in atopic dermatitis can regulate the expression of the immune checkpoint CTLA-4 
and enhance T cell proliferation (Sonkoly et al. 2010). These studies highlight that the 
activation of miRNAs such as miR-155 can facilitate the temporal release of the brakes of 
the immune system that adjust the balance between immune tolerance and autoimmunity. 
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NF-B activity has been suggested to regulate the macrophage inflammatory response 
through controlling the kinetics and stability of miR-155 and miR-146a, which functions as 
a negative regulator (Mann et al. 2017). I identified in some lung cancer cell lines that miR-
155 regulation of PD-L1 may not function in the same manner as HDLECs/HFFs suggesting 
there are different networks of PD-L1 regulation in place in these cells that may affect the 
inhibition of miRNA-mediated regulation or secondary effects such as posttranslational 
regulation that affect the stability or degradation. 
I speculate that in the context of tumour immunity, miR-155 regulation of PD-L1 expression 
would span across tumour/stromal/vascular cells in the tumour microenvironment and the 
draining LNs and affect the activation of T cells in a tumour-specific manner. IFN- and 
TNF- cytokines in the microenvironment, produced by T cells and NK cells, induce a 
defensive response from activated stromal/vascular cells to dampen the local immune 
response through PD-L1 expression. PD-L1 signalling can facilitate the survival of high PD-
L1-expressing cells by regulating apoptosis (Lucas et al. 2018). The induction of miR-155 
through IFN- and TNF- fine-tunes (rather than abolishes) the level of PD-L1 
immunosuppression in order to maintain pro-inflammatory Th1 and CD8+ T cell responses 
in the local microenvironment as well as to preserve the survival of PD-L1-expressing cells.  
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Table 7.1. A summary of PD-L1 regulation. Modified from Chapter 1 and (Sun et al. 
2018). 
Regulation of PD-L1  References 
Inflammatory signalling:  
IFN-/, IFN-, JAK/STAT/IRF 
TLR, NF-B, TNF-, LPS 
IL-6, IL-10, TGF- 
(Freeman et al. 2000; Dong et al. 
2002; Loke & Allison 2003; Mazanet 
& Hughes 2002; Kondo et al. 2010; 
Wölfle et al. 2011; Mariathasan et al. 
2018) 
Oncogenic signalling:   
ALK/STAT3 
MEK/ERK, RAS/ERK, PI3K/Akt/mTOR, 
EGFR, MYC, CDK5 
HIF-1, HIF-2 
(Marzec et al. 2008; Liu et al. 2007; 
Coelho et al. 2017; Akbay et al. 2013; 
Parsa et al. 2007; Casey et al. 2016; 
Dorand et al. 2016; Noman et al. 
2014; Messai et al. 2016) 
Genetic alteration: disruption of 3’-UTR, 
structural variations (amplification, insertion) 
(Twa et al. 2014; Roemer et al. 2016; 
Ikeda et al. 2016; George et al. 2017; 
Bellone et al. 2018; Kataoka et al. 
2016) 
MicroRNAs:  
Non-transformed cells: miR-513, miR-155 
Cancer cells: miR-200, miR-34a, miR-138, miR-
142-5p, miR-106b-5p/miR-93-5p, miR-570, miR-
152, miR-217, miR-17-5p, miR-15a, miR-16, miR-
193a, miR-20b/miR-21/miR-130b, miR-197  
(Gong et al. 2009; Chen et al. 2014; 
Cortez et al. 2016; Zhao et al. 2016; 
Jia et al. 2017; Cioffi et al. 2017; 
Wang et al. 2012; Xie et al. 2017; 
Miao et al. 2017; Audrito et al. 2017; 
Kao et al. 2017; Zhu et al. 2014; 
Fujita et al. 2015) 
Posttranslational regulation:  
Degradation: CSN5, CDK4, CMTM4/6  
Glycosylation: GSK3 
(Lim et al. 2016; Zhang et al. 2018; 
Burr et al. 2017; Mezzadra et al. 
2017; Li et al. 2016) 
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Table 7.2. An overview of miR-155 function and regulation in physiological and 
pathological processes. 
miR-155 References 
Stimuli: antigen receptor activation (TCR, BCR), 
inflammatory/TLR signalling (LPS, TNF-, IFNs, 
KSHV), TGF-β/SMAD signalling, hypoxia 
(Elton et al. 2013; Taganov et al. 
2006; Tili et al. 2007; Gottwein et al. 
2007; Kong et al. 2008; Stanczyk et 
al. 2008; Ceppi et al. 2009; Bruning et 
al. 2011) 
Negative regulators: NF-B, IL-10, TP53, 
BRCA1 
(McCoy et al. 2010; Mann et al. 2017; 
Van Roosbroeck et al. 2017; 
Bayraktar & Van Roosbroeck 2018) 
Key transcriptional activators: NF-B, AP-1, 
IRFs, SMAD4, MYB, FOXP3 
(Elton et al. 2013; Bayraktar & Van 
Roosbroeck 2018) 
Cell types:  
Haematopoietic stem-progenitor cells 
Myeloid: NK cells, monocytes (macrophages, 
dendritic cells), granulocytes 
Lymphocytes: B cells, CD4+ (Th1, Th17, T reg) 
and CD8+ T cells 
Fibroblasts, lymphatic endothelial cells     
(Elton et al. 2013; Taganov et al. 
2006; Rodriguez et al. 2007; Vigorito 
et al. 2007; Lu et al. 2009; Lu et al. 
2015) 
Functions: haematopoiesis, inflammation (innate 
immunity, adaptive immunity), infection, 
autoimmunity 
 
Regulation of development, differentiation, 
maturation and apoptosis of T cells, B cells, 
monocytes:  
AID, C/EBP, PU.1, IFN-R, c-Maf  
(Rodriguez et al. 2007; Thai et al. 
2007; Banerjee et al. 2010; Teng et al. 
2008; Dorsett et al. 2008; Lu et al. 
2014) 
Regulation of inflammatory responses: c-Maf, 
TAB2, SOCS1, STAT1, SHIP1, CTLA-4, PD-L1 
(Ceppi et al. 2009; Androulidaki et al. 
2009; Lu et al. 2009; O’Connell et al. 
2009; Sonkoly et al. 2010; Gracias et 
al. 2013; Dudda et al. 2013; Lu et al. 
2015) 
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Oncogenic miRNA: apoptotic resistance, 
proliferation, invasion, migration, resistance to 
chemo- and radiotherapy 
Haematological malignancies: diffuse large B cell 
lymphoma, Hodgkin lymphoma, acute myeloid 
leukaemia 
Solid tumours: melanoma, breast, colon, lung, 
kidney, head and neck, pancreas, stomach 
(Eis et al. 2005; Volinia et al. 2006; 
Yanaihara et al. 2006; Vigorito et al. 
2013; Bayraktar & Van Roosbroeck 
2018) 
Autoimmunity: generation of pathogenic self-
reactive T and B cell responses, regulation of 
cytokine/chemokine production 
Multiple sclerosis, rheumatoid arthritis, systemic 
lupus erythematosus 
(O’Connell, Kahn, et al. 2010; Blüml 
et al. 2011; Kurowska-Stolarska et al. 
2011; Alivernini et al. 2016) 
7.3 The modulation of stromal fibroblast/vascular cell function through IFN- 
and TNF- activation  
A critical role in the regulation of PD-L1 throughout the study was played by inflammatory 
cytokines IFN- and TNF- that are typically produced by CD4+ and CD8+ T cells and NK 
cells, and induce PD-L1 expression on stromal/vascular cells. These seemingly quiescent-
like cells become activated in response to cytokines and have an active role in the regulation 
of the inflammatory response. The synergy between IFN- and TNF- has been reported to 
involve the interplay of both STAT1 and NF-B in the induction of several inflammatory 
genes including IRF-1 and ICAM-1  (Ohmori et al. 1997). The promoter region of IRF-1 
was found to have both a STAT binding element and a NF-B sequence motif. Deletion of 
the STAT1 gene nearly ablated (90% reduction) the synergistic induction of IRF-1 promoter 
activity in fibroblasts. In addition, mutation of the STAT binding element and NF-B site on 
IRF-1 abolished the response to IFN- and TNF-. Since, IRF-1 has been reported to be 
involved in the induction of PD-L1 (Lee et al. 2006), it is likely the synergistic effect of 
IFN- and TNF- in the upregulation of PD-L1 on HDLECs/HFFs occurred through 
activation of IRF-1.  
Endothelial cells are characterised by two types of activation: type I refers to binding of G-
protein-coupled receptors to ligands that can lead to an increase in intracellular Ca2+ where 
there is a role for leukocyte recruitment and neutrophil extravasation (Pober & Sessa 2007). 
Type I signals typically last for 10-20 min until the receptors are desensitised. Type II 
activation, where inflammatory signals provided by TNF, IL-1, LPS or IFN- can 
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persistently stimulate endothelial cells for a longer time. IFN- and TNF- have been 
suggested to induce damage to the endothelial cell barrier which could affect the 
inflammatory response by increasing permeability to immune cells in inflammatory 
disorders such as psoriasis (Mehta et al. 2017). Acute inflammation of LECs in a mice 
model can affect the lymphatic propulsive flow and frequency, which could prevent the 
spread of pathogens or inflammatory mediators beyond LNs (Aldrich & M. 2013). In 
addition, high concentrations of IFN- and TNF- have been shown to modulate LEC 
proliferation in mice and human models (Chaitanya et al. 2010).  
IFN- and TNF- produced by antigen-activated CD8+ T cells were shown to be required for 
elimination of antigen loss variants (ALVs) in mouse tumours (Spiotto et al. 2004; Zhang et 
al. 2008). ALVs are a subpopulation of cancer cells that do not express antigens. These 
studies showed that for destruction of large solid tumours, CD8+ T cells moved to destroy 
the host stroma to prevent outgrowth or escape of tumours in a so-called bystander effect. 
Expression of receptors for IFN-, TNF- or MHC molecules on stroma were targeted by 
CD8+ T cells to generate anti-tumour immunity. In addition, cross-presentation of tumour 
antigen (from antigen-positive cancer cells) by non-bone marrow-derived stromal cells 
facilitated the removal of ALVs (Spiotto et al. 2004; Zhang et al. 2008). These studies show 
the importance of IFN- and TNF- and how responsive stromal cells are to these cytokines, 
which in turn influence the local microenvironment and inflammatory response. Although it 
was not investigated, PD-L1 expression on stromal/vascular cells in the tumour 
microenvironment may act as a defence mechanism against CD8+ T cells to prevent their 
own destruction. These studies could suggest another reason that the tumour stroma could be 
targeted for PD-1/PD-L1 immunotherapy to prevent the escape and metastasis of cancer 
cells.  
7.4  In perspective: PD-L1 expression on stromal fibroblasts and endothelial 
cells  
The significance of PD-L1 expression on stromal fibroblasts/vascular may affect anti-
tumour immunity. Although not the focus of the thesis, studies on the tumour 
microenvironment demonstrate the contribution of stromal fibroblasts or lymphatic vessel 
structure in the modulation of immune cells in their access, activation and function (Hendry 
et al. 2016). In the tumour microenvironment, there are a diverse number of interactions 
between malignant and non-transformed cells through the release of soluble factors (e.g. 
cytokines and chemokines) as well as cell-cell contacts that can be inflammatory, 
immunosuppressive or influence angiogenesis (Schaaf et al. 2018). The tumour 
microenvironment has been suggested to limit the effect of cancer immunotherapy due to a 
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shift towards an immunosuppressive phenotype, which has been acquired through cancer 
immunoediting (Adachi & Tamada 2015). This can occur off a combination of existing 
immunosuppressive populations (e.g.) T reg, MDSCs; cytokines or chemokines produced by 
stromal cells (e.g. TGF-, IDO, IL-10) or expression of immune checkpoint molecules (e.g. 
CTLA-4, PD-L1) on stromal cells and infiltrating immune cells (Adachi & Tamada 2015).   
Cancer immunoediting describes the dynamic anti-tumour response in order to protect the 
host and consists of three parts: elimination (cancer immunosurveillance), equilibrium and 
escape (Dunn et al. 2004; Vesely et al. 2011). Briefly, elimination represents the innate and 
adaptive immune responses to tumour cells due to the presentation of abnormal (tumour) 
antigens and destroys the tumour before it becomes clinically apparent. Equilibrium 
(dormancy) describes the period in which tumour cells escape the elimination phase after 
incomplete tumour destruction and co-exist with the immune system, particularly the 
adaptive arm. Escape is in reference to the outgrowth of tumours in an uncontrolled manner 
in which it becomes symptomatic and the failure of the immune system to control 
transformed cells (Dunn et al. 2004; Vesely et al. 2011). The latter part includes the 
immunosuppression of anti-tumour immunity where PD-L1 expression is a key mediator of 
peripheral tolerance (Vesely et al. 2011). In addition, the majority of experimental cancer 
cell lines are those that have escaped the control of the immune response.  
Cancer immunosurveillance is driven primarily by effector T cells, which become activated 
by antigen-presenting DCs in peripheral LNs (Schaaf et al. 2018). Activated T cells egress 
from LNs and travel to the tumour site where they leave from the blood vessels to infiltrate 
the tumour. On speculation, expression of PD-L1 on LECs could inhibit T cell function 
within peripheral lymphatic vessels or in the LN. This could include where activated T cells 
move into the LN from afferent vessels and are challenged by LECs on the subcapsular sinus, 
or by preventing the priming of naïve T cells in the medullary sinus of the LN (Tewalt et al. 
2012; Lucas et al. 2018). Lymphatic vessels (LVs) are more frequent, dilated and larger in 
the peritumoural region than intratumoural vessels, which were found to be small and 
collapsed (Ji et al. 2007; Zhang et al. 2009; Schaaf et al. 2018). Both types of tumoural LVs 
were significantly higher than those of normal cervix tissues (Zhang et al. 2009). 
Intratumoural LVs are in close contact with tumour cells and the collapse of these vessels 
may be due to mechanical stress caused by the outgrowth of tumour cells (Ji et al. 2007). 
Peritumoural LVs were filled with clusters of malignant cells which may preclude metastasis 
to regional LNs. Tumour-associated LVs were shown to upregulate PD-L1 in a similar 
manner to LN-resident LECs in both mice models of melanoma (B16F10-VEGFC) and 
breast cancer (4T1) (Dieterich et al. 2017). The expression of PD-L1 was significantly 
higher in intratumoural LVs, compared to normal mice. Peritumoural LVs expressed lower 
170 
 
amounts of PD-L1 than intratumoural LVs. Interestingly, there was a significant reduction in 
the expression of PD-L1 on BECs in the tumour microenvironment, compared to normal 
skin BECs. PD-L1 expression on immortalised mouse LECs was upregulated by IFN- (up 
to 40-fold after 24 h), whereas TNF- had a minor effect (2-fold), and VEGF-A and VEGF-
C had no effect. There was some evidence of interaction between T cells and tumour-
associated LVs in both mouse tumour models shown by immunofluorescence staining. By 
using the ovalbumin-derived, MHC class I-restricted peptide SIINFEKL, immortalised 
mouse LECs reduced the activation of OT-1 CD8+ T cells which could be restored upon 
blockade of PD-L1, resulting in elevated expression of CD25 and production of IFN- in 
vitro (Dieterich et al. 2017). This study in addition to the other studies (described in Chapter 
1) provide support in demonstrating that the inhibition of CD8+ T cell responses by PD-L1-
expressing LECs in both peripheral tissues and the LN are significant in maintenance of 
peripheral tolerance (Tewalt et al. 2012; Hirosue et al. 2014; Rouhani et al. 2015). In 
addition, miR-155 is often overexpressed in lymphatic cancers (Higgs & Slack 2013), 
further investigation is required to understand the differential effect on PD-L1 expression 
and function in both physiological and pathological contexts of the lymphatic system. 
CAFs (see Chapter 1), which are activated fibroblasts adjacent to a tumour, are the most 
common component of the cancer stroma and share similar characteristics to fibroblasts 
found in wounds and inflammatory sites (Mao et al. 2013). CAFs do not only arise from 
fibroblasts but also bone marrow-derived mesenchymal stems cells and epithelial cells 
(Bhome et al. 2016). CAFs express fibroblast activation protein (FAP) and are the only 
tumoural source of cancer-associated chemokine CXCL12, which is suggested to be 
involved in tumoural immunosuppression and evasion (Feig et al. 2013). The murine model 
of pancreatic ductal adenocarcinoma resembling a human disease lacks T cells in regions 
where cancer cells can be found in the tumour. Inhibition of CXCR4, a receptor for CXCL12, 
increased T cell accumulation and reduced tumour growth. In addition, the combination of 
the CXCR4 inhibitor with an anti-PD-L1 antibody showed significant decline in the relative 
volume of the tumour, whereas there was no augmentative effect with anti-CTLA-4 
treatment. There was no effect with anti-PD-L1 treatment alone, indicating that targeting 
CAFs may be instrumental in the response to PD-1/PD-L1 therapy (Feig et al. 2013). 
Similarly, TGF- signalling from peritumoural stromal fibroblasts can exclude CD8+ T cells 
from the tumour parenchyma, which leads to a lack of response from PD-L1 blockade in 
metastatic urothelial cancer (Mariathasan et al. 2018). As described in Chapter 1, CAFs also 
directly contribute to anti-tumour T cell responses by cross-presenting tumour antigen 
through MHC class I molecules and upregulate PD-L1 and PD-L2 to impair T cell 
suppression (Nazareth et al. 2007; Lakins et al. 2018). In human tumours, the exclusion of 
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infiltrating CD8+ T cells was a characteristic observed in patients that were non-responders 
to anti-PD-L1 therapy, even though PD-L1 expression was identified in tumour-infiltrating 
immune cells at the tumour margin (Herbst et al. 2014). Overall, these studies demonstrate 
that the response to PD-1/PD-L1 immunotherapy are influenced by the expression of CAFs 
in the tumour stroma, either through the exclusion of T cells in the tumour or in direct 
contact with T cells. Moreover, miR-155 is significantly upregulated in CAFs which 
contributes to the migration and invasion of ovarian cancer cells as well as programming 
normal fibroblasts into CAFs through the suppression of tumour protein 53-inducible 
nuclear protein 1 (TP53INP1) (Mitra et al. 2012; Gascard & Tlsty 2016). This also presents 
an opportunity to investigate the significance of miR-155/PD-L1 regulation in CAFs.  
In general, the microenvironment in which stromal/vascular cells are present in may 
determine the type of phenotype (immunoactivating/immunosuppressing) that these cells 
develop in responding to immune cells. In addition, there are multiple places of interaction 
that could potentially enable stromal/vascular cells to induce immunosuppression of T cells 
or facilitate miRNA regulation of immune checkpoints.  
7.5  Future experiments 
RNA-sequencing to study inflammation-induced transcriptional networks in HDLECs 
The aim of this work will be to determine the mRNA transcriptome of inflamed HDLECs 
and integrate with previously acquired data on small RNA profiles. Particularly, to 
characterise further targets of miR-155 in HDLECs. First, to perform and analyse RNA 
sequencing in HDLECs treated with IFN- and TNF- in the presence or absence of miR-
155 inhibitors to test the effect of miR-155 expression on the HDLEC transcriptome. The 
following conditions for the setup would be: control (no treatment), + IFN- and TNF-, + 
miR-155 inhibitors, and + IFN- and TNF- and + miR-155 inhibitors. With sequencing, 
this would provide a core dataset to reveal novel microRNA/mRNA inflammation-driven 
networks in HDLECs. Further experiments can include qRT-PCR to validate mRNA 
expression changes and western blot analysis to characterise the effects on downstream 
signalling components. In addition, overexpression and inhibition of affected genes will 
provide further data to expand these novel regulatory networks. 
Investigate the mechanism of miR-155 regulation of PD-L1 in NSCLC cell lines  
In some NSCLC cell lines, different miR-155 regulation of PD-L1 was observed in which 
PD-L1 expression was either suppressed or did not change after overexpression of miR-155. 
Luciferase assays would determine whether miR-155 directly binds the 3’-UTR of PD-L1 
via the two conserved binding sites. To address the differential regulation, one possibility 
may be due to RNA-binding proteins (Pumilio, DND1) or ARE-binding proteins (HuR, TTP) 
172 
 
that have been shown to affect miRNA-induced inhibition of mRNAs (Bhattacharyya et al. 
2006; Kedde et al. 2007; Kedde et al. 2010), or the stability of PD-L1 mRNA driven by 
RAS-MEK signalling (Coelho et al. 2017). Interestingly, low expression of TTP (ZFP36, 
bottom 25%) correlated with a shift towards high expression of PD-L1 mRNA in TCGA 
analysis of LUAD tumour samples (Figure 4.16). Whereas, high expression of TTP has a 
broader expression profile of PD-L1, which may inhibit miR-155 regulation of PD-L1 
expression. TargetScan software predicts that there is one poorly conserved miR-155 
binding site on TTP. Overexpression of miR-155 with mimics was reported to reduce TTP 
protein abundance in airway smooth muscle cells (Comer et al. 2016: American Thoracic 
2016 International Conference). In contrast, overexpression of TTP regulates miR-155 
expression via miR-1 in cystic fibrosis lung epithelial cells (Bhattacharyya et al. 2013) 
Therefore, I propose to characterise expression of TTP, a negative regulator of PD-L1, in 
lung cancer cell lines at normal levels and after knockdown. In addition, to overexpress 
miR-155 in lung cancer cell lines that have TTP or non-targeting control knockdown and 
subsequently characterise PD-L1 expression.  
Development of the PD-1/PD-L1 co-culture assay  
The development of this assay aimed to investigate the functional relevance of the effects of 
miRNA regulation of PD-L1 protein expression that was studied in Chapter 3. PD-1 Jurkat 
cells with the NFAT luciferase system represented the better of the two models and was able 
to detect a reproducible response from HFFs and HDLECs to target Jurkat cells. The specific 
mechanism of this response was not clearly identified. A positive control that only expresses 
PD-L1 and not any of the other known immune checkpoints would help optimise the assay 
better when further using antibodies to block PD-1/PD-L1. The number of immune 
checkpoint molecules found on HFFs and HDLECs may have interfered with the PD-1/PD-
L1 mechanism and therefore overshadowed the effects that I may have observed when 
investigating miRNA-mediated regulation of PD-L1 expression. 
7.6  Implications of miR-155 regulation of PD-L1 expression in a therapeutic 
context  
Therapeutic approaches that attempt to mimic or inhibit the miRNA function are one of the 
classes of RNA-based drugs that extend the number of ‘druggable’ targets to include nucleic 
acids (Lieberman 2018). The targeting of RNA is in its infancy but could likely revolutionise 
drug development in the future. The advantages in the use of RNA-based drugs over 
therapeutic antibodies are that RNAs can be chemically synthesised rather than using living 
cells, which reduce the costs of manufactured drugs as well as limit immunogenicity 
(Lieberman 2018). Identifying and utilising miRNAs to regulate PD-L1 expression may lead 
to additional avenues to regulate inflammatory responses. The miR-200/ZEB1 axis, which is 
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associated with metastasis, was demonstrated to target PD-L1 and contribute to 
immunosuppression in lung metastases (Chen et al. 2014). The effect of anti-PD-L1 
blockade did not significantly differ from tumours in mice that had high miR-200 levels, 
both treatments had reduced tumour burden and metastasis. Furthermore, the tumour 
suppressor miR-34a was reported to have several oncogenic and immune-related targets 
including PD-L1 (Cortez et al. 2016). In vivo delivery of miR-34 mimics (MRX34) in a 
mouse model of lung cancer increased the number of tumour-infiltrating CD8+ T cells and 
relieved exhausted PD-1-positive CD8+ T cells, macrophages and T reg. This effect was 
further augmented in combination with radiotherapy (Cortez et al. 2016). MRX34 is the first 
miRNA therapy based on miR-34a-loaded liposomes and was in Phase I trials 
(NCT01829971) with 47 patients carrying various solid tumours (Beg et al. 2017). Despite 
showing preliminary evidence of anti-tumour activity, MRX34 was halted following 
multiple immune-related serious adverse events (Beg et al. 2017).  
Using miRNA inhibitors can have a more acceptable safety profile compared to high doses 
of miRNA mimics but remains to be tested in future clinical trials (Bayraktar & Van 
Roosbroeck 2018). The use of therapeutics to overexpress or inhibit miR-155 expression 
could be a useful treatment but consideration needs to take into account the number of miR-
155/mRNA targets that are essential for normal development and function of the immune 
response and the context of the disease (Rodriguez et al. 2007). Therefore specific targeting 
of a cell type (immune, stromal or cancer cell) would need to be carefully chosen. 
Therapeutics have been proposed to suppress the activity of miR-155 in the treatment of 
cancer (Bayraktar & Van Roosbroeck 2018). Anti-miR-155 therapeutics using nanoparticles 
or locked nuclei acids (LNAs) can be delivered to B cells to induce rapid tumour regression 
in mouse models of lymphoma (Babar et al. 2012; Zhang et al. 2012). The expression of 
miR-155 in murine lung cancer models can be reduced by treatment with 1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC) liposomal nanoparticle-loaded anti-miR-155 with low 
toxicity (Van Roosbroeck et al. 2017). In addition, the suppression of miR-155 re-sensitised 
chemoresistant tumours to the chemotherapeutic agent, cisplatin, suggesting that targeting of 
miRNAs can be used to overcome drug resistance. Currently, MRG-106 (miRagen 
Therapeutics Inc.) is in the drug pipeline (phase 1: NCT02580552) for treatment of certain 
lymphomas and leukaemias by inhibition of miR-155. Preliminary results have indicate that 
MRG-106 is well tolerated and phase 2 trials are forthcoming. Furthermore, miR-155 
expression drives pathology in autoimmune diseases such as rheumatoid arthritis and 
inhibition of miR-155 in autoimmunity is a clear target for therapeutic intervention 
(Alivernini et al. 2018).  
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There is also an unmet need for a panel of biomarkers to evaluate the response to PD-1/PD-
L1 immunotherapy on top of PD-L1 expression on host and tumour cells. miR-155 could 
serve as a biomarker in the serum for human cancer detection (Sun et al. 2012; J. Wang et al. 
2016) and to determine the levels of  T cell activation in viral and cancer contexts (Dudda et 
al. 2013; Lind et al. 2013). A study in HIV-1-infected patients found that there was positive 
correlation between PD-1+ T cells and miR-155 levels in CD4+ and CD8+ T cells, although it 
is unclear the regulatory link between miR-155 and PD-1 (Jin et al. 2017). Would miR-155 
serve as a biomarker to predict the response to PD-1/PD-L1 immunotherapy? Mice with T 
cell-specific deletion of miR-155 and bearing tumour cells (B16-F10-OVA) were treated 
with an immune checkpoint blockade cocktail (anti-PD-1, anti-PD-L1 and anti-CTLA-4), 
which resulted in the rescue of anti-tumour immunity (Huffaker et al. 2017). There was a 
reduction in the size of tumour, similar to that of control mice, and the production of IFN- 
by CD4+ and CD8+ T cells were increased, suggesting immune checkpoint blockade rescues 
defective miR-155 regulation of the anti-tumour response. This indicates that the function of 
miR-155 may overlap with the restorative effect generated by immune checkpoint blockade 
(Huffaker et al. 2017). Since the expression of miR-155 in tumour-infiltrating myeloid cells 
(tumour-associated macrophages) is also important for anti-tumour responses (Zonari et al. 
2013). It would be interesting to investigate whether miR-155 deficiency in tumour-
associated stromal/vascular cells affects the anti-tumour response and whether modulation of 
miR-155 expression can improve the efficacy of immune checkpoint blockade. Furthermore, 
anti-PD-1/PD-L1 agents are associated with immune-related adverse events which was 
indicated to have a global incidence of 26.82% for any grade and 6.10% for severe grades, 
respectively (P. F. Wang et al. 2017). These adverse events were organ-specific and 
associated with the drug and types of tumour treated, such that there is a need for miRNA 
biomarkers that can predict the risk of immune-related adverse events (Dragomir et al. 2018).  
7.7  Concluding remarks 
In summary, stromal fibroblasts and endothelial cells respond to cytokines and their 
activation can determine the inflammatory response through surface ligands or secreted 
products. PD-L1 expression on host stromal cells inside and outside of the tumour 
microenvironment have a significant role on the efficacy of PD-1/PD-L1 immunotherapy by 
regulating the activation of T cells. Posttranscriptional mechanisms such as miRNAs can 
fine-tune the expression of PD-L1 in stromal fibroblasts and endothelial cells to regulate the 
inflammatory response. In this thesis, I investigated that during inflammatory cytokine 
activation of human fibroblasts and endothelial cells, miR-155 is activated and can regulate 
the expression of PD-L1 protein. This may lead to alterations in the balance between 
autoimmunity and immunosuppression which remains to be studied in further functional 
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assays. Targeting of miRNAs as a biomarker or therapeutic agent could be used to predict or 
adjust inflammatory responses in conjunction with PD-1/PD-L1 immunotherapy.  
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8. Abbreviations 
 
-gal -galactosidase 
-TrCP -transducin repeats-containing protein 
AGO Argonaute 
AID Activation-induced deaminase 
AIRE Autoimmune regulator 
ALK Anaplastic lymphoma kinase 
ALV Antigen loss variant 
ANG Angiopoietin 
AP-1 Activator protein-1 
APC Antigen-presenting cell 
ARE Adenylate-uridylate (AU)-rich element 
B3GNT3 β-1,3-N-acetylglucosaminyl transferase 
BCA Bicinchoninic acid assay 
BCR B cell receptor 
BEC Blood endothelial cell 
BMP Bone morphogenetic protein 
BSA Bovine serum albumin 
C/EBP CCAAT/enhancer-binding protein beta 
CAF Cancer-associated fibroblast 
CAT-1 Cationic amino acid transporter 1 
CCL Chemokine (C-C motif) ligand 
CD Cluster of differentiation 
CDK Cyclin-dependent kinase 
ChIP Chromatin immunoprecipitation 
cHL Classical Hodgkin lymphoma 
CHO Chinese hamster ovary 
CKS1B Cyclin-dependent kinases regulatory subunit 1 
CLIP Class II-associated invariant chain peptide 
c-MAF V-maf musculoaponeurotic fibrosarcoma oncogene homolog 
CMTM6 CKLF-like MARVEL transmembrane domain containing protein 6 
COUP-TFII COUP transcription factor 2 
COX-2 Cyclooxygenase-2 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
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CSN5 COP9 signalosome 5 
CTL Cytotoxic T lymphocytes 
CTLA-4 Cytotoxic T lymphocyte antigen-4 
CXCL Chemokine (C-X-C motif) ligand 
DAG Diacylglycerol 
DC Dendritic cells 
DGCR8 DiGeorge syndrome critical region 8 
DMEM Dulbecco’s Modified Eagle Medium 
dMMR Mismatch repair deficient 
DMSO Dimethyl sulfoxide 
DNC Double-negative cells 
DND1 Dead end 1 
dsRBD dsRNA-binding domains 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGFR Epidermal growth factor receptor 
ELISA Enzyme-linked immunosorbent assay 
EMT Epithelial-mesenchymal transition 
ER Endoplasmic reticulum 
ERAP ER aminopeptidase 
ERK Extracellular signal-regulated kinase 
FACS Fluorescence assisted cell sorting 
FAP Fibroblast activation protein 
FasL Fas ligand 
FCS Fetal calf serum 
FOXC2 Forkhead box protein C2 
FoxO1 Forkhead box protein O1 
FOXP3 Forkhead box P3 
FRC Fibroblastic reticular cells 
GAS IFN--activated sequence 
GITR Glucocorticoid-induced TNFR-related protein 
GSK3 Glycogen synthase kinase 3 
HDLECs Human dermal lymphatic endothelial cells 
HER2 Human epidermal growth factor receptor 2 
HFFs Human foreskin fibroblasts 
HIF-1 Hypoxia-inducible factor 1-alpha 
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HLA Human leukocyte antigen 
HRP Horseradish peroxidase 
HuR Hu antigen R 
HUVEC Human umbilical vein endothelial cells 
ICAM-1 Intercellular adhesion molecule 1 
ICOS Inducible T cell co-stimulator 
IDO Indoleamine 2,3-dioxygenase 
IFN Interferon 
IFNGR IFN- receptor 
Ig Immunoglobulin 
IKK Inhibitor of NF-B kinase 
IL Interleukin 
IP3 Inositol-1,4,5-triphosphate 
IRAK IL-1 receptor-associated kinase 1 
IRF Interferon regulatory factor 
ISG15 Interferon-stimulated gene 15 
ITAM Immunoreceptor tyrosine-based activation motifs 
ITK IL-2-inducible T cell kinase 
ITSM Immunoreceptor tyrosine-based switch motif 
JAK Janus kinase 
KSHV Kaposi’s sarcoma-associated herpesvirus 
LAG-3 Lymphocyte activation gene 3 
LAT Linker of activated T cells 
LCK Lymphocyte-specific protein tyrosine kinase 
LCMV Lymphocytic choriomeningitis virus 
LEC Lymphatic endothelial cell 
LN Lymph node 
LNSC Lymph node stromal cells 
LPS Lipopolysaccharide 
LV Lymphatic vessel 
LYVE-1 Lymphatic vessel hyaluronan receptor-1 
MAPK Mitogen-activated protein kinase 
MCP Monocyte chemoattractant protein 
MDSC Myeloid-derived suppressor cell 
MFI Median fluorescence intensity 
MHC Major histocompatibility complex 
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MIIC MHC class II-containing compartment 
MIP Macrophage inflammatory protein 
miRNAs MicroRNAs 
MMP Matrix metalloproteinase 
MPN Myeloproliferative neoplasms 
MSCs Mesenchymal stem cells 
MSI Microsatellite instability 
mTOR Mammalian target of rapamycin 
mTORC mTOR complex  
MYD88 Myeloid differentiation primary response 88 
NF-B Nuclear factor kappa-light-chain-enhancer of activated B cells 
NFAT Nuclear factor of activated T cells 
NK Natural killer 
NOS2 Nitric oxide synthase 2 
NRP2 Neuropilin 2 
NSCLC Non-small-cell lung cancer 
NTC Non-targeting control 
ORF Open reading frame 
OVA Ovalbumin 
PACT Protein activator of the interferon-induced protein kinase 
PBS Phosphate-buffered saline 
PD-1 Programmed cell death protein 1 
PD-L1 Programmed death ligand-1 
PD-L2 Programmed death ligand-2 
PGE-2 Prostaglandin E2 
PHA Phytohemagglutinin 
PI3K Phosphoinositide 3-kinase 
PIP2 Phosphatidylinositol-4,5-bisphosphate 
PKCθ Protein kinase C 
PLC Phospholipase C 
PLGRKT Plasminogen receptor, C-terminal lysine  
PMA Phorbol 12-myristate 13-acetate 
PMBCL Primary mediastinal large B cell lymphoma 
PNGase F Peptide: N-glycosidase F 
PolyI:C Polyinosinic:polycytidylic acid 
PROX1 Prospero-related homeodomain protein 1 
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PTA Peripheral tissue antigen 
PTEN Phosphatase and tensin homolog 
PTPN2 Tyrosine-protein phosphatase non-receptor type 2 
PUM Pumilio 
qRT-PCR Quantitative real-time polymerase chain reaction 
RA Rheumatoid arthritis 
RANTES Regulated on activation, normal T cell expressed and secreted 
RBP RNA-binding protein 
RCC Renal clear cell carcinoma 
RIP Receptor interacting protein kinase 
RIPA Radioimmunoprecipitation assay 
RISC RNA-induced silencing complex 
S1P Sphingosine 1-phosphate 
SEE Staphylococcal enterotoxin E 
SHIP1 SH2 domain-containing inositol 5’-phosphate 1 
SHP2 Src homology phosphatase 2 
siRNA Small interfering RNA 
SLP-76 Src homology 2 domain-containing leukocyte phosphoprotein of 76 
kDa 
SOCS1 Suppressor of cytokine signalling 1 
SPRED-1 Sprout-related protein-1 
STAT Signal transducer and activator of transcription 
STRING Search Tool for the Retrieval of Interacting Genes/Proteins 
database 
TAB2 TGF- activated kinase 1 
TAM Tumour-associated macrophage 
TAP Transporter associated with antigen processing 
TBST Tris-buffered saline and Tween 20 
TCGA The Cancer Genome Atlas 
TCR T cell receptor 
TGF Transforming growth factor-β 
Th T helper 
TIE TEK tyrosine kinase 
TIGIT T cell immunoreceptor with Ig and ITIM domains 
TIL Tumour-infiltrating lymphocyte 
TIM3 T cell immunoglobulin and mucin-domain containing-3 
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TLR Toll-like receptor 
TMB 3,3’,5,5’-tetramethylbenzidine 
TNF- Tumour necrosis factor- 
TNFR Tumour necrosis factor receptor 
TP53INP1 Tumour protein 53-inducible nuclear protein 1 
TRAF2 TNF receptor-associated factor 2 
TRBP Transactivating response RNA-binding protein 
TTP Tristetraprolin 
UTR Untranslated region 
VCAM-1 Vascular cell adhesion molecule 1 
VEGFR Vascular endothelial growth factor receptor  
VHL Von Hippel-Lindau 
VISTA V-domain Ig suppressor of T cell activation 
XPO5 Exportin-5 
ZAP70 Zeta-chain-associated protein kinase 70 
ZEB1 Zinc-finger E-box-binding homeobox 1 
 
Abbreviations for tumour types can be found in Table 4.1. 
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